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ABSTRACT 
 
Background The postnatal failures of expression of the hepatic glucose-6-
phosphatase system suggest there are developmental deficiencies in the 
mechanism to ‘switch-on’ this key enzyme of gluconeogenesis at the time of 
birth in both preterm and term infants.  The evidence for hormonal regulation 
of this critical enzyme system in animal studies, in adult humans, and studies 
of cell lines make the possible failure of hormonal control around the time of 
birth an important hypothesis to test, but before this can be done, further 
studies of perinatal metabolism and its hormonal control need to be 
undertaken. 
 
Objective To describe the hormonal and metabolic profiles of ‘unstressed’ 
term infants delivered by elective caesarean section.   
 
Methods One hundred and fifty three women who had an elective 
caesarean section for a singleton pregnancy at term in Ninewells Hospital 
and Medical School, Dundee were recruited between July 2004 and April 
2006.  Maternal venous blood was taken for glucose and lactate estimations.  
Umbilical venous cord blood was obtained for the measurement of glucose, 
lactate, 3-hydroxybutyrate,  free fatty acids, amino acids (alanine, arginine, 
citruline, cystine, GABA, glutamic acid, glutamine, glycine, histidine, 
isoleucine, leucine, lysine, methionine ornithine, phenyalanine, serine, 
taurine, threonine, tyrosine and valine), insulin, glucagon, human growth 
hormone, cortisol, catechols (EPI, NE, DA, DOPA, DHPG, DOPAC) and their 
sulfated conjugates (EPI sulfate, NE sulfate, DA sulfate, DOPA sulfate, 
DHPG sulfate, DOPAC sulfate), and blood gas and acid-base profiles. 
 
Results The mean maternal glucose and lactate levels were 4.28 mmol/l and 
1.8 mmol/l respectively.  Three infants were hypoglycaemic with umbilical 
blood glucose levels of less than 2.6 mmol/l.  The mean infant glucose and 
lactate levels were as expected for full term infants at 3.3 mmol/l and 2.2 
mmol/l respectively.  High mean levels of insulin and catechols  were noted 
at birth.  There was a significant positive association between umbilical 
venous cord glucose levels and maternal venous glucose levels (p=<0.001) 
but no association of umbilical venous cord glucose levels with amino acids, 
insulin, glucagon, human growth hormone, cortisol and catechols.   
 
Conclusions This extensive data set of levels of metabolites and hormones 
in infants at birth acts as a reference source and will be valuable for 
evaluating any effects of antenatal or intrapartum factors on the hormonal 
and metabolic profiles of infants at birth as well as to investigate the 
mechanisms to ‘switch-on’ the key enzyme glucose-6-phosphatase.  
 
 
 
 
 
 
 
 1
CHAPTER 1 
INTRODUCTION 
 
1.1 CEREBRAL DAMAGE AND HYPOGLYCAEMIA 
Glucose is the primary essential fuel for the brain.  The adult brain has high 
energy requirements, estimated at approximately 1.0mg/kg/min (5.6 
mmol/kg/min) glucose, which corresponds to approximately 100g (555 mmol) 
over 24 hours (Bolli and Fanelli, 1999).  The brain does not make sufficient 
glucose for its own needs; it is dependent on a constant supply of glucose 
from blood.  
 
The brain has an amazing ability to regulate cerebral blood flow during 
periods of hypoglycaemia.  Anwar and Vannucci demonstrated significant 
increases in cerebral blood flow and a positive correlation between mean 
arterial blood pressure and cerebral cortical blood flow, suggesting a loss of 
cerebral blood flow autoregulation, in newborn dogs when blood glucose 
concentrations fall to around 2.2 mmol/l (Anwar and Vannucci, 1988).  
Glucose enters human brain cells by facilitated diffusion mediated by specific 
glucose transporters, GLUT1 and GLUT3; both of these are present in the 
brains of both preterm and term infants (Mantych et al., 1993).   
 
Newborn infants remain asymptomatic even at a low blood glucose level that 
would cause severe symptoms in adults (Griffiths, 1968).  Such 
asymptomatic hypoglycaemia suggests that newborn infants may be using 
alternative metabolic substrates for brain metabolism.  Bolli and Fanelli 
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reported that the adult brain cannot oxidize substrates other than glucose 
acutely during hypoglycaemia (Bolli and Fanelli, 1999).  In contrast, studies 
show that fetal and neonatal brains have the capacity to use alternative 
substrates especially lactic acid, ketone bodies (e.g. 3-hydroxybutyrate), free 
fatty acids (FFA) and certain amino acids (Adam et al., 1975; Persson et al., 
1972; Vannucci and Vannucci, 2000).   A study on the fasting human 
newborn showed that glucose oxidation can only supply up to 70% of the 
estimated brain metabolic requirements which suggests that alternative brain 
fuels are important for newborn brain metabolism during fasting (Denne and 
Kalhan, 1986).  A tracer study has confirmed active consumption of ketone 
bodies and ketogenesis even in regularly fed human newborns (Bougneres 
et al., 1986).  Studies in newborn dogs have shown that lactic acid is an 
important alternative substrate for the brain during hypoglycaemia and it can 
support up to 60% of the total brain energy metabolism (Hernández et al., 
1980; Hellmann et al., 1982).  Lactate has also been shown to be an 
important cerebral substrate for children with glucose-6-phosphatase 
deficiency, a condition where children have a problem generating glucose 
(Fernandes et al., 1984).  These alternative brain fuels may be protective of 
brain integrity in the event of hypoglycaemia. 
 
Glucose and oxygen are required for optimal energy generation and defects 
in the supply of either can cause cerebral impairment in infants and children.  
Oxygen deprivation is a well established cause of brain damage during 
labour and delivery, but glucose deprivation during labour and delivery has 
not been investigated as a cause of brain damage.  
  
3 
1.1.1 Neuropathological consequences of hypoglycaemia 
Brain damage caused by hypoglycaemia is a result of a sequence of events 
which include activation of neuronal glutamate receptors and release of zinc, 
leading to production of reactive oxygen species from mitochondria and 
activation of poly (ADP-ribose) polymerase-1 (Suh et al., 2007).  The pattern 
and distribution of neural damage from hypoxic-ischaemic brain injury are 
different from hypoglycaemic injury.  Hypoxic-ischaemic injury is 
characterised by infarction, a predominance of boundary zone injury and 
greater involvement of the deeper cortical layers (Williams, 2005).  In 
contrast, following hypoglycaemia, the predominant features are diffuse 
damage of the cortical and subcortical white matter with the parietal and 
occipital lobes affected most severely (Anderson et al., 1967; Banker, 1967).  
With the development of imaging techniques, Spar and colleagues described 
the first case of extensive occipital cortical loss from neonatal hypoglycaemia 
on computerised tomography and magnetic resonance imaging (MRI) 
studies (Spar et al., 1994).  Subsequent studies also confirmed a similar 
pattern of injury with severe hypoglycaemia (Barkovich et al., 1998; Filan et 
al., 2006).  This pattern of injury is also seen in neonates with transient 
hypoglycaemia i.e. symptomatic hypoglycaemia with a glucose level less 
than 2.5 mmol/l but the symptoms disappear after restoration of normal blood 
glucose levels (Kinnala et al., 1999).  Kinnala and colleagues described four 
infants who suffered from transient hypoglycaemia with patchy hyperintensity 
lesions, either in the occipital periventricular white matter, or the thalamus on 
T1 weight images on MRI, but the lesions were transient and most of them 
were absent two months later; the clinical relevance of these abnormal 
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findings remains unknown (Kinnala et al., 1999).  As yet, there is still no clear 
explanation of why the parietal and occipital lobes are most severely 
affected.  However, it has been suggested that it may be related to the 
development of receptors for excitatory amino acids which can be stimulated 
by aspartate and glutamate and result in selective neuronal necrosis 
(Barkovich et al., 1998). 
 
1.2 DEFINITION OF HYPOGLYCAEMIA 
The definition of what constitutes hypoglycaemic blood glucose levels in infants 
remains contentious (e.g. Schwartz, 1997; Cornblath et al., 2000).  A large 
survey of 508 neonatal paediatricians in the United Kingdom and Australia, and 
a review of fourteen neonatal textbooks in 1992 showed that there is a wide 
range in the levels of blood glucose that are used to define hypoglycaemia with 
values from less than 1 mmol/l to 4 mmol/l (Koh and Vong, 1996).  Furthermore 
different values were suggested for term and for premature/small for 
gestational age infants (Koh and Vong, 1996)  
 
Four approaches have been used to define hypoglycaemia in the neonate: 
clinical, statistical, physiological and neurodevelopmental.  
 
1.2.1 Clinical definition of hypoglycaemia 
The diagnosis of hypoglycaemia based on clinical manifestation was first 
introduced by Whipple and Fratz in 1935 using three criteria - known as the 
Whipple triad, which required to be fulfilled (Whipple and Fratz, 1935).  First, 
there had to be evident signs and symptoms of hypoglycaemia; secondly, an 
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accurate method had to be available to measure (low) glucose levels; thirdly, 
there should be a prompt resolution of clinical signs once normoglycaemia was 
re-established.  However there are difficulties with this clinical approach to 
define hypoglycaemia.  For example, the symptomatic response of the neonate 
to low blood glucose is variable with clinical features which are, in general, 
non-specific and which include pallor, feeding difficulties, hypotonia, 
tachypnoea, abnormal cry, jitteriness, apnoea, irritability, coma and 
convulsions (e.g. Hume, 1998).  This lack of symptomatic specificity can make 
the interpretation of biochemical hypoglycaemia difficult.  This is particularly so 
in the intensively cared for infant where concurrent pathologies cause the same 
pattern of clinical features or where symptomatic responses may be depressed 
with therapeutic muscle paralysis, severe birth asphyxia or extreme 
prematurity.  Hypoglycaemia may be intermittent and it is important to check 
blood glucose levels at times of vague but suspicious symptoms (e.g. Hume, 
1998).  Some otherwise well infants with low blood glucose levels are 
asymptomatic suggesting that alternative metabolic substrates are available for 
brain metabolism and such infants in general have a more favourable 
prognosis (Cornblath and Schwartz, 1976). 
 
1.2.2 Statistical definition 
Hypoglycaemia has been defined by using a level of more than two standard 
deviations (SD) below the mean obtained from populations of full term and low 
birth-weight infants (Pildes et al., 1967; Heck and Erenberg, 1987).  However, 
the findings of this statistical approach reflects the population distribution of 
values - both physiological and potentially pathological, and this has generated 
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anomalies, for instance, where hypoglycaemia was defined as a blood glucose 
concentration for a particular population.  For example, hypoglycaemia in the 
preterm or low birthweight infant was defined as less than 1.1 mmol/l during the 
first week of life, whereas, in full-term infants, the corresponding value was less 
than 1.7 mmol/l for the first 72 h of life with a value of less than 2.2 mmol/l after 
72 h of age (Cornblath and Schwartz, 1976).  These criteria imply that preterm 
infants compared to term are less prone to neurological impairment secondary 
to hypoglycaemia and that resistance to hypoglycaemia is greatest in the 
immediate postpartum period.  A more satisfactory approach may be to define 
significant biochemical hypoglycemia in the context of acute or chronic 
neurological dysfunction. 
 
1.2.3 Physiological definition 
1.2.3.1 Hormonal responses to hypoglycaemia 
Blood glucose levels are regulated by hormonal mechanisms and the blood 
glucose reducing effect of insulin is counter-regulated by cortisol, 
catecholamines, human growth hormone (hGH) and glucagon (Bolli and 
Fanelli, 1999).  As blood glucose levels fall, the counter-regulatory hormones 
increase.  For example in adults, the blood glucose threshold level for initiating 
the response of cortisol is 3.2 mmol/l (Schwartz et al., 1987); a cortisol 
response at this blood glucose level may indicate a physiological requirement 
to maintain blood glucose levels above 3.2 mmol/l and indicate the lower limit 
of normoglycaemia.  In infants and children more than six months old, who 
were spontaneously hypoglycaemic (glucose level less than 2.5 mmol/l), a 
similar glycaemic threshold for cortisol was noted (Crofton and Midgley, 2004).  
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However, poor cortisol response to hypoglycaemia was found in infants who 
were less than three months old and it has been suggested that this could be 
due to the relatively low glucose levels at birth resulting in poor hypothalamic-
pituitary response to hypoglycaemia (Crofton and Midgley, 2004).  By contrast, 
studies of metabolic and hormonal responses to hypoglycaemia in preterm and 
small for dates term infants demonstrated an elevated cortisol response to a 
relatively short duration of hypoglycaemia (Hume et al., 1999; Jackson et al., 
2004).  There remains a lack of consensus in the limited studies available in 
the newborn to define a blood glucose level that defines hypoglycaemia in 
terms of the threshold level for a cortisol response.   
 
Definitions of infant hypoglycaemia based on a blood glucose level that 
induces a counter-regulatory response in hormones other than cortisol are also 
problematic.  In adults, a blood glucose level of 3.7 mmol/l is the threshold level 
for hGH response (Schwartz et al., 1987) and indirect evidence has suggested 
that older infants and children more than six months old have a similar hGH 
threshold but their hGH response to spontaneous hypoglycaemia is reduced in 
magnitude (Crofton and Midgley, 2004).  However this is not evident in preterm 
infants as hGH levels were similar in fasted normoglycaemic and 
hypoglycaemic preterm infants prior to discharge from hospital (Hume et al., 
1999) and also in less than three months old infants who were normo- or 
hypoglycaemic at sampling (Crofton and Midgley, 2004).  
 
In human adults, glucagon and epinephrine (EPI) play an important role in 
increasing glucose levels during acute (Cryer et al., 1984) as well as in 
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prolonged hypoglycaemia (Bolli et al., 1984).  However, in preterm infants at 
the time of discharge from hospital or small for dates term infants studied in 
the neonatal period, there was a lack of glucagon response to 
hypoglycaemia (Hume et al., 1999; Jackson et al., 2004).  The counter-
regulatory hormonal response to hypoglycaemia in early infancy appears to 
be limited to elevations of cortisol and EPI (Jackson et al., 2004) and there is 
insufficient current data to define a blood glucose threshold level to initiate 
these responses. 
 
1.2.3.2 Neurophysiological definition 
In 1988, Koh and colleagues demonstrated that acute cerebral dysfunction 
(auditory and somatosensory evoked potentials) occurred in ten of eleven 
children when blood glucose levels fell below 2.6 mmol/l and when 50% were 
asymptomatic (Koh et al., 1988).  They recommended that blood glucose 
concentration in children should be maintained above 2.6 mmol/l to ensure 
normal neural function, regardless of the presence or absence of abnormal 
clinical signs.  The critical level of 2.6 mmol/l was supported in a further study 
of cerebral blood flow, which was found to be increased in hypoglycaemic 
preterm infants when the blood glucose level was less than 2.5 mmol/l 
although the neonates had no clinical signs of hypoglycaemia (Pryds et al., 
1988; Pryds et al., 1990).  In contrast, a subsequent small study found no 
correlation between glucose concentrations, ranging from 1.39 to 6.83 mmol/l, 
and the brainstem auditory evoked response; they concluded that tighter 
clinical control of glucose homeostasis is probably not required in the neonatal 
period (Cowett et al., 1997).  The findings from these studies are not clear; they 
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were small studies and underpowered to show definitely whether there is a 
significant correlation with brain damage.   
 
1.2.4 Neurodevelopmental approach 
Studies have shown that prolonged or recurrent neonatal hypoglycaemia 
may lead to permanent neurological damage in term infants (Aynsley-Green 
and Soltesz, 1985; Cowett, 1999).  Lucas and colleagues carried out a 
detailed multicentre study of 661 preterm infants who weighed less than 
1850g at birth and evaluated the neurodevelopment outcomes relative to 
hypoglycaemia at 18 months of age (Lucas et al., 1988).  They found that 
two-thirds of the neonates had blood glucose levels less than 2.6 mmol/l for 
a period ranging from 3 to 30 days.  If hypoglycaemia existed for five or more 
separate days, the Bayley motor and mental developmental scores were 
significantly reduced at 18 months (after adjustment for identifiable 
confounders) and the incidence of the neurodevelopmental impairment was 
increased by a factor of 3.5.  This study only included preterm infants who 
weighed less than 1850g. Therefore, the results may not be applicable to 
term infants.  Subsequently, Duvanel and colleagues reported that recurrent 
episodes of hypoglycaemia with a blood glucose level below 2.6 mmol/l were 
strongly correlated with reduced head circumferences at 18 months and 
lower psychometric scores at five years of age in small-for gestational age 
preterm neonates (Duvanel et al., 1999).  Head circumference at birth has 
been suggested to be predictive of cognitive function in childhood.  In a 
cohort of 249 very low birth weight children, those with a normal head 
circumference at birth have better cognitive function when compared to 
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those whose head size was more than two SDs below the mean at eight 
years of age (Hack et al., 1991).  Another study carried out by Peterson and 
colleagues looking at the effect of head circumferences on academic 
achievement and behaviour in a cohort of 128 children who weighed less 
than 1500g at birth, found that a head circumference more than two SDs 
below the mean was associated with poorer IQ, perceptual motor skills, 
academic achievement and adaptive behaviour than those whose head size 
was normal (Peterson et al., 2006) 
 
None of these approaches to the definition of hypoglycaemia has been 
entirely satisfactory.  A recent review suggested that it is time to move away 
from a single threshold definition of ‘hypoglycaemia’ towards a more flexible 
approach which takes into account not only the plasma glucose 
concentration but also the presence of risk factors and the clinical state of 
the infant (Williams, 2005). 
 
1.2.5 Conclusion 
There is no universal definition of hypoglycaemia in infants and hence an 
operational threshold for hypoglycaemia which is defined as “the 
concentration of plasma or whole blood glucose at which clinicians should 
consider intervention, based on the evidence currently available from the 
literature” has been suggested (Cornblath et al., 2000). Currently, the 
general consensus from the neonatologists in the United Kingdom for the 
operational threshold for hypoglycaemia is 2.6mmol/l.   
 
  
11 
1.3 FETAL METABOLISM DURING DELIVERY  
In labour, the oxygen level in the fetal blood decreases during a normal uterine 
contraction and for a period the fetus will not metabolise glucose completely to 
carbon dioxide but instead to acidic metabolic intermediates such as lactate.  
This only partially releases the potential energy of glucose and depletes fetal 
liver glucose reserves (which is in the form of glycogen).  With the relaxation 
between contractions, restitution of gas exchange occurs but it is not possible 
to restore the depleting hepatic glycogen stores.  Anaerobic metabolism is an 
inefficient use of glucose and may result in depletion of reserves and 
subsequent lowering of fetal blood glucose levels.  The fetus is dependent on 
restoration of blood glucose levels from the maternal circulation which is re-
established between contractions.  This restoration may be compromised if the 
mother has sub-optimal blood glucose levels.  Intrauterine growth restriction 
fetuses are particularly at risk of hypoglycaemia during labour due to limited 
hepatic glycogen storage (Shelley and Neligan, 1966).  Similarly, preterm 
fetuses are at risk too as hepatic glycogen only accumulates in the human 
fetus in the late third trimester (Shelley, 1964).  During labour, lactic acid 
accumulates in the fetus and eventually lactic acidaemia develops.  Carbon 
dioxide diffuses rapidly across the placenta but a fixed acid such as lactic acid 
diffuses slowly across the placenta into the maternal circulation (Gilstrap, 
1999a).  Accumulation of lactate in the brain tissue can lead to oedema and 
necrosis (Gilstrap, 1999a).  Carbon dioxide levels in general are higher in the 
fetus than in the infant.  In solution, carbon dioxide is acidic and this combined 
with lactate means that the fetus during delivery is in an even more acidic 
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environment.  The degree of acidity is routinely assessed by measuring cord 
pH, and oxygen and carbon dioxide levels in the blood.  
 
1.3.1 Perinatal glucose homeostasis  
In-utero the human fetus is dependent upon a maternal supply of glucose 
which is transported by facilitated diffusion across the placenta; there is no 
significant production of glucose by fetus in-utero (Kalhan et al., 1979).  It 
has been shown in fetal sheep that the rate of placental glucose transfer to 
the fetus is enhanced by increasing the maternal-fetal glucose concentration 
gradient (Hay and Meznarich, 1989).  The maternal-fetal glucose 
concentration gradient is especially important in the intrauterine growth 
restriction fetus where there is a reduction in placental glucose transport 
capacity, and hence, high maternal-fetal glucose concentration gradients 
increase the maternal-fetal glucose transfer (Hay, 2006).   
  
 
Placental and fetal glucose consumption has a major influence on the 
maternal-fetal glucose concentration gradient and hence the transfer of 
glucose from the maternal circulation to the fetus.  The placenta has a high 
glucose consumption, using approximately 75% of the glucose supply to the 
utero-placental unit (Sparks et al., 1983).  In the fetal sheep, placental 
glucose consumption is directly related to fetal arterial plasma glucose levels 
and is independent of maternal glucose levels (Hay et al., 1990).  The fetal 
side of the placenta has an eightfold greater glucose transport capacity 
compared to the maternal side, which means fetal blood glucose 
concentration has a great influence on the glucose metabolism in the 
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placenta (Hay, 2006).  With advancing gestation, the placental glucose 
transfer to the fetus increases by increasing the placental glucose transport 
capacity as well as increasing the maternal-fetal glucose concentration 
gradient (Hay, 2006). 
 
Immediately after delivery, with the ligation of the umbilical cord, the fetal 
glucose concentration falls, and thereafter stabilisation is dependent on the 
mobilisation of hepatic glycogen stores (Shelley and Neligan, 1966), 
maturation and activation of key gluconeogenic and glycogenolytic enzymes 
(Girard, 1986), an integrated metabolic and hormonal response (Girard, 1986), 
and the initiation of milk feeding. 
 
1.3.2 Hepatic glycogen stores 
Fetal hepatic glycogen stores rise appreciably from 36 weeks gestation but the 
level falls considerably soon after birth (Shelley and Neligan, 1966).  Hepatic 
glycogen stores are lower in preterm infants and infants who have suffered 
severe respiratory distress compared to normal term infants (Shelley, 1964).  
In newborn term infants, the hepatic glycogen concentration falls within 24 
hours to 10% of that at birth, but in premature infants, the hepatic glycogen 
level becomes nearly depleted within 12 hours of birth (Shelley and Neligan, 
1966). 
 
1.3.3 Hepatic microsomal glucose-6-phosphatase system 
The induction of the key regulatory enzymes of gluconeogenesis and 
glycogenolysis e.g. hepatic glucose-6-phosphatase (G-6-Pase), must take 
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place post-delivery to allow liver glucose production and the maintenance of 
blood glucose levels.  G-6-Pase catalyses the hydrolysis of glucose-6-
phosphate (G-6-P) to glucose and phosphate, which is the final step in the 
metabolic pathways by which liver produces glucose (Ganong, 1995a).  
 
The G-6-Pase system consists of at least two integral membrane proteins, G-
6-P transporter and the G-6-Pase catalytic subunit (G-6-PC1) (Arion et al., 
1975).  The G-6-PC1 is an endoplasmic reticulum (ER) membrane protein and 
its active site is inside the lumen of the ER (Burchell et al., 1990).  Therefore 
for hydrolysis, G-6-P needs to be transported across the ER membrane from 
the cytoplasm to reach the G-6-PC1.  The products, glucose and phosphate, 
also need to be shuttled from the lumen of ER into the cytoplasm for release 
into the circulation.  Arion and colleagues proposed a model of the G-6-Pase 
system, which consisted of separate microsomal transporters, T1 for G-6-P, 
T2 for phosphate and T3 for glucose (Arion et al., 1975).  To date, T1 has 
been identified (Chen and Burchell, 1995) but T2 and T3 have yet to be 
characterised.  From the cytoplasm, glucose is released into the bloodstream 
via the facilitative plasma membrane glucose transport protein, GLUT 2 (Chen 
and Burchell, 1995).  
 
Any genetic or regulatory deficiency of the different protein component parts of 
the G-6-Pase system results in abnormally low liver glucose production with 
the potential to cause severe episodes of fasting hypoglycaemia (Chen and 
Burchell, 1995).  Type I glycogen storage disease (GSD) is an autosomal 
recessive genetic disorder of the hepatic microsomal G-6-Pase system (Chen 
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and Burchell, 1995).  The condition may present in the newborn period with 
hypoglycaemia and/or lactic acidosis but more characteristically presents at 
three to four months of age with hepatomegaly and fasting hypoglycaemia with 
seizures (Chen and Burchell, 1995).  However some individuals with Type I 
GSD remain undiagnosed until adulthood (Burchell et al., 1987).  Long term 
complications include delayed puberty, reduced adult height, gout, renal 
disease, pancreatitis, premature arteriosclerosis, hepatic adenomas and 
hypertension (Chen and Burchell, 1995).  
 
1.3.3.1 The ontogeny of the human hepatic microsomal glucose-6-
phosphatase 
Hepatic G-6-Pase enzyme activity first appears as early as eleven weeks 
gestation in humans and the level remains low before birth, gradually 
increasing to about 10% of adult values by term (Burchell et al., 1990).  
However after birth, the activity rises rapidly in term infants reaching adult 
values by about three to four days of age and the increase of the enzyme 
activity is equalled by an increase in the concentration of the G-6-Pase 
enzyme protein (Burchell et al., 1990).  After the first week, the level remains 
constant until adulthood (Burchell et al., 1990).  Burchell and colleagues also 
showed that T1 developed at the same time and rate as the G-6-PC1 whereas 
T2 developed later in gestation, between 20 and 24 weeks gestation, which is 
when the human liver production of glucose reported reaches full activity 
(Burchell et al., 1990). 
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The ontogeny of G-6-Pase enzyme activity in preterm infants and term infants 
is different.  Hume and Burchell studied the hepatic microsomal G-6-Pase 
enzyme in liver samples from 76 preterm infants between 3 and 360 days of 
age and demonstrated that most had G-6-Pase activities which were below the 
extreme lower limit of the normal term infant range and which could render 
these infants at risk of repeated hypoglycaemic episodes and brain damage 
(Hume and Burchell, 1993).  In a subsequent study, they found that 18% of a 
cohort of 79 consecutively delivered preterm infants who were ready for 
discharge home failed to maintain normoglycaemia, suggesting a significant 
number of preterm infants are at risk of hypoglycaemia at home if a feed is 
omitted or delayed (Hume et al., 1999). 
 
1.3.3.2 Perinatal factors and the regulation of glucose-6-phosphatase 
gene expression 
Since the 1950s, animal studies have shown that the activity of G-6-Pase is 
influenced by various hormones and metabolites.  For example, G-6-Pase 
enzyme activity (Ashmore et al., 1954; Burchell and Cain, 1985), protein levels 
(Burchell and Cain, 1985) and mRNA levels (Liu et al., 1994) all increase in 
diabetic rats.  Starvation also causes a two to threefold increase in hepatic G-
6-Pase activity (Ashmore et al., 1954).  However, the activity is depressed by 
administration of insulin in diabetic (Ashmore et al., 1954) as well as normal 
state rats (Nordlie et al., 1965a).  Studies in rat hepatoma cells have also 
shown that insulin decreases G-6-Pase mRNA (Argaud et al., 1996).  
Glucocorticoids in vivo increases hepatic G-6-Pase activity levels by about 
40% in the adrenalectomized rats (Nordlie et al., 1965b).  Glucocorticoids also 
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stimulate the transcription of the gene encoding the catalytic subunit of the G-
6-Pase (Streeper et al., 1997; Hiraiwa and Chou, 2001) whereas insulin 
strongly inhibits both basal G-6-Pase gene transcription and the stimulatory 
effect of glucocorticoids (Streeper et al., 1997).  Argaud and colleagues have 
demonstrated in rats that glucose causes a 20-fold increase of the level of G-
6-Pase mRNA transcripts in cultured hepatocytes and a threefold increase in 
hepatoma cells (Argaud et al., 1997).  The transcription of the human G-6-
Pase gene has also been shown to be down regulated by insulin (Schmoll, 
1996) and up regulated to a lesser extent by glucose, cyclic AMP and 
dexamethasone (Schmoll et al., 1999).  
 
However the response of post-mortem hepatic G-6-Pase activity in 36 preterm 
infants who had therapeutic administration of insulin during the postnatal 
period yielded surprising results (Burchell et al., 2000).  Instead of a negative 
correlation with insulin levels, the levels of hepatic G-6-Pase activity was 
positively correlated with the amount of insulin prescribed whilst the infant was 
alive.  Currently, the understanding of the in vivo regulation of human hepatic 
G-6-Pase in preterm infants is rudimentary and based on a cohort of infants 
who have different basal levels of a variety of hormones and metabolites.  
Another study carried out by Hume and colleagues on 45 preterm infants 
demonstrated that infants with severe respiratory distress and/or those 
exposed to pathogenic bacterial infections, whether in-utero or the early 
postnatal period, have higher levels of G-6-Pase enzyme activity (Hume et al., 
2000). Hume and colleagues found that the perinatal factors that are 
associated with the changes in hepatic G-6-Pase enzyme activity were the 
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presence of pathologic bacteria mainly Streptococcus agalactia isolated from 
maternal high vaginal swabs taken during labour, the duration of prenatal 
exposure to ritrodrine, and delivery by caesarean section.   
 
In the study of fetal sheep, the rise of G-6-Pase and phosphoenolpyruvate 
carboxykinase enzyme activities in the liver and kidney were prevented when 
the rise in plasma triiodothyronine (T3) was prevented by thyroidectomy prior 
to delivery (Forhead et al., 2003).  This result suggests that thyroid hormones 
play an important part in the activation of gluconeogenesis pathway in the 
fetal life. 
 
1.3.4 Perinatal hormonal and metabolic responses to extrauterine life 
Within minutes of delivery, catecholamines rise three to tenfold in the human 
(Sperling et al., 1984).  Glucagon also increases three to fivefold and remains 
elevated throughout the first day of life in the human fetus (Sperling et al., 
1974).  Simultaneously, hGH and cortisol rise with a concomitant fall in insulin 
secretion in the human fetus (Menon and Sperling, 1988).  There is also a 
marked postnatal surge of thyroid stimulating hormones at about 30 minutes 
of age secondary to the exposure of the infants to cold in the extrauterine 
environment.  This in turn leads to secretion of thyroidal thyroxine (T4) and T3 
which peak at between 24 to 36 hours of age (Fisher, 1996). 
 
Over the first few days of life, with increases in enteral intake and with 
continued maturation of hepatic gluconeogenesis (Lucas et al., 1978), blood 
glucose levels stabilise.  Transient disturbances in neonatal glucose 
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homeostasis are common during this time, especially where metabolic 
reserves are low as in prematurity and intra-uterine growth retardation or, 
where expenditure of energy is high as seen, for example, with sepsis, birth 
asphyxia and hypothermia (Lyall et al., 1994; Hume et al., 1998).  Preterm 
infants have lower hepatic glycogen reserves (Shelley, 1964), lower activities of 
key gluconeogenic enzymes (Burchell et al., 1990), an initially limited hormonal 
response (Lucas et al., 1978) and, even where regimens of postnatal care 
were similar to those of term infants (i.e. oral milk feeds), blood glucose values 
were lower and the postnatal rise was slower (Smallpeice and Davies, 1964). 
 
1.3.4.1 The physiological role of amino acids in the perinatal period 
Amino acids are important substrates for protein synthesis and oxidation during 
intrauterine life.  The plasma amino acid concentrations do not change 
significantly from second to third trimester during pregnancy (Cetin et al., 
1990).  It has been well established that plasma amino acid concentrations in 
the fetus at mid-gestation as well as at term (Cetin et al., 1990), are higher than 
those in the mother which suggests that amino acids are actively transported 
from the mother to the fetus (Galan et al., 2009).  The transport is regulated by 
specific amino acid transporters which have been found on the microvillous 
(Johnson and Smith, 1988) and basal membranes of the syncytiotrophoblastic 
cells of human placenta (Hoeltzli and Smith, 1989).    
 
There are a number of factors which regulate the activity of the transport 
system.  The capacity of amino acid transport systems gradually increases 
with gestation to support the increasing nutrient demands of the developing 
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fetus (Mahendran et al., 1994).  Increasing maternal amino acid 
concentration also increases the transport capacity and ultimately the amino 
acid concentration in the fetus.  This has been demonstrated in sheep for 
alanine (Timmerman et al., 1998) and lysine (Wilkes et al., 2003).  However 
not all the amino acid levels will increase in the fetus when a mother is given 
a large number of amino acids, due to the competition for the shared 
transporters (Józwik et al., 2001).  Animal studies have demonstrated that 
the amino acid transport across the placenta is reduced in the growth 
restricted fetuses and logically this would suggest a lower amino acid 
concentration in the growth restricted fetus compared to the normal well 
grown fetus.  However there is conflicting evidence of this.  Economides and 
colleagues and Cetin and colleagues have demonstrated reduced umbilical 
venous amino acid concentrations in the growth restricted fetus (Economides 
et al., 1989; Cetin et al., 1990) but a more recent study by Paolini and 
colleagues found no difference in the umbilical venous amino acid 
concentration in the normal and growth restricted fetuses (Paolini et al., 
2001).  There is also a significant increase in a number of amino acids in the 
umbilical cord vein in pregnancies complicated with gestational diabetes 
mellitus, prexisting diabetes and preeclampsia (Cetin et al., 2005).  
 
1.3.4.2 The physiological role of insulin and glucagon in the perinatal 
period 
In fetal sheep, there is a gradual increase in glucose and arginine stimulated 
insulin secretion, as well as basal insulin levels from mid-gestation to term 
(Aldoretta et al., 1998). In human fetus, umbilical insulin levels obtained by 
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cordocentesis showed that insulin levels increased exponentially from 20 
weeks to 38 weeks gestation which suggests a progressive maturation of 
pancreatic activity with gestation (Economides et al., 1989). However the 
levels appear to fall after 37 weeks gestation (Godfrey et al., 1996) and 
remain low at birth (Thomas et al., 1967).  
 
Insulin secretion can be down-regulated in chronic and constant 
hyperglycaemia as demonstrated in fetal sheep in mid and late gestation 
(Carver et al., 1995; Aldoretta et al., 1998).  Interestingly, pulsatile 
hyperglycaemia can stimulate insulin secretion in fetal sheep (Carver et al., 
1996).  Chronic hypoglycaemia can also decrease the insulin secretion 
response in fetal sheep and the response to hypoglycaemia can still be 
blunted after recovery from the hypoglycaemic episodes (Limesand and Hay, 
2003).  Hence, Limesand and Hay suggested that this could be the possible 
mechanism of developing type II diabetes in adult life in intrauterine growth 
restricted infants (Limesand and Hay, 2002).  
 
Conversely, hypoinsulinaemia, which can result from a number of conditions 
such as pancreatic agenesis and transient diabetes can lead to intrauterine 
growth retardation in the fetus (Fowden, 1995). Osmanağaoğlu and 
colleagues have demonstrated that umbilical venous insulin levels were 
significantly lower in small for gestational age infants and that the levels 
correlated with birth weight, birth length and placental weight 
(Osmanağaoğlu et al., 2005).  Umbilical cord insulin levels were higher in 
infants delivered by elective caesarean section compared to infants delivered 
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by spontaneous vaginal delivery (Wang et al., 1995, Godfrey et al., 1996, 
Shields et al., 2007).  Infants whose mothers went into labour spontaneously 
were also found to have higher umbilical insulin levels compared with those 
whose mothers were induced (Godfrey et al., 1996).  There is conflicting 
evidence on the influence of gender on umbilical insulin levels.  A study 
carried by Godfrey and colleague on 391 term infants concluded that gender 
does not appear to influence the levels of insulin in venous cord blood 
(Godfrey et al., 1996) but the more recent study by Shields and colleagues 
suggest that female infants have higher umbilical venous insulin levels 
compared to male infants (Shields et al., 2007).  
 
There is paucity of evidence on the differences on insulin levels in the umbilical 
vein and artery.  Thomas and colleagues studied the umbilical cord insulin 
levels in 14 appropriate weight-for-gestation term infants, concluded that the 
levels were similar in the umbilical artery and vein (Thomas et al., 1967). 
Similarly there is paucity of evidence on the umbilical cord glucagon levels at 
birth in the human fetus.  At term, umbilical venous and arterial glucagon levels 
in the human fetus are similar to maternal levels (Milner et al., 1973), but the 
level rises three to fivefold acutely and remains elevated throughout the first 
day of life in the human infant (Sperling et al., 1974).  Simultaneously, insulin 
secretion falls in the human fetus after delivery (Menon and Sperling, 1988). 
 
1.3.4.3 The physiological role of cortisol in the perinatal period 
In vivo studies measuring serum cortisol levels by cordocentesis in the fetus 
from mid-gestation showed that the levels remain constant between 18 and 
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36 weeks gestation (Economides et al., 1988) and thereafter the level 
gradually increases (Oh et al., 2006).  Serón-Ferré and colleagues 
investigated umbilical cord cortisol levels of 57 term infants delivered by 
elective caesarean section over a 24 hour period and concluded that there is 
a 24-hour rhythm of cortisol secretion from the adrenal gland in the fetus at 
term (Serón-Ferré et al., 2001).  However there is equally substantial 
evidence that there is no diurnal variation until about three months postnatal 
age (Price et al., 1983; Spangler, 1991).  Cortisol levels are transiently 
elevated at birth in term infants delivered vaginally and decrease to lower 
and stable levels by 24 hours (Kraiem et al., 1985).   
 
Fetal cortisol levels are linked to antenatal or intrapartum stressful events,   
spontaneous onset of labour and mode of delivery.  In vivo studies looking at 
human fetal stress responses to invasive stimuli between 17 and 35 weeks 
gestation showed that an elevated plasma fetal cortisol levels, independent 
of the maternal responses, to transfusion via the intrahepatic vein 
(Giannakoulopoulos et al., 1999; Gitau et al., 2001).  Umbilical cord cortisol 
levels were also found to be elevated in associated with spontaneous onset 
of labour (Leong and Murphy, 1976; Mears et al, 2004).  It is well established 
that infants delivered by elective caesarean section have the lowest umbilical 
cord cortisol levels compared to other mode of deliveries (Mears et al., 2004; 
Miller et al., 2005; Vogl et al., 2006).     
 
Many studies have used mixed or venous cord blood.  The largest study to 
date is by Garagorri and colleague looking at the umbilical cord cortisol 
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levels in 138 infants delivered by spontaneous vaginal deliveries (Garagorri 
et al, 2008).  Unfortunately there was no detail on whether the sample was 
taken from umbilical vein or artery recorded.  A study by Gitau and 
colleagues which looked at the cortisol levels in both umbilical cords arterial 
and venous found that plasma cortisol levels were significantly higher in the 
umbilical cord artery than in the umbilical cord vein (Gitau et al, 2001).  They 
also showed that there was a significant high correlation between umbilical 
cord arterial and venous cortisol levels.    
 
Gluconeogenesis has been demonstrated in fetal sheep during late gestation 
with a concomitant rise in cortisol and catecholamines (Fowden et al., 1998).  
Cortisol plays an important role in the regulation of hepatic glycogen 
synthesis in the fetus.  Studies in fetal rats have shown that cortisol 
increases glycogen synthetase activity and thus glycogen synthesis (Monder 
and Coufalik, 1972).  Cortisol also enhances hepatic G-6-Pase activity and 
the removal of the pituitary gland results in low levels of fetal ovine plasma 
cortisol, and hepatic and renal G-6-Pase activity (Fowden et al., 1990).  
Besides this, cortisol plays an important role in promoting the maturation of 
organ systems including lung, thyroid, pancreas and small intestine (Liggins, 
1976).  In the 1960s, Liggins and colleagues showed that cortisol secretion 
by the fetal adrenal cortex in sheep plays a critical role in the process of 
triggering a cascade of events leading to parturition (Liggins, 1976).  
However in the human, cortisol does not appear to be involved in the 
regulation of parturition (Ohrlander et al., 1976; Sybulski and Maughan, 
1976).  
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After delivery, cortisol plays an important role in the hormonal counter-
regulation of glucose homeostasis, particularly in preterm infants.  A study 
that investigated counter-regulatory hormonal reactions to hypoglycaemia in 
small for gestational age term infants showed that infants with severe and 
persistent hypoglycaemia had elevated cortisol and EPI, but not glucagon or 
hGH levels (Jackson et al., 2004).  Preterm and small for gestational age 
term infants thus appear to display different cortisol responses when 
exposed to repeated hypoglycaemia compared to an adult.   
 
1.3.4.4 The physiological role and metabolism of catecholamines in the 
perinatal period 
At birth, there are significant transitions in many vital organ systems which 
are critical for effective and successful adaptation to extrauterine life.  
Catecholamines have been shown to play an important role in the neonatal 
cardiovascular, respiratory and metabolic adaptation at birth (Sperling et al., 
1984).    
 
Lung inflation and oxygenation at birth results in increased pulmonary blood 
flow, left atrial pressure and left ventricular output (Padbury and Martinez, 
1988).  Adrenal catecholamines release has been suggested to further 
promote these transitional events by enhancing the contractility of the left 
ventricle (Padbury and Martinez, 1988).  Impaired left ventricular contractile 
responses have been found in adrenalectomized newborn dogs (Erath et al., 
1982).  
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There is considerable evidence to show that high levels of endogenous 
catecholamines may be important for accelerating the absorption of lung fluid 
at birth (Faxelius et al., 1983; Finley et al., 1998).  This clearance is mainly 
mediated in the alveolar epithelial cells by transepithelial sodium 
reabsorption through the amiloride-sensitive sodium channels (Hummler et 
al., 1996; Finley et al., 1998).  Beta-agonists have been shown to increase 
the activity of sodium channels in the lung through a cAMP-PKA-mediated 
mechanism (Chen et al., 2002).  
 
It is well known that infants delivered vaginally demonstrate improved 
functional lung residual capacity and mean thoracic gas volume when 
compared with infants not exposed to labour and delivered by caesarean 
section (Vyas et al., 1981; Lee et al., 1999).  Animal studies have suggested 
that catecholamines are important in both the synthesis and release of lung 
surfactant, which is essential for normal pulmonary function (Padbury et al., 
1987).  Therefore, there is a higher occurrence of respiratory morbidity in 
term infants delivered by elective caesarean section (Zanardo et al., 2004; 
Hansen et al., 2008) due to the combined effect of failure to switch off lung 
fluid production and reduced surfactant levels.  
 
Catecholamines also play an important role in perinatal glucose homeostasis 
(Sperling et al., 1984).  Padbury and colleagues have demonstrated a 
significant decrease in glucose and FFA levels in surgically 
adrenalectomised ovine term fetuses (Padbury et al., 1987). There is 
evidence to show that there is an arterio-venous difference in EPI and NE in 
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cord infant blood with venous levels lower than arterial (Eliot et al., 1980, 
Falconer and Lake, 1982).  Postnatal levels of EPI and NE are high (e.g. 
Eliot et al., 1980) consistent with high amounts of vanillylmandelic acid 
(VMA) and homovanillic acid (HVA) in postnatal urine (Gabriel et al., 1983).  
Together, these observations suggest that there is a feto-placental-maternal 
metabolism or transport of catechols.   
 
Human plasma contains six readily detectable catechols.  The main plasma 
catechols are the three catecholamines, epinephrine (EPI), norepinephrine 
(NE), and dopamine (DA); their precursor, 3,4-dihydroxyphenylalanine 
(DOPA); and their deaminated metabolites, 3,4-dihydroxyphenylacetic acid 
(DOPAC) from DA and 3,4-dihydroxyphenyglycol (DHPG) from NE 
(Eisenhofer et al., 2001, Figure 1.1).  The major end product of NE and EPI 
metabolism is 4-hydroxy-3-methoxymandelic acid (VMA) which is produced 
mainly (94%) in the liver by oxidation of 3-methoxy-4-hydroxylphenylglycol 
(MHPG) (Eisenhofer et al., 2004).  The major end product of DA metabolism 
is 3-methoxy-4-hydroxyphenyl acetic acid (HVA) which is mostly formed 
outside the liver by O-methylation of DOPAC or oxidative deamination of 3-
methoxytyramine (Eisenhofer et al., 2004).  Both VMA and HVA are excreted 
in the urine. 
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Figure 1.1: Pathways of metabolism of catecholamines 
(Enzymes responsible for each pathway are shown at the head of arrows. 
Adapted from Eisenhofer et al., 2001 with permission).    
 
 
DBH dopamine β-hydroxylase, PNMT phenoxyethanolamine N-methyltransferase, 
MAO monoamine oxidase, COMT catechol-O-methyltransferase, AR aldose 
reductase, AD aldehyde dehydrogenase, ADH alcohol dehydrogenase, DOPET 
3,4-dihyroxyphenylethanol, DOPAC 3,4-dihydroxyphenylacetic acid, MOPET 3-
methoxy-4-hydroxyphenolethanol, HVA homovanillic acid, DHPG 3,4-
dihydroxyphenolglycol, DHMA 3,4-dihydroxymandelic acid, MHPG 3-methoxy-4-
hydroxyphenylglycol, VMA, vanillymandelic acid  
 
  
29 
The mechanisms for clearance of the high fetal production rate of 
catecholamines may be critical for fetal homeostasis.  As EPI, NE and DA 
have potent effects throughout the body, their concentrations are tightly 
regulated.  In the extracellular compartment, specific membrane bound 
transporter proteins that mediate re-uptake from the extracellular space are 
the most important regulators of catecholamine levels (Torres and Amara, 
2007).  
 
A range of transporter proteins expressed primarily in neuronal tissue have 
been characterized and include the 5-hydroxytryptamine (5-HT) transporter 
(Blakely et al., 1991), norepinephrine transporter (NET) (Ramamoorthy et al., 
1993) and the dopamine transporter (Usdin et al., 1991).  These neuronal 
monoamine transporters function not only as part of the metabolizing system 
but perhaps more importantly as part of recycling systems to maintain the 
catecholamine levels in the vesicular stores (Eisenhofer, 2001). 
 
In the extraneuronal tissue, the three known transporter proteins responsible 
for extraneuronal corticosterone-sensitive monoamine uptake are the organic 
anion transporters (OCT1, OCT2) and the extraneuronal monoamine 
transporter (EMT) (Gorboulev et al., 1997; Grundemann et al., 1998), which 
are mainly expressed in the intestine, liver, kidney and placenta (Kekuda et 
al., 1998; Hayer-Zillgen et al., 2002).  They have a broad compound affinity, 
transporting all biogenic amines as well as exogenous drugs and xenobiotics 
(Eisenhofer, 2001).  Unlike the neuronal monoamine transporters which 
regulate synaptic levels of monoamines, extraneuronal transporters play a 
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key role in clearance of monoamines from the blood stream.  In general, 
neuronal reuptake is quantitatively more important than extraneuronal uptake 
for clearance of neuronally released catecholamines but the clearance of 
circulating catecholamines is mainly by non-neuronal mechanisms 
(Eisenhofer, 2001).  
 
Neuronal metabolism of recaptured catecholamines is by oxidative 
deamination catalysed by monoamine oxidase (MAO) or by re-packing in 
vesicles in order to be available for re-release.  Vesicular monoamine 
transporters (VMAT1 and VMAT2) mediate the accumulation of monoamines 
into vesicles (Peter et al., 1995).  In extraneuronal tissue, subsequent 
metabolism of catecholamines following transport uptake involves MAO and 
catechols-O-methyltransferase (COMT), as well as sulfation processes.  
 
Oxidative deamination is performed by MAO, an integral protein of the outer 
mitochondrial membrane (Greenawalt and Schnaitman, 1970) which consists 
of two isoenzymes, MAO-A and MAO-B (Billett, 2004) which are encoded by 
different genes (Bach et al., 1988; Grimsby et al., 1991), have different 
substrate preferences (Billett, 2004), and tissue and cell distributions 
(Boulton and Eisenhofer, 1998).  MAO-A oxidises serotonin (5-
hydroxytryptamine) and NE preferentially, whereas MAO-B oxidises 
phenylethylamine preferentially in normal physiological conditions (Billett, 
2004).  In humans, MAO-A is found in the highest concentration in the liver, 
lung and intestine whereas MAO-B is predominant in the brain and liver 
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(Boulton and Eisenhofer, 1998).  MAO is the only metabolising enzyme 
present in catecholaminergic neurons (Boulton and Eisenhofer, 1998). 
 
Oxidative deamination of catecholamines involves a two-step reaction where 
MAO catalyses the first step, deaminating DA to 3,4-
dihydroxyphenylacetaldehyde (DOPAL) and NE and EPI to 3,4-
dihydroxyphenylglycolaldehyde (DOPEGAL) (Eisenhofer et al., 2004, Figure 
1.2).  DOPAL and DOPEGAL are further metabolised by aldehyde 
dehydrogenase to DOPAC and 3,4-dihydroxymandelic acid (DHMA) 
respectively.  Alternatively DOPAL and DOPEGAL can be metabolised by 
aldehyde reductase to 3,4-dihydroxyphenylethanol (DOPET) and DHPG  
respectively (Figure 1.2).  
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Figure 1.2: Pathways of oxidative deamination of catecholamines 
(Adapted from Eisenhofer et al., 2004 with permission).    
 
 
 
DβH dopamine β-hydroxylase, PNMT phenolethanolamine-N-methyltransferase, AR 
aldose or aldehyde reductase, AD aldehyde dehydrogenase  
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COMT catalyses the O-methylation of the 3-hydroxyl group of most catechols 
in extraneuronal tissue (Goldstein et al., 2003).  In the presence of COMT, 
the substrates of L-DOPA, DA, NE and EPI are converted to 3-
methoxytyrosine, 3-methoxytyramine, normetanephrine and metanephrine 
respectively (Eisenhofer et al., 2001, Figure 1.1).  COMT is expressed in 
high concentrations in liver, kidney, extraneuronal cells and adrenomedullary 
chromaffin cells (Eisenhofer et al., 1998).  
 
Sulfoconjugation represents an important protective mechanism for 
inactivating catecholamines, so protecting the body from the adverse effects 
of excess catecholamines (Boulton and Eisenhofer, 1998).  Catecholamines 
in humans and higher primates, in contrast to other animals, circulate mainly 
(up to 99%) in the sulfoconjugated forms (Dousa and Tyce, 1988; Eisenhofer 
et al., 1999).  Sulfoconjugation is catalysed by members of the 
sulfotransferase (SULT) enzyme family, which to date comprises at least 12 
isoforms in human tissues (Coughtrie, 2002).  The SULT1 and SULT2 
families are the largest and probably the most important for endobiotic and 
xenobiotic metabolism (Coughtrie, 2002).  Sulfoconjugation of 
catecholamines is catalysed by SULT1A3 (Richard et al., 2001).   
 
SULT1A3 is widely expressed in the human fetus but the adrenal and thyroid 
glands have little or no enzyme activity (Stanley et al., 2005).  Early in fetal 
life, SULT1A3 is expressed at high levels in liver but this decreases 
significantly in the late fetal-early neonatal period (Richard et al., 2001).  In 
contrast, the enzyme SULT1A3 is essentially absent in adult human liver 
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(Richard et al., 2001).  Developing liver haematopoietic cells have 
substantial expression of SULT1A3 (Richard et al., 2001).  In human fetal 
brain, SULT1A3 activity is low and widespread in various brain regions 
(Stanley et al., 2005).  SULT1A3 is expressed at high levels in placenta from 
13 weeks gestation with no significant developmental change to term, and in 
general activities are higher in the villous than membranous tissues (Stanley 
et al., 2001).  
 
1.4 AIM OF THESIS 
At present there is little information about the normal hormonal and 
metabolic profiles in term and preterm infants at the time of delivery.  Work 
that exists has focussed on single or small combinations of hormones which 
can create a very misleading picture. The developmental deficiencies 
described predominantly in preterm, but also in some term infants, in the 
failures of expression of the postnatal hepatic G-6-Pase system suggest that 
there are deficiencies in the mechanism to switch on this key enzyme of 
gluconeogenesis at the time of birth.  The evidence for hormonal regulation 
of this enzyme system in animal studies, in adult humans, and in studies of 
cell lines make the possibility of failure of hormonal control around the time of 
birth an important hypothesis to test. Before this can be done, however, 
comprehensive studies of perinatal metabolism and its hormonal control 
need to be undertaken. The aim of this thesis is to describe comprehensively 
the hormonal and metabolic profiles of term infants delivered by elective 
caesarean section.   
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1.4.1 Objectives 
1. To quantify the proportion of term infants who are hypoglycaemic at birth. 
2. To describe the hormonal and metabolic responses in the regulation of 
blood glucose levels in infants delivered by elective caesarean section. 
3. To describe the relationship between maternal and infant glucose status 
at delivery. 
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CHAPTER 2 
PILOT STUDY 1: GLUCOSE AND LACTATE LEVELS IN CORD 
BLOOD SAMPLES ROUTINELY COLLECTED AT DELIVERY 
FOR ESTIMATION OF BLOOD GAS AND ACID-BASE STATUS 
IN TERM INFANTS 
 
2.1 INTRODUCTION 
The aim of the first pilot study was to determine the incidence of 
hypoglycaemia in infants at delivery and to identify any antenatal or 
intrapartum factors associated with hypoglycaemia.  Since 1994, sampling of 
umbilical arterial and venous cord blood for blood gas and acid-base status 
has been routine practice for all deliveries in Ninewells Hospital and Medical 
School, Dundee.  It was decided to use this established practice to 
determine the incidence of hypoglycaemia in term infants and to identify any 
antenatal or intrapartum factors which might be associated with 
hypoglycaemia.  As described previously (see Chapter 1 pages 4-10) the 
definition of what constitutes hypoglycaemic blood glucose levels in infants 
remains contentious, but as evidence to support a level higher than 2.6 
mmol/l is lacking, hypoglycaemia was pre-defined as a blood glucose 
concentration less than 2.6 mmol/l. 
  
37 
2.2 METHODS 
2.2.1 Mothers and infants 
Three hundred and ninety nine infants between 37 and 42 weeks gestation 
who were delivered in Ninewells Hospital and Medical School, Dundee were 
recruited from April to July 2003.  The study population of Dundee is stable 
with a reported 92.45% of the population staying in the same area according 
to the 2001 census (General Register Office for Scotland, 2003).  Dundee 
has a very small ethnic minority population; the majority of the population is 
white (96.34%) and the remainder: Indian, Pakistani and other South Asian, 
Chinese and others (General Register Office for Scotland, 2003).  About 
80% of pregnant women living in Tayside deliver in Ninewells Hospital, 
Dundee and this study aimed to recruit a consecutive sample of eligible 
pregnant women.  Exclusion criteria were known Hepatitis B, Hepatitis C or 
HIV positivity, or if the mother was unable to provide informed consent.   
 
Mothers were given the Study Information Sheets by a midwife (see 
Appendix pages 144-145) when they were admitted to the labour ward.  All 
mothers had a period of at least 24 hours before a decision regarding 
consent was sought; written informed consent was obtained for all 
participants.  The study was approved by the Tayside Committee on Medical 
Research Ethics (Ref: 033/04).  If mothers agreed to participate, they were 
asked to allow an extra sample of blood to be taken at the time of the routine 
blood gas and acid-base status measurements of their infant and to allow 
data to be abstracted from their medical records.  If it was not possible to 
obtain consent before delivery, the extra blood sample could be obtained 
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after delivery but before it was analysed for lactate and glucose levels.  
Samples would be discarded if the mothers declined to participate.  
 
2.2.2 Blood sample collection 
The midwife who primarily looked after the mother in labour collected cord 
arterial and venous blood for measurement of blood gas levels and acid- 
base status.  Blood gas levels and acid-base status were analysed in an AVL 
OMNI Modular System blood gas analyser (Roche Diagnostics GmbH, Graz, 
Austria) which is located in the labour ward and serviced by the Department 
of Biochemical Medicine, Ninewells Hospital and Medical School as part of 
the UK national accreditation scheme.  
 
 At the same time of this routine clinical practice, an additional 
(approximately) five ml of blood was taken by the midwife from the umbilical 
vein using a 19 gauge needle (Hospira, Lake Forest, USA) for glucose and 
lactate measurements.  The method of sample collection was not 
standardised on the ward and could be from either a single or double 
clamped cord.  The blood sample was collected into a fluoride-oxalate tube 
and stored in a fridge for a maximum of 12 hours. The blood sample was 
sent for analysis of glucose and lactate levels in the Department of 
Biochemical Medicine, Ninewells Hospital and Medical School.  
 
2.2.3 Data collection 
There is limited information about the antenatal, intrapartum or postpartum 
factors which affect fetal glucose homeostasis.  Therefore, a range of 
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epidemiological data was abstracted from the case notes about maternal 
health, labour, delivery and infant characteristics.  Extensive antenatal data 
of the women were collected which included age and smoking history; 
booking height and weight, and delivery weight; presence of disease 
including: antepartum haemorrhage, asthma, epilepsy, thyroid disease, 
diabetes, hypertension, treated genito-urinary and vaginal infection (in the 
week before delivery); antenatal medications such as tocolytic, 
anticonvulsant, antihypertensive and corticosteroid usage.  Body mass index 
(BMI) was calculated for each woman using booking weight and height.  
Extensive labour details were collected including multiple birth, time of onset 
of labour, use of oxytocin, mode of delivery, drugs and fluid received during 
labour, analgesia, duration of labour; Apgar scores at one and five minutes, 
mode of resuscitation (facial oxygen, intermittent positive pressure ventilation 
by mask or tube and drugs) and placental weight.  Infant characteristics 
collected included occipital frontal circumference (OFC), length, gender, birth 
weight and birth weight ratio.  Birth-weight ratios were calculated for each 
infant using reference values (denominator) obtained from the Scottish 
Morbidity Record SMR2 (supplied by the Information and Statistics Division 
of the Common Services Agency, Edinburgh).  The denominator was the 
mean weight for each week of gestation for all infants born in Scotland from 
1987 to 1998 (See Appendix X for a copy of the Data Abstraction Form).  
 
2.2.4 Data handling and Statistical analyses 
All data were entered into Epi Info™ version 3.4.3 by an experienced data 
manager, doubled checked, and verified.  Any discrepancies were identified, 
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checked and rectified as appropriate.  Data were exported from Epi Info™ to 
SPSS version 14 statistical software for analysis.  The association of 
maternal and infant antenatal, intrapartum and postpartum factors with infant 
hypoglycaemia (glucose levels less than 2.6 mmol/l) in venous cord blood 
samples were determined using the Student’s two tailed t-test for continuous 
variables and the Fisher exact test for categorical variables.  Means and 
standard deviations (SD) of glucose, lactate, pH, pO2, pCO2, bicarbonate 
(cHCO3) and base excess (BE) levels were calculated for each mode of 
delivery (spontaneous vaginal delivery, vaginal breech, operative vaginal 
delivery, emergency caesarean section and elective caesarean section)  
 
Further detailed analysis was carried out using univariate general linear 
modelling; the dependent factors were cord blood glucose, lactate, pH, pO2, 
pCO2, cHCO3 and BE levels and the independent factors were type of 
delivery with spontaneous vaginal delivery group as the referent category. 
 
2.2.5 Biochemical Analysis 
2.2.5.1 Glucose (mmol/l) 
Plasma glucose was measured using a Roche Gluco-quant kit (Roche 
Diagnostics GmbH, Mannheim, Germany) on a Roche Modular Serum Work 
Area Analyser (Roche Diagnostics GmbH, Mannheim, Germany) in the 
Department of Biochemical Medicine, Ninewells Hospital and Medical 
School, Dundee.  The venous cord blood sample was collected into a 
fluoride-oxalate tube and stored in a fridge until onward transport to the 
Department of Biochemical Medicine, Ninewells Hospital and Medical 
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School, Dundee for analysis.  The assay uses hexokinase (yeast) to catalyze 
the phosphorylation of glucose to G-6-P by adenosine triphosphate (ATP), 
which is converted to adenosine diphosphate (ADP). Glucose-6-phosphate 
dehydrogenase (G-6-PDH) then oxidises G-6-P in the presence of 
nicotinamide adenine dinucleotide (NADP) to gluconate-6-phosphate 
(gluconate-6-P).  The reaction is specific for glucose and no other 
carbohydrate is oxidised.  The rate of reduced nicotinamide adenine 
dinucleotide phosphate (NADPH) formation during the reaction is directly 
proportional to the glucose concentration and can be measured 
photometrically at 340nm.         
 
Hexokinase 
Glucose + ATP     G-6-P + ADP 
   G-6-PDH 
G-6-P + NADP+                   Gluconate-6-P + NADPH + H+  
 
The assay measures glucose concentrations between 0.11 and 41.6 mmol/l 
and has an inter-assay coefficient of variation of 1.33%.  
 
2.2.5.2 Lactate (mmol/l) 
Plasma lactate was also measured based on an enzymatic method using a 
Cobas Lactate kit (Roche Diagnostics GmbH, Mannheim, Germany) on a 
Roche Modular Serum Work Area Analyser (Roche Diagnostics GmbH, 
Mannheim, Germany), in the Department of Biochemical Medicine, Ninewells 
Hospital and Medical School, Dundee.  L-lactate is oxidised to pyruvate by 
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the specific enzyme lactate oxidase with the production of stoichiometric 
amounts of hydrogen peroxide.  Horseradish peroxidase is used to generate 
a coloured dye using the hydrogen peroxide generated in the first reaction.  
4-aminophenazone (4-APP) as a colour coupler with sulphonated 2,4-
dichlorophenol (2,4-DCP) is used to determine the amount of hydrogen 
peroxide produced.  The intensity of the colour formed is proportional to the 
L-lactate concentration and is measured as an endpoint reaction at 658 nm.         
 
                              Lactate oxidase 
Lactate + O2      pyruvate + H2O2 
 
       Horseradish peroxidase  
H2O2 + 4-APP + 2,4-DCP                              chromagen+ + 2H20 
 
The venous cord blood was collected into a fluoride-oxalate tube.  The assay 
measures lactate concentrations between 0.2 and 15.5 mmol/l and has an 
inter-assay coefficient of variation of 1.7%. 
 
2.2.5.3 Blood gas and acid-base profiles 
Blood gas and acid-base analysis (pH, pO2, pCO2, cHCO3, and BE) were 
performed on an AVL OMNI Modular System blood gas analyzer (Roche 
Diagnostics GmbH, Mannheim, Germany).  The OMNI uses a new 
generation of sensors and a patented liquid calibration system for blood 
gases, acid-base status and electrolyte estimations.  The advantage of these 
new sensors is that they use generally proven principles and technologies 
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but implement these principles in a way that the sample volume needed is 
exceedingly low.  After each procedure, the analyser undergoes an 
automatic self cleaning process.  Three levels of auto-calibration takes place 
every hour, 12 hours and 24 hours.  Staff from the Department of 
Biochemical Medicine, Ninewells Hospital and Medical School carry out 
quality control checks daily and preventative maintenance services twice 
weekly.  The blood gas analyser is also monitored in an external UK quality 
assurance scheme.  The inter-assay coefficient of variation for pH, pO2 and 
pCO2  were 0.20%, 9.84% and 4.24% respectively. 
 
2.3 RESULTS 
Three hundred and ninety nine term infants were recruited; 11.3% (45) were 
hypoglycaemic at delivery with a cord venous blood glucose levels less than 
2.6 mmol/l.  Only one maternal antenatal factor distinguished infants who 
were hypoglycaemic from normoglycaemic; mothers of hypoglycaemic 
infants were slightly older than mothers whose infants were normoglycaemic 
(p=0.024, Table 2.1). 
 
During the intrapartum period, more events distinguished hypoglycaemic 
from normoglycaemic infants.  Elective caesarean section increased the 
likelihood of being hypoglycaemic almost sixfold (OR 5.59, p<0.001).  The 
use of epidural or spinal analgesia in the women during labour and delivery 
doubled the likelihood of the infant being hypoglycaemic (OR 2.03, p=0.039).  
In contrast, opiate use in labour and delivery appeared to have a ‘protective’ 
effect with an odds ratio of 0.27 (p=0.001) in the hypoglycaemic group 
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compared to the normoglycaemic group (Table 2.2).  Normoglycaemic 
infants experienced a significantly longer first (p=0.001) and second 
(p=0.005) stages of labour compared to hypoglycaemic infants (Table 2.2). 
 
Seven postpartum factors distinguished hypoglycaemic from 
normoglycaemic infants (Table 2.3).  Multiple birth was associated with an 
increased likelihood of hypoglycaemia in the infants (OR 6.3, p=0.002, Table 
2.3).  Hypoglycaemic infants had significantly lower umbilical cord venous 
pO2 (p=0.004), but higher umbilical cord arterial pH (p=0.005), umbilical cord 
arterial and venous BE (p<0.001, p=0.003 respectively), umbilical cord 
arterial and umbilical cord venous cHCO3 (p=0.001, p=0.004 respectively) 
compared to the normoglycaemic infants (Table 2.3).  The mean birth weight 
was also significantly lower in the hypoglycaemic group compared to the 
normoglycaemic group (3365g v 3526g, p=0.224, Table 2.3).   
 
Cord glucose, lactate, pH, pO2, pCO2, cHCO3 and BE levels varied 
significantly according to the type of delivery (Table 2.4).  Infants delivered 
by elective caesarean section had the lowest mean levels of glucose (2.73 
mmol/l) and lactate (3.37 mmol/l) amongst the five groups of delivery (Table 
3.4).  This group of infants also had the highest cord arterial pH (7.28) and 
cord arterial BE (-3.43 mmol/l) levels (Table 2.4).  By contrast infants 
delivered by operative vaginal delivery had the highest mean levels of 
glucose (4.2 mmol/l) and lactate (6.08 mmol/l) (Table 2.4).  Compared to 
spontaneous vaginal deliveries, infants delivered by elective caesarean 
section had significantly lower mean levels of glucose (-1.26 mmol/l), lactate 
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(-1.97 mmol/l) and cord arterial pO2 (-0.57 kPa); and significantly higher 
levels of cord arterial pCO2 (+0.59 kPa), cord venous pCO2 (+0.55 kPa), cord 
arterial BE (-2.51 mmol/l), cord venous BE (-1.54 mmol/l) cord arterial cHCO3 
(+2.55 mmol/l) and cord venous cHCO3 (+1.93 mmol/l) (Table 2.4).
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Table 2.1: Association of maternal antenatal factors with infant hypoglycaemia (glucose levels less than  
2.6 mmol/l) in venous cord blood samples  
 
 Hypoglycaemic infants 
Mean ± SD (n) or N % 
Normoglycaemic infants 
Mean ± SD (n) or N % 
Test statistic 
t-statistic (t) or  Odds ratio (95% CI) 
p  value# 
Maternal age, years 30.93 ± 6.12 (45) 28.69 ± 6.67 (353) t=2.29 0.024* 
Maternal BMI 26.20 ± 4.54 (42) 25.44 ± 5.16 (323) t=1.00 0.322 
Maternal smokers  13/104, 12.5%  91/104, 87.5%  OR=1.16 (0.582, 2.299) 0.733 
Antenatal events:     
 Antepartum haemorrhage  2/32,  6.3%  30/32, 93.7%  OR=0.52 (0.120, 2.259) 0.586 
 Asthma  3/40, 7.5%  37/40, 92.5%  OR=0.61 (0.180, 2.066) 0.620 
 Epilepsy  2/8, 25.0%  6/8, 75.0%  OR=2.69 (0.526, 13.750) 0.451 
 Thyroid disease  2/10, 20.0%  8/10, 80.0%  OR=2.02 (0.415, 9.809) 0.630 
 Diabetes  0/4, 0%  4/4, 100%  - - 
 Hyperemesis gravidarum  2/13, 4.4%  11/13, 84.6%  OR=1.43 (0.307,  6.684) 0.896 
 Tractocile treatment  0/1, 0%  1/1, 100%  - - 
 Nifedipine treatment  2/4, 50.0%  2/4, 50.0%  OR=8.16 (1.121,  59.430) 0.130 
 Betamethasone injection  4/16, 25.0%  12/16, 75.0%  OR=2.77 (0.855,  8.995) 0.188 
 Hypertension  4/24, 16.7%  20/24, 83.3%  OR=1.63 (0.531,  5.000) 0.560 
 Treated UTI  0/3, 0%  3/3, 100%  - - 
 Treated vaginal discharge  1/3, 33.3%  2/3, 66.7%  OR=3.99 (0.354,  44.890) 0.606 
 
BMI body mass index, OR odd ratio, UTI urinary tract infection 
# Student t- test or Fisher-exact test  
Significant  * p< 0.05  
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Table 2.2: Association of maternal intrapartum factors with hypoglycaemia (glucose levels less than 2.6 
mmol/l) in venous cord blood samples  
 
 Hypoglycaemic infants 
Mean ± SD (n) or N % 
Normoglycaemic infants 
Mean ± SD (n) or N % 
Test statistic 
t-statistic (t) or Odds ratio 
(95% CI) 
p  value# 
Labour onset - spontaneous  19/243, 7.8%   224/243, 92.2%  OR=0.67 (0.326, 1.440) 0.318 
Labour augmented  7/94, 7.4% 87/94, 92.6%  OR=0.87 (0.371, 2.080) 0.968 
Type of delivery     
 Spontaneous vaginal delivery  24/255, 9.4% 231/255, 90.6% OR=0.61 (0.326, 1.137) 0.163 
 Vaginal breech  1/3, 33.3% 2/3, 66.7% OR=4.00 (0.355, 45.021) 0.605 
 Instrumental cephalic vaginal  3/65, 4.6% 62/65, 95.4% OR=0.34 (0.101, 1.120) 0.083 
 Emergency caesarean section  4/39, 10.3% 35/39, 89.7% OR=0.89 (0.301, 2.630) 1.080 
 Elective caesarean section 13/37, 35.1% 24/37, 64.9% OR=5.59 (2.596, 12.020) <0.001*** 
Type of analgesia received     
 None received  2/24, 8.3%  22/24, 91.7%  OR=0.70 (0.159, 3.080) 0.950 
 Entonox  28/292, 9.6%  264/292, 90.4%  OR=0.55 (0.290, 1.062) 0.112 
 General anaesthesia  0/3, 0%  3/3, 100%  - - 
 Epidural/spinal  27/178, 15.2%  150/178, 84.3%  OR=2.03 (1.078, 3.821) 0.039* 
 Opiate  7/149, 4.7%  142/149, 95.3%  OR=0.27 (0.119, 0.630) 0.001** 
Duration of first stage mins 256.93 ± 279.57 (45) 417.31 ± 386.99 (354) t=-3.45 0.001** 
Duration of second stage mins 28.89 ± 55.65 (45) 54.68 ± 62.91 (352) t=-2.88 0.005** 
Duration of membrane ruptured mins 525.44 ± 966.43 (45) 463.46 ± 634.15 (352) t=0.42 0.677 
OR odd ratio  
 # Student t-test or Fisher-exact test 
Significant  * p< 0.05,  ** p< 0.01,  *** p< 0.001 
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Table 2.3: Association of infant factors with hypoglycaemia (glucose levels less than 2.6 mmol/l) in venous 
cord blood samples 
 
 Hypoglycaemic infants 
Mean ± SD (n) or  N % 
Normoglycaemic infants 
Mean ± SD (n) or N % 
Test statistic 
t-statistic (t) or Odds ratio (95% CI) 
p  value# 
Male infant  19/191, 10.0%  172/191, 90.0%  OR=0.77 (0.408, 1.432) 0.497 
Multiple births  7/17, 41.2%  10/17, 58.8%  OR=6.30 (2.266, 17.510) 0.002** 
Apgar score < 3 at 1 min  0/45, 0%  0/352, 0%  - - 
Apgar score < 7 at 5 min  0/45, 0%  0/353, 0%  - - 
Cord blood arterial pH  7.28 ± 0.06  7.25 ± 0.01 (336) t=2.05 0.005** 
Cord blood venous pH 7.31 ± 0.06  7.31 ± 0.08 (262) t=0.51 0.610 
Cord blood arterial BE  -4.21 ± 2.21 (43) -6.01 ± 2.98 (336) t=4.81 <0.001*** 
Cord blood venous BE  -3.95 ± 1.84 (27) -5.17 ± 2.50 (262) t=3.16 0.003** 
Cord blood arterial pO2 kPa 3.03 ± 1.40 (42) 2.95 ± 1.13 (331) t=0.36 0.723 
Cord blood venous pO2 kPa 3.31 ± 0.94 (27) 4.10 ± 3.15 (258) t=-2.96 0.004** 
Cord blood arterial pCO2 kPa 6.67 ± 1.18 (43) 6.86 ± 1.70 (336) t=-0.97 0.333 
Cord blood venous pCO2 kPa 5.99 ± 1.26 (27) 5.75 ± 1.21 (262) t=0.93 0.359 
Cord blood arterial cHCO3 mmol/l 22.89 ± 2.19 (43) 21.62 ± 2.65 (335) t=3.50 0.001** 
Cord blood venous cHCO3 mmol/l 22.18 ± 2.17 (27) 20.84 ± 2.17 (262) t=3.07 0.004** 
Neonatal resuscitation  4/29, 13.8%  25/29, 86.2%  OR=1.28 (0.423, 3.850) 0.844 
Infant birth weight grams 3365.44±669.25 (45) 3526.06 ± 1613.31 (354) t=-1.22 0.224 
Infant birth weight ratio 1.01 ± 0.15 (44) 1.00 ± 0.13 (352) t=0.41 0.686 
Infant OFC cm 34.52 ± 1.53 (45) 34.84 ± 1.62 (354) t=-1.30 0.198 
Infant birth length cm 49.06 ± 2.75 (45) 49.48 ± 2.36 (354) t=-0.97 0.336 
BE base excess, cHCO3 bicarbonate, OFC occipital-frontal head circumference, OR odd ratio 
# Student t-test or Fisher-exact test 
Significant  ** p < 0.01, *** p<0.001 
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Table 2.4: The relationship of mode of delivery and levels of cord blood glucose, lactate, pH, pO2, pCO2, 
bicarbonate and base excess 
 
 Spontaneous 
vaginal delivery 
Mean ± SD (n) 
Vaginal breech 
 
Mean ± SD (n) 
Operative Vaginal 
delivery 
Mean ± SD (n) 
Emergency 
caesarean section 
Mean ± SD (n) 
Elective caesarean 
section 
Mean ± SD (n) 
Glucose mmol/l 3.99 ± 1.17 (254) 3.83 ± 2.14 (3) 4.2 ± 1.04 (65) 3.64 ± 1.04 (39) 2.73 ± 0.60 (36)*** 
Lactate mmol/l 5.34 ± 1.75 (253) 5.60 ± 0.85 (3) 6.08 ± 2.49 (65)** 5.06 ± 2.76 (39) 3.37 ± 1.32 (35)*** 
Cord blood arterial pH  7.26 ± 0.10 (239) 7.16 ± 0.14 (3) 7.23 ± 0.09 (65)* 7.23 ± 0.11 (36) 7.28 ± 0.09 (36) 
Cord blood venous pH 7.32 ± 0.07 (180) 7.27 ± 0.09 (2) 7.27 ± 0.08 (47)*** 7.27 ± 0.10 (32) 7.32 ± 0.06 (28) 
Cord blood arterial BE mmol/l -5.94 ± 2.76 (239) -5.73 ± 1.66 (3) -6.70 ± 2.86 (65) -5.7 ± 3.89 (36) -3.43 ± 2.20 (36)*** 
Cord blood venous BE mmol/l -4.91 ± 2.11 (180) -5.8 ± 0.14 (2) -6.19 ± 2.73 (47)*** -5.6 ± 3.45 (32) -3.37 ± 1.92 (28)** 
Cord blood arterial pO2 kPa 3.14 ± 1.14 (235) 2.69 ± 1.09 (3) 2.94 ± 1.21 (64) 2.19 ± 0.84 (35)*** 2.57 ± 1.18 (36)** 
Cord blood venous pO2 kPa 4.40 ± 3.69 (178) 4.58 ± 2.16 (2) 3.56 ± 0.99 (46) 2.89 ± 0.93 (31)* 3.60 ± 1.00 (28) 
Cord blood arterial pCO2 kPa 6.63 ± 1.64 (239)** 9.62 ± 4.12 (3)** 7.07 ± 1.69 (65) 7.23 ± 1.53 (36)* 7.22 ± 1.08 (36)* 
Cord blood venous pCO2 kPa 5.50 ± 1.07 (180) 6.42 ± 2.11 (2) 6.13 ± 1.28 (47) 6.49 ± 1.58 (32)*** 6.05 ± 0.95 (28)* 
Cord blood arterial cHCO3 mmol/l 21.47 ± 2.51 (238) 24.33 ± 3.50 (3) 21.16 ± 2.65 (65) 22.31 ± 2.39 (36) 24.02 ± 2.29 (36)*** 
Cord blood venous cHCO3 mmol/l 20.70 ± 2.08 (180) 21.2 ± 2.69 (2) 20.61 ± 2.29 (47) 21.47 ± 2.15 (32) 22.63 ± 2.19 (28)*** 
 
 
Spontaneous vaginal delivery is the reference category 
Significant  * p<0.05, ** p<0.01, *** p<0.001
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2.4 COMMENTARY  
Compared to other modes of delivery, infants delivered by elective caesarean 
section had the highest pH and BE but lowest glucose and lactate levels (Table 
2.4).  Similar results for pH and BE levels in infants delivered by elective 
caesarean section have been reported in other studies (Suidan et al., 1984; 
Nodwell et al., 2005).  It has been suggested that the umbilical cord gases of 
infants delivered by caesarean section, without labour, results in values more 
closely approximating adult blood gas levels and acid-base status (Johnson et 
al., 1990).  In terms of fetal metabolic and hormonal responses to mode of 
delivery, infants delivered by elective caesarean section have the lowest lactate 
(Suidan et al., 1984; Shirey et al., 1996), cortisol (Mears et al., 2004; Vogl et al., 
2006), EPI and NE levels (Irestedt et al., 1982; Wang et al., 1999) compared to 
other mode of deliveries.  It could be argued that infants delivered by elective 
caesarean section were in the most ‘stress-free’ environment compared to other 
modes of delivery.  Following this argument, it appears contradictory that the 
incidence of hypoglycaemia was higher in infants delivered by elective 
caesarean section than in those delivered by emergency caesarean section or 
spontaneous vaginal delivery (Table 2.2).   
 
These contradictory results raised the question of the validity of the results, with 
the possibility that the glucose levels might have changed significantly with time.  
There is clear evidence from the literature that cord blood gas levels and acid-
base status change with time post-delivery (Sykes and Molloy, 1984; Duerbeck 
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et al., 1992; Armstrong and Stenson, 2006; Lynn and Beeby, 2007); but there is 
a paucity of evidence on levels of other blood sample constituents – such as 
lactate and glucose.  Currently, there is limited evidence about the changes in 
cord blood lactate levels with time post-delivery (Armstrong and Stenson, 2006), 
and there are no comparable studies on blood glucose, which is the likely major 
precursor for cord blood lactate generation subsequent to delivery.  
 
This rationale led to a further pilot study (pilot study 2) which was designed to 
investigate the changes with time after delivery in umbilical cord blood levels of 
glucose, lactate, pH, pO2, pCO2, cHCO3 and BE. 
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 CHAPTER 3 
PILOT STUDY 2: MEASURING CHANGES IN VENOUS CORD 
BLOOD GLUCOSE, LACTATE, pH, pO2, pCO2, BICARBONATE 
AND BASE EXCESS VALUES WITH TIME  
FOLLOWING DELIVERY 
 
3.1 INTRODUCTION 
The purpose of this study was to measure the change in venous cord blood 
glucose, lactate, pH, pO2, pCO2, cHCO3 and BE values post-delivery.  Previous 
work in this area has used fairly wide time intervals and ranged from 20 to 30 
minutes (e.g. Armstrong and Stenson, 2006; Lynn & Beeby, 2007) and it is 
possible that the time taken for levels to reduce significantly was obscured.  To 
provide a finer detail of information, we decided to monitor the changes in levels 
at eight points during the first 62 minutes post-delivery. 
 
3.2 METHODS 
3.2.1 Mothers and infants 
Twenty-two women who had an elective caesarean section for a singleton 
pregnancy at term (37 to 42 weeks) in Ninewells Hospital and Medical School, 
Dundee were recruited over a five month period from May to September 2005.  
All women had an uneventful antenatal period.  Gestational age was calculated 
using the dating ultrasound scan taken in the first trimester.  Exclusion criteria 
were known Hepatitis B, Hepatitis C or HIV positivity, placenta praevia, or if the 
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mother was unable to provide informed consent.  Women who had placenta 
praevia were excluded in this study because of the difficulty in obtaining a 
sufficient volume of blood for analysis.  All women fasted for at least six hours 
prior to their caesarean section.  
 
Eligible women were identified by looking through the Labour Suite work diary.  
Once identified, a letter inviting the woman to join the study was sent out at least 
one week before their elective caesarean section date.  Recruitment and 
consent were obtained in the morning of the day the woman was admitted for 
delivery.  All women had a period of at least 24 hours before making a decision 
about participation in the study.  In all cases written informed consent was 
obtained. The study was approved by the Tayside Committee on Medical 
Research Ethics (Ref: 033/04). 
 
3.2.2 Blood sample collection 
Cord blood samples for measurement of glucose, lactate and blood gas levels, 
and acid-base status were obtained by me from the umbilical vein at the 
placental cord insertion i.e. single clamped samples using a 19 gauge Butterfly 
needle (Hospira, Lake Forest, USA) at 2, 7, 12, 22, 32, 42, 52, and 62 minutes 
after delivery of infants.  Post-delivery placentas were placed in an open 
container, at room temperature, during the blood sampling period.  Venous 
blood samples were collected into one ml heparinised plastic syringes (BD 
Diagnostics, Plymouth, UK) for blood gas estimations and into fluoride–oxalate 
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tubes for glucose and lactate determinations.  Blood gases were analysed 
immediately on sampling in an AVL OMNI Modular System blood gas analyser 
(Roche Diagnostics GmbH, Graz, Austria) in the labour ward whereas blood 
samples in fluoride-oxalate tubes for glucose and lactate levels were batched 
and sent to the Department of Biochemical Medicine, Ninewells Hospital and 
Medical School, Dundee for analysis at the end of an hour’s study.  
 
3.2.3 Statistical analyses 
Data were entered into a Microsoft Excel XP spreadsheet, checked and verified 
before use.  The analysis was carried out using Microsoft Excel XP.  Means and 
SD values were calculated for venous cord blood glucose, lactate, pH, pO2, 
pCO2, cHCO3 and BE values at 2, 7, 12, 22, 32, 42, 52, and 62 minutes after 
delivery.  The relative temporal changes in venous cord blood glucose, lactate, 
pH, pO2, pCO2, cHCO3 and BE values following delivery compared to baseline 
levels were determined using the Student’s two tailed t-test.  Baseline levels was 
the first cord blood sample which was taken at two minutes post-delivery of the 
infant and which allowed time for delivery of the placenta. 
 
3.2.4 Biochemical Analysis 
3.2.4.1 Glucose 
The glucose analysis was identical to that of the first pilot study (see page 40-41 
for details). 
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3.2.4.2 Lactate 
The lactate analysis was identical to that of the first pilot study (see pages 41-42 
for details). 
 
3.2.4.3 Blood gas and acid-base profiles 
The analysis of blood gas and acid-base status was identical to that of the first 
pilot study (see pages 42-43 for details). 
 
3.3 RESULTS 
During the 62 minutes after delivery, there were considerable changes in venous 
cord blood glucose, lactate, pH, pO2, pCO2, cHCO3 and BE values in term 
infants delivered by elective caesarean section (Table 3.1, Figure 3.1).  Glucose 
levels decreased over time and were significantly lower at 12 minutes compared 
to the baseline levels at two minutes post-delivery of infants  (p<0.01).  There 
was a gradual increase in lactate levels which were significantly different from 
the baseline levels by seven minutes post-delivery of infants (p<0.001).  Cord 
venous pH (p<0.01)  and pO2 (p<0.01) values fell steadily over time and were 
significantly lower at seven minutes post-delivery of infants compared to the 
baseline values at two minutes.  The base excess decreased (more negative) 
significantly from seven minutes post-delivery of infants compared to the 
baseline values (p<0.001).  From 12 minutes post-delivery of infants, there were 
increaments in pCO2 tensions compared to baseline levels (p<0.01).  
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Table 3.1: Venous cord blood glucose, lactate, pH, pO2, pCO2, cHCO3 and BE values with time following 
delivery of infants by elective caesarean section 
 
Time 
(mins) 
Glucose 
(mmol/l) 
Mean±SD (n) 
Lactate  
(mmol/l) 
Mean±SD (n) 
pH 
 
Mean±SD (n) 
pO2 
(kPa) 
Mean±SD (n) 
pCO2 
(kPa) 
Mean±SD (n) 
cHCO3 
(mmol/l) 
Mean±SD (n) 
BE 
(mmol/l) 
Mean±SD (n) 
2 3.01±0.58 (21) 
 
2.09±0.40 (19) 7.35±0.03 (22) 2.61±0.71 (22) 6.17±0.66 (22) 24.97±1.49 (22) -0.98±1.11 (22) 
7 2.88±0.55 (21) 
 
2.46±0.53 (19)*** 7.34±0.03 (22)** 2.54±0.71 (22)** 6.32±0.76 (22) 24.93±1.62 (22) -1.26±1.09 (22)*** 
12 2.79±0.53 (21)** 
 
2.70±0.58 (19)*** 7.33±0.04 (22)** 2.33±0.68 (22)*** 6.55±1.03 (22)** 25.23±1.78 (22) -1.17±1.11 (22) 
17 2.69±0.57 (21)*** 
 
3.04±0.72 (19)*** 7.32±0.06 (22)** 2.22±0.72 (22)*** 6.77±1.27 (22)** 25.14±1.71 (22) -1.62±1.10 (22)** 
22 2.60±0.57 (20)*** 
 
3.27±0.67 (18)*** 7.30±0.07 (21)*** 2.17±0.70 (21)*** 7.13±1.45 (21)** 25.23±1.43 (22) -1.98±1.43 (21)*** 
32 2.42±0.80 (19)*** 
 
3.98±0.90 (17)*** 7.26±0.08 (20)*** 2.06±0.74 (20)*** 7.60±2.87(20)* 25.71±1.86 (22) -2.49±1.48 (20)*** 
42 2.14±0.64 (17)*** 
 
5.20±1.64 (15)*** 7.20±0.12 (18)*** 1.94±0.75 (18)*** 9.37±2.88 (18)*** 25.54±1.39 (18) -4.11±2.55 (18)*** 
52 2.04±0.93 (8)*** 
 
5.55±2.21 (6)** 7.17±0.14 (8)** 2.19±0.83 (8)*** 9.49±3.07 (8)* 24.33±1.35 (8) -5.68±3.76 (8)** 
62 1.78±0.59 (16)*** 
 
6.95±2.25 (14)*** 7.10±0.17 (16)*** 1.91±0.70 (16)*** 11.40±4.18 16)*** 24.45±2.05(16) -7.22±4.92 (16)*** 
cHCO3 bicarbonate, BE base excess 
* p< 0.05, **p<0.01, ***p<0.001 
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Figure 3.1: Venous cord blood glucose, lactate, pH, pO2, pCO2, cHCO3 and BE values with time following 
delivery of infants by elective caesarean section 
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3.4 COMMENTARY 
The importance of measuring umbilical cord blood gas to quantify the acid-
base status of infants at birth was first recognised by James and colleagues 
in 1958 (James et al., 1958).  It has since been widely accepted that 
measurement of umbilical cord gas and acid-base status gives an important 
measure of the infant’s condition at birth.  Many studies have investigated 
the influence of sampling site and time interval after delivery on umbilical 
cord blood gas levels and acid-base status (Sykes and Molloy, 1984; 
Duerbeck et al., 1992; Armstrong and Stenson, 2006; Lynn and Beeby, 
2007), but there is a paucity of evidence on how soon these occur post-
delivery, and of the modifications that might occur in levels of other blood 
sample constituents – such as lactate and glucose.  This pilot study is the 
first to report data on the change of glucose levels with time in umbilical cord 
blood post-delivery.   
 
During the 62 minutes after delivery, there were significant changes in 
venous cord blood glucose, lactate, pH, pO2, pCO2, cHCO3 and BE values 
with time.  For instance depending on the time lapse in analysing venous 
cord glucose levels, an infant might be categorised as normoglycaemic if 
sampled up to 21 minutes post-delivery, but had the sample analysis been 
delayed to 22 or more minutes, such an infant could be categorised as 
hypoglycaemic and in need of clinical management (Hume, 1998).  This 
novel observation of a temporal change in blood glucose levels post-delivery 
is perhaps not surprising given the extensive previous literature on 
increments of cord blood lactate levels in-situ in the cord and placenta post-
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delivery (Armstrong and Stenson, 2006; Lynn and Beeby, 2007).  The 
majority of circulating blood cells in the fetus at term are non-nucleated red 
blood cells without mitochondria and hence no capacity for aerobic 
glycolysis.  There may be minor contributions to aerobic glycolysis in the 
placenta and cord from nucleated red blood cells, white blood cells and 
platelets, as well as from endothelial lining cells, but the majority of blood 
glucose consumed will be metabolised to lactic acid and not carbon dioxide.  
This phenomenon of glucose consumption and lactate production in blood 
samples is well known and is the basis for the addition of fluoride-oxalate to 
inhibit glycolysis in blood samples in-transit to the laboratory.  The significant 
changes in reducing oxygen and increasing carbon dioxide levels suggest 
aerobic glycolysis but as the majority of circulating blood cells in the fetus at 
term are non-nucleated red blood cells without mitochondria there is 
therefore no capacity for aerobic glycolysis.  The likely explanation is due to 
the artefact of the model as successive blood sampling draws blood from the 
placenta. This is further supported by the result findings of Owen and 
colleagues who have shown no significant changes in pO2 and pCO2 levels 
from a double clamped umbilical vein over 30 minutes (Owen et al., 1995). 
 
There is limited evidence about the changes in cord blood lactate levels with 
time post-delivery.   In a recent study, Armstrong and Stenson showed that 
cord arterial and venous lactate levels from unclamped arteries (effectively 
single clamped) were significantly higher by 20 minutes post-delivery 
compared to baseline, but it is important to note that in their study the blood 
samples were taken at three 20 minute intervals (up to 60 minutes) post-
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delivery (Armstrong and Stenson, 2006).  The results of this current pilot 
study showed that cord venous blood lactate levels had changed significantly 
as early as seven minutes post-delivery; that the lactate level gradually 
increases with time, implies continuous anaerobic glycolysis in the blood 
cells trapped in the placenta.  It has also been shown that the lactate level 
increased significantly and within five minutes in a syringe blood sample 
stored at room temperature (Sinn et al., 2001).  In recent years, lactate 
measurements in cord or fetal scalp samples have been evaluated as a 
potential tool in the assessment of fetal status at birth as well as a measure 
of the degree of intrapartum hypoxia (Wiberg-Itzel et al., 2008) as blood 
lactate analysing devices only need five µl of blood as opposed to 30µl to 
50µl for blood gas analysis.  Furthermore, fetal scalp blood gas analysis has 
been reported to have a sampling failure rate of 20.6% as compared to 1.2% 
for lactate measurement (Westgren et al., 1998).  Lactate is the major 
component of metabolic acidosis which develops in the late stage of fetal 
hypoxia when there is an insufficient supply of oxygen.  Both animal (Milley, 
1988) and human studies (Piquard et al., 1991; Nordström et al., 2001) have 
suggested that umbilical cord blood lactate is predominantly fetal in origin but 
minor transfer from the mother to fetus cannot be excluded.  Umbilical cord 
blood lactate levels have been shown to correlate with the pH and BE 
(Gjerris et al., 2008).  
 
Several studies have investigated the influence of sampling site and time 
interval after delivery on umbilical cord blood gas levels and acid-base status 
(Sykes and Molloy, 1984; Duerbeck et al., 1992; Armstrong and Stenson, 
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2006; Lynn and Beeby, 2007).  From where the blood is drawn is important, 
as samples from a double or single clamped umbilical cord yield different 
results.  For example Lynn and Beeby found, in paired samples, that mean 
pH and BE levels were significantly lower in arterial bloods from double 
clamped cords at the time of delivery of the infant, compared to bloods from 
surface arteries of the subsequently delivered placenta and whose cords 
were effectively single clamped (Lynn and Beeby, 2007).  The cord arterial 
pH fell steadily and significantly from delivery levels (at 30, 60 and 90 
minutes) and pH levels from the placental surface artery also fell significantly 
over 90 minutes, but at twice the rate (Lynn and Beeby, 2007).  Armstrong 
and Stenson, in paired arterial samples, found that mean pH levels from 
‘unclamped’ umbilical cord samples were significantly higher than from 
clamped umbilical cord samples at delivery; but found no differences 
between paired mean venous pH levels in clamped or unclamped cord 
samples (Armstrong and Stenson, 2006).  (Unclamped was defined as from 
a vessel at the base of the cord that remained in continuity with the placenta 
and before the first clamp (Armstrong and Stenson, 2006).)   
 
The change over time of pH and BE levels in blood drawn from a single 
clamped umbilical artery compared to those from a double clamped umbilical 
artery appears to be inconsistently reported in the literature.  For instance, 
Lynn and Beeby found that the arterial pH and BE levels were significantly 
reduced at 30 minutes post-delivery in both the placental surface artery 
(effectively single clamped) and double clamped cord samples (Lynn and 
Beeby, 2007).  Whereas Armstrong and Stenson reported a significant 
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reduction in mean arterial pH at 40 minutes post-delivery in unclamped 
arteries (effectively single clamped) but no differences over 60 minutes in 
double clamped arteries (Armstrong and Stenson, 2006).  Significant 
changes in mean arterial BE levels were seen at 20 minutes post-delivery in 
unclamped arteries and in 40 minutes in double clamped arteries (Armstrong 
and Stenson, 2006).  
 
Results can also differ when cord blood samples are analysed from 
apparently comparable sites.  For instance, in studies which sampled from 
double clamped sections of cord, the arterial pH levels reduced significantly, 
though modestly, from delivery in 10 minutes (Paerregaard et al., 1987), in 
30 minutes (Lynn and Beeby, 2007),  and not at all (i.e. up to 60 minutes) 
(Armstrong and Stenson, 2006).  Mean BE levels in double clamped arterial 
cord samples showed no change over 30 minutes in one study (Paerregaard 
et al., 1987),  but a significant reduction at 30 minutes in a different study 
(Lynn and Beeby, 2007),  and also at 40 minutes (Armstrong and Stenson, 
2006).  In double clamped venous cord blood, significant reductions in pH 
levels were found at 10 minutes (Paerregaard et al., 1987), and at 40 minutes 
(Armstrong and Stenson, 2006).  In studies which sampled from single 
clamped cord (referred to variously as unclamped, placental artery or single 
clamped samples), arterial pH levels were significantly reduced from delivery 
by 30 minutes (Lynn and Beeby, 2007) and 40 minutes (Armstrong and 
Stenson, 2006).  Single clamped venous cord pH levels is less reported in 
the literature but in one study pH levels were significantly reduced from 
delivery at 40 minutes (Armstrong and Stenson, 2006).   In our study, which 
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also used venous samples from a single clamped umbilical cord, we found a 
significant change in pH and BE levels within seven minutes post-delivery.   
 
The reason(s) for the discrepancy in the time taken for the pH and BE levels 
to fall between studies is not clear.  Most of the studies were relatively small; 
the largest study had between 51-87 pairs of samples.  The sampling time 
intervals for pH and BE measurements, both from single and double clamped 
samples, were often too wide at 20 or 30 minute intervals, to allow accurate 
timing of changes in levels (e.g. Armstrong and Stenson, 2006; Lynn and 
Beeby, 2007).  Differences in the way samples are handled prior to sampling 
also may affect the rate of change in levels.  For example storing blood in 
heparinised syringes, on ice (i.e. 0oC) has been shown to prevent significant 
decreases in pH levels over 30 minutes; whereas there are significant albeit 
small decreases if stored at room temperature (Pel and Treffers, 1983).   
 
In Ninewells Hospital and Medical School, umbilical cord blood sampling 
post-delivery is normally carried out by the midwife who has cared for the 
mother, but immediate sampling sometimes may not be possible especially 
when a midwife’s attention is focused on resuscitation of the infant.  A normal 
metabolic status at delivery, as assessed by cord blood sample estimations 
of pH, BE and lactate levels, can rapidly become classified as abnormal 
simply as a result of delayed blood sampling and/or delayed sample 
analysis.  These conclusions are very relevant to the metabolic and 
hormonal studies planned for this study and underline the importance of the 
need for as rapid as possible blood sampling.  It is possible, therefore, in the 
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first pilot study in the series reported here that there may have been delays 
in collection and/or analysis of the cord blood samples which resulted in 
glucose consumption and hence giving an artefactually high incidence of 
hypoglycaemia in infants delivered by elective caesarean section.  In that 
first study, information was not recorded on the time interval from delivery of 
the infant to analysis of the corresponding cord venous blood sample.  To 
confirm whether or not the incidence of hypoglycaemia in our sample of 
elective caesarean sections was likely to be valid, a further study was 
undertaken to determine the time interval between delivery and first blood 
sample analysis in routine clinical practice at Ninewells Hospital and Medical 
School, Dundee (pilot study 3).    
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CHAPTER 4 
PILOT STUDY 3: TIME INTERVAL FROM DELIVERY TO 
UMBILICAL CORD BLOOD GAS AND ACID-BASE STATUS 
MEASUREMENT: ROUTINE CLINICAL PRACTICE 
 
4.1 INTRODUCTION 
The purpose of this study was to record the time interval from delivery of the 
infant to the analysis of the first cord blood sample taken for routine blood 
gas and acid-base status after spontaneous vaginal deliveries and following 
elective caesarean sections.  
 
4.2 METHODS  
4.2.1 Mothers and infants 
 
The clinical records of 100 consecutive women who had a spontaneous 
vaginal delivery and 100 consecutive women who had an elective caesarean 
section in the period April to May 2005 were identified retrospectively using 
the “Protos” database.  Protos is an electronic system where all deliveries in 
the Tayside Region are recorded and information for each patient is entered 
by midwives and obstetricians at the time of delivery.  The time of birth and 
that of the delivery of the placenta were identified from the delivery summary 
of each individual included in this study from their Protos record; the time of 
analysis of the respective cord blood gas levels and acid-base status were 
obtained from the AVL OMNI Modular System blood gas analyser (Roche 
Diagnostics GmbH, Graz, Austria) located in the Labour Suite which 
electronically stored all the records and the time of analysis of individual 
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blood samples.  The times recorded by Protos and that recorded by AVL 
OMNI Modular System blood gas analyser were accurate within ± two 
minutes. No ethical approval was required for this study. 
 
 
4.2.2 Statistical analyses 
Data were entered into Microsoft Excel XP for analysis.  The means and SD 
of the time taken from delivery to measurement of blood gas levels and acid- 
base status, as well as the time taken from delivery of the placenta to 
measurement of blood gases were calculated for both the spontaneous 
vaginal delivery and caesarean section groups.  
 
4.3 RESULTS 
One hundred consecutive cases were identified each of spontaneous vaginal 
deliveries and of elective caesarean sections.  The mean time taken to 
obtain an umbilical blood gas was 17 minutes following caesarean section 
and 30 minutes after delivery of the infant by spontaneous vaginal delivery 
(Table 4.1).  After the delivery of the placenta, the mean time taken was 15 
minutes for the caesarean section group compared to 23 minutes in the 
spontaneous vaginal group (Table 4.1). 
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Table 4.1: Time taken to measure blood gases after delivery: routine 
clinical care 
 
 
Elective caesarean section 
n=100 
Mean ± SD (range) 
 
Spontaneous vaginal delivery 
n=100 
Mean ± SD (range) 
After second stage (min) 
 
17 ± 6.40 (7-53) 30 ± 14.00 (13-109) 
After third stage (min) 15 ± 6.36 (5.52) 
 
23 ± 15.00 (4-101) 
 
4.4 COMMENTARY 
Umbilical cord blood gas and acid-base status is considered to be a more 
objective measure of the condition of the infant at birth than Apgar scores, 
and abnormal results may indicate the occurrence of an acute intra-partum 
hypoxic event with consequent medico-legal implications.  Some studies 
recommend routine cord blood sampling and analysis for all deliveries (Thorp 
et al., 1989; Johnson et al., 1990) whereas others suggested selective 
sampling of at risk populations (Duerbeck et al., 1992).   In the UK, 
guidelines from the National Institute for Health and Clinical Excellence 
(NICE) recommend that “paired [arterial and venous samples] cord blood 
gases do not need to be taken routinely.  They should be taken when there 
has been concern about the baby either in labour or immediately following 
birth” (NICE, 2007).    In contrast, the American College of Obstetricians and 
Gynecologists (ACOG) recommends taking paired arterial and venous cord 
blood samples from: all infants delivered by caesarean section for fetal 
compromise; those infants with low five minute Apgar scores, severe growth 
restriction or abnormal fetal heart rate tracings; or when there is maternal 
thyroid disease, intrapartum fever or a multiple birth (ACOG Committee on 
Obstetric Practice, 2006).  A recent systematic review and meta-analysis 
suggested that there are strong associations between low umbilical cord 
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artery pH at birth and neonatal mortality, hypoxic ischaemic encephalopathy, 
intraventricular haemorrhage or periventricular leucomalacia, and cerebral 
palsy (Malin et al., 2010). 
 
In 1994, routine sampling of umbilical arterial and venous cord blood for 
estimation of pH, pO2, pCO2, cHCO3 and BE for all infant deliveries was 
introduced into routine practice in Ninewells Hospital and Medical School, 
Dundee.  However there was no written protocol for umbilical cord blood 
sampling procedures although it was expected that the midwife who attended 
the birth would sample and analyse the blood as soon as possible after 
delivery.  Neither the RCOG nor Royal College of Midwives (RCM) have 
produced any guidelines on the technique of umbilical cord blood sampling.  
There is no protocol for this procedure in the labour ward in Ninewells 
Hospital and Medical School, despite the acceptance of routine umbilical 
blood gas and acid-base status analysis being the norm for all deliveries 
since 1994.  In general, midwives in the labour ward have been taught not 
only to obtain umbilical blood gases but also to analyse the sample using a 
blood gas analyser within the labour ward.  The general assumption is that 
this sampling and analysis is done as soon as possible after deliveries but 
there is no time interval specified, nor guidance on where the blood samples 
should be obtained i.e. for example either from the umbilical cord or placenta 
insertion.  In addition, there is no guidance on the technique of isolation of a 
segment of cord through double-clamping which is recommended by the 
ACOG (ACOG Committee on Obstetric Practice, 2006).  The ACOG has also 
recommended that an arterial umbilical cord blood sample is the preferred 
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blood sample, but where possible, and ideally, both a venous and arterial 
sample (paired specimen) should be collected and analysed; it is further 
emphasized that it is important to label the samples as either venous or 
arterial.  The validity of the latter point has been emphasised by Tong and 
colleagues who have reported that 53 out of 289 (18.3%) supposedly paired 
umbilical arterial and venous samples were invalid; of the 53 samples, nine 
had been incorrectly labelled (Tong et al., 2002).  Paired samples are 
normally taken by the midwives in our labour ward but unfortunately the 
samples are generally not routinely labelled as arterial or venous; when there 
is only one blood sample obtained, it is sometimes difficult in retrospect to 
determine whether it is an arterial or venous sample.  
 
The sampling and subsequent analysis of umbilical cord blood samples 
needs to be a simple and fast procedure, but immediate sampling and 
analysis of cord blood sometimes may not be possible, especially if a 
midwife’s attention is focused for example on resuscitation of an infant.  Our 
study showed that the mean time taken to obtain an umbilical blood gas was 
17 minutes after delivery of the infant by caesarean section and 30 minutes 
after delivery of the infant by spontaneous vaginal delivery.  In one extreme 
case, a sample was taken 109 minutes after spontaneous vaginal delivery of 
an infant.  A normal metabolic status at delivery, as assessed by cord blood 
sample estimations of pH and BE, can rapidly become classified as 
abnormal simply as a result of delayed blood sampling and/or delayed 
sample analysis.  When we looked at the temporal changes in cord blood 
gas, acid base status, glucose and lactate levels with time (pilot study 2), we 
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found that the glucose level had changed significantly by 12 minutes 
whereas lactate, pH and BE levels had changed significantly as early as 
seven minutes.  Both studies suggest that infants delivered by spontaneous 
vaginal deliveries are at a higher risk of hypoglycaemia. Surprisingly, when 
we measured the incidence of hypoglycaemia (pilot study 1) we found a 
higher incidence of hypoglycaemia in infants delivered by elective caesarean 
sections than in infants delivered by spontaneous vaginal deliveries.  
However, the numbers of the infants delivered by elective caesarean section 
in this sample (n=37) whom we found to be hypoglycaemic were relatively 
small (n=13).  A combination of delay in blood sampling and/or analysis 
could easily account for the apparent contradictory findings.  Because of the 
potential importance of unrecognised hypoglycaemia in term infants, and 
using the methodological knowledge gained during the pilots, we designed a 
study to describe the hormonal and metabolic profiles of term infants 
delivered by elective caesarean section.   
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 CHAPTER 5 
STUDY 4: METABOLIC AND HORMONAL RESPONSES IN 
THE REGULATION OF BLOOD GLUCOSE LEVELS  
IN INFANTS DELIVERED BY  
ELECTIVE CAESAREAN SECTION 
 
5.1 INTRODUCTION 
The results of the three pilot studies clarified the methodology for the main 
study.  The key methodological concept derived from these pilot studies was 
the importance of prompt sampling of cord blood and prompt analysis of 
samples; as some hormones and metabolites, such as glucose, lactate and 
catechols, changed significantly with time.  The aim of the main study was to 
describe the hormonal and metabolic profiles of ‘unstressed’ term infants 
delivered by elective caesarean section.  Women who planned for an 
elective caesarean section were chosen in the light of the results from the 
pilot study 2 and 3, which showed possible reasons for the highest proportion 
of hypoglycaemic infants were delivered by elective caesaresan section in 
the pilot study 1. Furthermore in terms of practicality, it was easier to recruit 
and to obtain umbilical cord samples within five minutes of delivery of these 
infants.  The objectives have been listed in the introduction chapter (see 
page 35). 
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5.2 METHODS 
5.2.1 Mothers and infants 
The study population were women undergoing elective caesarean section in 
Ninewells Hospital and Medical School, Dundee, at 37+ weeks gestation with 
a singleton pregnancy.  Women were recruited into the study between July 
2004 and April 2006.  The eligibility criteria and recruitment procedures were 
the same as those for pilot study 2 (see page 37 and Appendix for 
Information Sheets, pages 156-157). 
 
Analysis of the first pilot study’s data showed that a lower umbilical venous 
pO2 was significantly associated with hypoglycaemia.  This was used to 
determine the sample size.  Using a ratio of two controls (i.e. 
normoglycaemic) to one case (i.e. hypoglycaemic), a sample size comprising 
96 controls and 48 cases would have sufficient power (α= 5%, β= 80%) to 
detect a change in mean value of pO2 between normo- and hypoglycaemic 
groups of 0.5kPa. 
 
5.2.2 Blood sample collection 
All the blood samples were taken by me. A venous blood sample for glucose 
and lactate estimations was taken from a maternal foot vein using a 21 
gauge butterfly needle (Hospira, Lake Forest, USA) immediately after 
delivery of the infant.  The reason for taking a blood sample from a foot vein 
was to reduce any discomfort to the mother as the majority had spinal 
anaesthesia for the delivery.  Blood samples for glucose and lactate 
estimations were collected into fluoride-oxalate tubes before transportation to 
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the Department of Biochemical Medicine, Ninewells Hospital and Medical 
School, Dundee for analysis.  
 
Approximately 20 ml of blood was taken from the umbilical vein at the point 
of placental cord insertion (singly-clamped sample) using a 19 gauge 
butterfly needle (Abbott Ireland, Sligo, Republic of Ireland) and aliquoted 
within five minutes of delivery into a variety of tubes according to the analyte 
to be measured.   Venous cord blood was assayed for glucose, lactate, 3-
hydroxybutyrate, FFA, amino acids (alanine, arginine, citruline, cystine, 
GABA, glutamic acid, glutamine, glycine, histidine, isoleucine, leucine, lysine, 
methionine ornithine, phenyalanine, serine, taurine, threonine, tyrosine and 
valine), insulin, glucagon, hGH, cortisol, catechols (EPI, NE, DA, DOPA, 
DHPG, DOPAC) and their sulfated conjugates (EPI sulfate, NE sulfate, DA 
sulfate, DOPA sulfate, DHPG sulfate, DOPAC sulfate), pH, pO2, pCO2, 
cHCO3 and BE.  Blood for glucose, lactate, 3-hydroxybutyrate and FFA 
estimations was collected into fluoride-oxalate tubes.  Blood for analysis of 
amino acids, insulin, glucagon, hGH, cortisol and catechols was collected 
into lithium heparin tubes and placed onto ice; they were sent immediately to 
the Department of Biochemical Medicine, Ninewells Hospital and Medical 
School, Dundee for plasma preparation and subsequent assaying.  Blood 
samples for blood gas levels and acid-base status were collected using one 
ml heparinised plastic syringes (BD Diagnostic, Plymouth, UK).  Blood gas 
levels and acid-base status were analysed in the AVL OMNI Modular System 
blood gas analyser (Roche Diagnostics GmbH, Graz, Austria) located in the 
labour ward and serviced by the Department of Biochemical Medicine, 
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Ninewells Hospital and Medical School as part of the UK national 
accreditation scheme.   
 
Venous cord blood was the preferred source for this study as the majority of 
hormonal and metabolites research studies to date had used umbilical 
venous samples to measure hormones and metabolites at birth (see Chapter 
1).  There were also practical considerations as large volumes of blood 
would be required for measurement for the range of hormones and 
metabolites as mentioned above.   This would enable a range of analytes 
measured for each infant as opposed to many other studies which were only 
able to measure one or two analytes. Sampling from the umbilical artery is 
more challenging than from the vein as the artery has smaller lumen and 
contains less blood.   
 
5.2.3 Data collection 
The core epidemiological data were abstracted from the maternal case 
notes, as described for pilot study 1, (see page 38 and Appendix for a copy 
of the Data Abstraction Form, pages 158-166).  Additional data were 
collected, including delivery weight and height of the mother to calculate BMI 
(delivery BMI was felt to be more physiologically appropriate to investigate 
the impact of delivery on the fetal hormonal and metabolic responses in the 
regulation of blood glucose levels); drugs, fluid (volume and type) and 
analgesia received during the preoperative period; and the reason for the 
elective caesarean section.  All data were double-entered into Epi Info™ 
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version 3.4.3 by an experienced data manager.  The data were exported 
form Epi Info™ to SPSS for statistical analysis. 
 
5.2.4 Statistical analyses 
SPSS version 14 statistical software was used to conduct all analyses.  
Means and SDs were calculated for levels of glucose, lactate, 3-
hydroxybutyrate, FFA, amino acids, insulin, glucagon, hGH, cortisol, 
catechols and their sulfated conjugates, pH, pO2, pCO2, and cHCO3 and BE.  
Statistical significance was determined, as appropriate, by linear regression 
analysis, Student’s two tailed t-test, or Chi-square test.   
 
The analysis of the data was done in two steps using univariate general 
linear modelling.  First, the impact of each categorical and continuous 
variable was assessed singly upon the levels of glucose and lactate.  
Secondly, factors that were significantly associated as well as those 
supported by literature were entered together into a final model to determine 
their adjusted impact. All of the variables included in the first and second 
steps are listed in Table 5.6 and Table 5.7 respectively (see Appendix pages 
141-143).  The one sample Kolmogorov-Smirnov test was used to evaluate 
the normality of the distribution.  Data that were not normally distributed were 
log transformed before analysis.  Statistical significance was taken at p value 
≤ 0.05. 
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5.2.5 Biochemical analyses 
5.2.5.1 Glucose (mmol/l) 
The analysis of glucose levels was identical to that described for the first pilot 
study (see pages 40-41 for details). 
 
5.2.5.2 Lactate (mmol/l) 
The analysis of lactate levels was identical to that described for the first pilot 
study (see pages 41-42 for details). 
 
5.2.5.3 3-Hydroxybutyrate (mmol/l) 
3-hydroxybutyrate concentrations were measured at the Metabolic 
Biochemistry laboratory of the Royal Hospital for Sick Children, Edinburgh 
using a Randox kit (Randox Laboratories Ltd, Antrim, United Kingdom) on a 
Roche Modular P Analyser (Roche Diagnostics GmbH, Mannheim, 
Germany).  Venous blood samples were collected into fluoride-oxalate tubes. 
Following centrifugation at 4000 g for five minutes at 4oC, the resulting 
plasma was immediately frozen and stored at -20oC in the laboratory freezer 
in the Department of Biochemical Medicine, Ninewells Hospital and Medical 
school.  The samples remained frozen until analysis at the Metabolic 
Biochemistry laboratory of the Royal Hospital for Sick Children, Edinburgh. 
 
The method of analysis is based on the reaction which converts 3-
hydroxybutyrate to acetoacetate using 3-hydroxybutyrate dehydrogenase in 
the presence of nicotinamide dinucleotide (NAD).  During this reaction an 
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equimolar amount of NAD is reduced to NADH which is measured at 340nm 
and is proportional to the 3-hydroxybutyrate concentration. 
 
     3-hydroxybutyrate dehydrogenase 
 3-hydroxybutyrate + NAD+     acetoacetate + NADH 
 
The production of NADH by the action of endogenous lactic dehydrogenase 
(LDH) on lactic acid is prevented by incorporating oxalic acid, an inhibitor of 
LDH activity, in the assay reagents.  The assay sensitivity was 0.1 mmol/L 
and the inter-assay coefficient of variation was 2.4%. 
 
5.2.5.4 Free fatty acids (mmol/l) 
Free fatty acids concentrations were measured at the Metabolic Biochemistry 
laboratory of the Royal Hospital for Sick Children, Edinburgh using a Wako 
NEFA C kit (Wako Chemicals GmbH, Neuss, Germany) on a Roche Modular 
P Analyser (Roche Diagnostics GmbH, Mannheim, Germany).  Venous blood 
was collected into a fluoride-oxalate tube.  After centrifugation at 4000 g for 
five minutes at 4oC, the plasma was separated and kept frozen at -20oC in 
the laboratory freezer in the Department of Biochemical Medicine, Ninewells 
Hospital and Medical School, Dundee prior to transfer to Edinburgh for 
analysis.  The samples remained frozen until analysis in the Metabolic 
Biochemistry laboratory of the Royal Hospital for Sick Children, Edinburgh.  
 
This assay is based on enzymatic spectrophotometric techniques and relies 
upon the acylation of coenzyme A (CoA) by the fatty acids in the presence of 
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added acyl-CoA synthetase (ACS).  The acyl-CoA thus produced is oxidized 
by added acyl-CoA oxidase (ACOD) with generation of hydrogen peroxide; in 
the presence of peroxidase (POD) this permits the oxidative condensation of 
3-methy-N-ethyl-N(β-hydroxyethyl)-aniline (MEFA) with 4-aminoantipyrine to 
form a purple coloured adduct which can be measured colorimetrically at 550 
nm.  The assay sensitivity was 0.006 mmol/l and the inter-assay coefficient 
of variation was 1.1%. 
 
5.2.5.5 Amino acids (µmol/l) 
The amino acid analyses were performed using a Biochrom 20 Amino Acid 
Analyser (Biochrom Ltd, Cambridge, United Kingdom) in the Department of 
Biochemical Medicine, Ninewells Hospital and Medical School, Dundee, using 
a technique based on ion exchange liquid chromatography.  A plasma sample 
containing a mixture of amino acids was loaded, automatically, onto a column 
of cation-exchange resin.  Buffers of varying pH and ionic strength are used in 
the system to separate the various amino acids.  The temperature of the 
column is also accurately controlled and can be changed at any point in the 
analysis cycle to produce the required separation.  The column eluent is 
mixed with the ninhydrin reagent and the mixture passes through the high 
temperature reaction coil.  In the reaction coil, the ninhydrin reacts with the 
amino acids present in the eluent to form coloured compounds, which is 
measured using a photometer; the amount of light absorbed is directly 
proportional to the quantity of amino acid present. The photometer output is 
connected to a computer, which plots the amino acid concentrations as a 
series of peaks.  The retention time of the peak on the chart identifies the 
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amino acid, the area under the peak indicates the quantity of amino acid 
present.  As an amino acid analyser is a comparative instrument, a calibration 
analysis must be performed before commencing each series of analyses, to 
produce a standard trace for comparison purposes. 
 
Blood samples were collected into lithium heparin tubes, placed onto ice and 
immediately brought to the laboratory to be spun at 4000 g for five minutes at 
4oC.  The minimum volume of plasma required for amino acid assay is 100 
µL. The inter-assay coefficient of variation for amino acids was less than 
10%. 
 
5.2.5.6 Insulin (mU/l) 
 Insulin was measured using the IMMULITE2000 Insulin kit (Euro/DPC Ltd, 
Gwynedd, United Kingdom) on an IMMULITE2000 analyser (Euro/DPC Ltd, 
Gwynedd, United Kingdom) in the Department of Biochemical Medicine, 
Ninewells Hospital and Medical School, Dundee.  IMMULITE2000 Insulin is 
a solid phase, two-site chemiluminescent immunometric assay.  The solid 
phase which is a bead coated with murine monoclonal anti-insulin antibody, 
is incubated with the plasma and alkaline phosphatase conjugated sheep 
polyclonal anti-insulin antibody for 30 minutes at room temperature.  The 
unbound alkaline phosphatase conjugated sheep polyclonal anti-insulin 
antibodies are removed by a centrifugal wash.  In the final step, a 
chemiluminescent substrate, adamanthyl dioxetane phosphate, is added to 
the bead and the resulting photon emission signal is this time directly 
proportional to the concentration of insulin in the sample.  
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Blood samples were collected directly into lithium heparin tubes and 
transferred immediately on ice to the laboratory for plasma preparation and 
assaying.  The minimum volume of plasma required for insulin assay is 100 
µL and the assay can measure insulin concentrations between 2 mU/l and 
300 mU/l.  The inter-assay coefficient of variation for insulin was 6.24%. 
 
5.2.5.7 Glucagon (ng/l) 
Blood samples were collected into lithium heparin tubes, placed onto ice and 
immediately brought to the laboratory to be spun at 4000 g for five minutes at 
4oC.  The plasma was then stored and kept frozen at -20oC in the laboratory 
freezer in the Department of Biochemical Medicine, Ninewells Hospital and 
Medical School, Dundee.  All of the samples were sent by air to the 
Metabolic Laboratory of the Royal Victoria Hospital, Belfast, Northern Ireland 
for analysis.  All the samples remained frozen until analysis.  
 
The assay is based on radioimmunoassay techniques.  The principle of 
radioimmunoassay depends on the assumption that radio-labelled and 
unlabelled antigen compete equally for sites on an antibody.  A standard 
quantity of tracer radio-labelled peptide is added into the antibody-antigen 
system and displaced antibody-bound peptide.  The quantity of bound 
labelled trace is inversely proportional to the quantity of peptide being 
assayed.  There is no external quality assurance scheme for glucagon 
estimations and hence, there were two internally prepared control specimens 
in each assay.  The assay had an inter-assay coefficient of variation of less 
than 15% and a sensitivity of 15 ng/l. 
  
81 
5.2.5.8 Human growth hormone (mU/l) 
Human growth hormone was measured using the IMMULITE2000 hGH kit 
(Euro/DPC Ltd, Gwynedd, United Kingdom) on an IMMULITE2000 analyser 
(Euro/DPC Ltd, Gwynedd, United Kingdom) in the Department of 
Biochemical Medicine, Ninewells Hospital and Medical School, Dundee.  The 
principle of the procedure is similar to insulin, using a solid phase, two-site 
chemiluminescent immunometric assay.  The solid phase which is a bead 
coated with murine monoclonal anti-hGH antibody, is incubated with plasma 
and alkaline phosphatase conjugated rabbit polyclonal anti-hGH antibody for 
30 minutes at room temperature.  The unbound alkaline phosphatase 
conjugated rabbit polyclonal anti-hGH antibodies are then removed by a 
centrifugal wash.  The amount of alkaline phosphatase conjugated rabbit 
polyclonal anti-hGH antibody bound is directly proportional to the 
concentration of the hGH in the sample.  In the final step, a 
chemiluminescent substrate, adamantyl dioxetane phosphate, is added to 
the bead.  In the luminogenic reaction, the adamantyl dioxetane phosphate is 
dephosphorylated into an unstable intermediate by the alkaline phosphatase 
bound to the bead.  The unstable intermediate rapidly and spontaneously 
breaks down emitting a photon of light, which is detected by a photomultiplier 
tube.  The amount of light emitted is directly proportional to the amount of 
bound alkaline phosphatase.  
 
The blood samples were collected directly into lithium heparin tubes and 
placed immediately onto ice for transport to the laboratory where they were 
centrifuged at 4000g for five minutes.  The minimum volume of plasma 
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required for the assay is 25 µl and the assay could measure hGH 
concentrations between 0.01 mU/l and 40 mU/l.  The assay had an inter-
assay coefficient of variation of 4.27%. 
 
5.2.5.9 Cortisol (nmol/l) 
Plasma cortisol was measured using a Cobas Cortisol kit (Roche 
Diagnostics GmbH, Mannheim, Germany) on a Roche Modular Serum Work 
Area Analyser (Roche Diagnostics GmbH, Mannheim, Germany) in the 
Department of Biochemical Medicine, Ninewells Hospital and Medical 
School, Dundee.  The assay makes use of a competition test principle using 
a polyclonal antibody which is specifically directed against cortisol.  Twenty 
µl of plasma is incubated with a cortisol specific biotinylated antibody and a 
ruthenium complex labelled cortisol derivative.  Depending on the 
concentration of the analyte in the sample and the formation of the 
respective immune complex, the labelled antibody binding site is occupied in 
part with sample analyte and in part with ruthenylated hapten.  After addition 
of streptavidin-coated microparticles, the complex becomes bound to the 
solid phase via interaction of biotin and streptavidin.  The reaction mixture is 
aspirated into the measuring cell where the microparticles are magnetically 
captured onto the surface of the electrode. Application of a voltage to the 
electrode then induces chemiluminescent emission which is measured by a 
photomultiplier.   
 
The blood samples were collected directly into lithium heparin tubes and 
placed immediately onto ice prior to transport to the laboratory for immediate 
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analysis where they were centrifuged at 4000g for five minutes.  The 
separated plasma is stable for 30 days at 2 – 8oC and 3 months at -20oC.  
The lowest and maximum detection limits for the assay were 0.5 nmol/l and 
1750 nmol/l respectively.  The assay had an inter-assay coefficient of 
variation of 8.14%.  
 
5.2.5.10 Catechols (pg/ml) 
Six plasma catechols and their respective sulfated conjugates were 
measured: DOPA, DOPA sulfate, DA, DA sulfate, NE, NE sulfate, EPI, EPI 
sulfate, DHPG, DHPG sulfate, DOPAC and DOPAC sulfate.  Umbilical cord 
blood samples were collected into lithium heparin tubes, placed onto ice and 
immediately brought to the Department of Biochemical Medicine, Ninewells 
Hospital and Medical School, Dundee, where they were centrifuged at 4000 
g for five minutes at 4oC.  The resulting plasma was separated into a further 
tube without anticoagulant, the tube placed immediately into solid carbon 
dioxide pellets to freeze the contents and then stored in a -80oC freezer.  All 
plasma samples were transported in batches by air in solid carbon dioxide to 
the Clinical Neurochemistry Laboratory, National Institute of Health (NIH), 
Bethesda, Maryland, USA.  All arrived in a frozen state and were kept in a 
-80oC freezer until analysis.   
 
All the catechols assays in this study were undertaken by me following 
training and under the supervision of Professor Graeme Eisenhofer, who is 
an internationally acknowledged expert in catecholamine metabolism, and 
who has established a laboratory with the expertise and technologies to 
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measure a wide range of catechols and their conjugates not currently 
available in the UK.  The assays were done in the Clinical Neurochemistry 
Laboratory, NIH, Bethesda, Maryland, USA, using an alumina extraction step 
followed by high-performance liquid chromatography (HPLC) with 
electrochemical detection.  The alumina extraction procedure serves to 
isolate and concentrate the low fentomolar concentrations of catechols in 
plasma into a purified low volume form appropriate for injection onto the 
HPLC apparatus.  Alumina adsorbs catechols at alkaline pH and desorbs 
catechols at acidic pH.  The alumina at alkaline pH was washed with water, 
to remove compounds other than catechols.  At the end of the assay, the 
alumina was acidified, desorbing the catechols into the supernatant.  Finally, 
an aliquot of the supernatant was injected into the HPLC apparatus.  The 
function of the electrochemical detection system is to detect and quantify the 
analytes of interest after their separation in and elution from the analytical 
column.  The ordered elutions from the column were analysed by measuring 
the currents generated from oxidation or reduction of the analytes by 
electrochemical analysis.  The same testing principle applies for the sulfated 
conjugates.   
 
The plasma was incubated with sulfatase at 37oC for 30 minutes prior to 
analysis.  One normal level adult plasma control was used on each HPLC 
run.  The inter-assay coefficient of variation for catechols assays in this study 
were 10.27% for EPI, 2.76% for NE, 6.44% for DOPA, 5.69% for DHPG, 
5.47% for DOPAC, 6.16% for EPI sulfate, 13.52% for NE sulfate, 13.62% for 
DOPA sulfate, 11.75% for DHPG sulfate and 5.43% for DOPAC sulfate.  
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5.2.5.11 Blood gas and acid-base profiles 
The analysis of blood gas and acid-base status was identical to that 
described for the first pilot study (see pages 42-43 for details). 
 
5.3 RESULTS 
One hundred and fifty three women were recruited into the study; all were 
scheduled for elective caesarean section.  The mean maternal age and BMI 
at delivery of the women recruited was 32.03 years and 31.14 respectively 
(Table 5.1).  Only a small proportion of women (13.1%) admitted to smoking 
during pregnancy (Table 5.1); the majority of the women were healthy with 
no significant past medical history and had had an uneventful pregnancy 
(Table 5.1).  
 
The main reasons given for having an elective caesarean section were: 
previous caesarean section (65.4%), breech presentation (20.9%) and 
maternal request (8.5%) (Table 5.2).  The majority of women had spinal or 
epidural anaesthesia (98.0%) for their caesarean section; only a small 
proportion (2.0%) had general anaesthesia (Table 5.2).  The majority of 
women (83.7%) had at least one drug prescribed prior to delivery and some 
(5.9%) were prescribed up to maximum of three drugs, which included 
ephedrine, phenylephrine, glycopyrrolate and atropine (Table 5.2).   
 
Only one infant was born with an Apgar score of less than three at one 
minute and no infant had an Apgar score of less than seven at five minutes 
(Table 5.2).  Only one infant had an umbilical cord arterial BE greater than -
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12 (Table 5.2).  The mean values for cord arterial pH, BE, pO2, pCO2, and 
cHCO3 were 7.29, -1.94, 2.29 kPa, 7.21 kPa and 25.10 mmol respectively 
(Table 5.3).  The mean birth weight ratio, OFC and birth length of the infants 
were 1.08, 35.1 cm and 49.3 cm respectively (Table 5.2). 
 
At the time of elective caesarean section, the mean maternal glucose level 
was 4.28 mmol/l which is within the normal range (Table 5.3).  The mean 
maternal lactate level of 1.80 mmol/l was at the upper limit of the normal 
venous blood reference range (Table 5.3).  Three infants had an umbilical 
cord blood glucose level of <2.6 mmol/l at birth.  The mean infant glucose 
and lactate levels were, as expected for a full term infant, 3.3 mmol/l and 2.2 
mmol/l respectively (Table 5.3).  The mean insulin level (8.3 mU/l) and the 
mean glucagon level (251 ng/l) seems high.  Twenty-one amino acids were 
measured in umbilical venous cord plasma and the mean values are 
summarised in Table 5.3.   
 
Venous cord plasma glucose levels were significantly positively associated 
with ephedrine given to the mother prior to delivery, the reasons for 
caesarean section, maternal glucose, alanine, lysine, insulin, EPI and EPI 
sulphate, and were significantly negatively associated with the need for 
neonatal resuscitation and 3-hydroxybutyrate.  These variables, as well as 
those supported by literature i.e. maternal diabetes, and levels of glucagon, 
hGH, cortisol and NE were entered into an univariate general model to 
determine their adjusted impact.  Only three factors affected the umbilical 
venous cord glucose levels (Table 5.4).  There was a significantly positive 
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association between maternal venous glucose level and umbilical venous 
cord glucose levels (p<0.001).  A decrement of umbilical venous cord 
glucose levels was associated with the presence of maternal diabetes 
(p<0.001) and cord NE levels (p=0.020) (Table 5.4).  
 
A much greater number of factors were found to influence the venous 
umbilical cord plasma lactate levels than the cord plasma glucose levels 
(Table 5.5).  There was a significant positive association between umbilical 
venous cord lactate levels and maternal glucose levels (p=0.004), maternal 
lactate levels (p<0.001), arterial pCO2 (p<0.001), cord glucose levels 
(p=0.023) and marginally with cord NE (p=0.053) levels.  On the other hand 
there was a negative association between umbilical cord lactate levels and 
arterial BE (p<0.001) and cord glucagon levels (p=0.014).  
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Table 5.1: Characteristics of the women recruited 
 Mean ± SD (n) or N, % Range 
Maternal age, years  32.03 ± 5.65 (153) 16.81-44.39 
Maternal BMI  31.14 ± 6.32 (150) 17.97-31.16 
Maternal smokers   20/153,  13.1% - 
Antenatal events:   
 Antepartum haemorrhage   3/153,  2.0% - 
 Asthma   9/153,  5.9% - 
 Epilepsy   1/153,  0.7% - 
 Thyroid disease   2/153,  1.3% - 
 Diabetes   3/153,  2.0% - 
 Hyperemesis gravidarum   1/153,  0.7% - 
 Tractocile treatment   1/153,  0.7% - 
 Bethamethasone injection   4/153,  2.6% - 
 Hypertension   3/153,  2.0% - 
 Treated UTI   1/153,  0.7% - 
 Treated vaginal discharge   2/153,  1.3% - 
Reasons for elective caesarean section   
 Previous caesarean section  100/153,  65.4% - 
 Breech presentation  32/153,  20.9% - 
 Maternal request  13/153,  8.5% - 
 Other reasons#  8/153,  5.2% - 
Type of analgesia received 
 None received  0/153,  0.0% - 
 Entonox  0/153,  0.0% - 
 General anaesthesia  3/153,  2.0% - 
 Epidural/spinal  150/153,  98.0% - 
 Opiate  0/153,  0.0% - 
Other drugs received  during delivery 
 No drug  24/153,  15.7% - 
 One drug  72/153,  47.1% - 
 Two drugs  47/153,  30.7% - 
 Three drugs  9/153,  5.9% - 
 
BMI body mass index, UTI urinary tract infection 
#Other reasons included cephalopelvic disproportion, Crohn’s disease, bowel problems as a 
result of a previous delivery, and an unstable lie.  
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Table 5.2: Postpartum characteristics of the infants and women 
recruited   
 
 Mean ± SD (n) or N, % Range 
Male infant   68/153,  44.4% - 
Apgar score < 3 at 1 min   1/153,  0.7% - 
Apgar score < 7 at 5 min   0/153,  0.0% - 
Cord blood arterial pH   7.29 ± 0.05 (145)  7.039  - 7.386 
Cord blood venous pH  7.33 ± 0.05 (151)  7.047  - 7.415 
Cord blood arterial BE >-12   1/148,  0.7% - 
Cord blood venous BE >-12   0/151,  0.0% - 
Cord blood arterial BE  -2.13 ± 1.88 (145)  -12.40 - 0.80 
Cord blood venous BE  -2.04 ± 1.59 (151)  -10.40 - 0.50 
Cord blood arterial pO2 kPa  2.15 ± 0.72 (145)  0.33 - 4.97 
Cord blood venous pO2 kPa  2.88 ± 0.69 (140)  1.01 - 4.44 
Cord blood arterial pCO2 kPa  7.21 ± 1.01 (145)  4.68 - 10.58 
Cord blood venous pCO2 kPa  6.30 ± 1.34 (151)  2.48 - 16.24 
Cord blood arterial cHCO3 mmol/l  25.10 ± 2.35 (145)  15.00 - 29.80 
Cord blood venous cHCO3 mmol/l  24.05 ± 1.82 (151)  15.00 - 28.00 
Neonatal resuscitation required  7/152,  4.6% - 
Infant birth weight grams    3581 ±  527 (153)   2380  -  4900 
Infant birth weight ratio  1.08 ± 0.15 (153)  0.70 - 1.63 
Infant OFC cm  35.10 ± 1.70 (149)  23.40 - 39.00 
Infant birth length cm  49.30 ± 2.30 (149)  44.20 - 57.00 
 
BE base excess, cHCO3 bicarbonate, OFC occipital-frontal head circumference 
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Table 5.3: The mean values, standard deviation and range of maternal 
glucose and lactate levels in peripheral venous plasma, and various 
hormones and metabolites in umbilical venous cord blood of term 
infants at birth 
 
 Mean ± SD (n)    Range 
Maternal glucose mmol/l  4.28 ± 0.56 (153)  3.2 - 7.3 
Maternal lactate mmol/l  1.80 ± 0.49 (153)  0.8 - 3.4 
Glucose mmol/l  3.3 ± 0.5 (153)  2.0 - 5.4 
Lactate mmol/l  2.2 ± 1.0 (153)  0.8 - 9.5 
3-hydroxybutyrate mmol/l         0.18   ±       0.14 (148) 0.01 - 0.79 
FFA mmol/l         0.10   ±       0.04 (148) 0.03 - 0.21 
Amino acids µmol/l   
 Alanine   353.16 ± 65.92 (150)  205 - 543 
 Aminobutyric acid  20.39 ± 7.06 (150)  7 - 45 
 Arginine   90.92 ± 26.76 (150)  16 - 230 
 Citrulline   18.41 ± 5.40 (146)  10 - 39 
 Cystine   27.66 ± 16.80 (146)  0 - 84 
 GABA  60.89 ± 40.48 (150)  17 - 221 
 Glutamic acid  66.21 ± 45.42 (150)  7 - 266 
 Glutamine  609.49 ± 213.42 (150)  256 -1425 
 Glycine   257.03 ± 36.54 (149)  174 - 376 
 Histidine   122.88 ± 19.79 (150)  78 - 194 
 Isoleucine   65.46 ± 10.09 (150)  28 - 96 
 Leucine  125.10 ± 17.71 (150)  87 - 177 
 Lysine   343.58 ± 54.15 (150)  131 - 479 
 Methionine  37.37 ± 10.92 (150)  10 - 88 
 Ornithine   63.59 ± 10.31 (150)  42 -    96 
 Phenyalanine   74.39 ± 11.45 (150)  50 - 125 
 Serine   133.97 ± 17.42 (150)  95 - 182 
 Taurine   172.95 ± 94.31 (150)  67 - 656 
 Threonine   271.76 ± 59.55 (150)  150 - 508 
 Tyrosine  68.58 ± 12.88 (150)  40 - 120 
 Valine   217.89 ± 30.19 (150)  151 - 310 
Insulin mU/l  8.3 ± 5.0 (149)  1 - 39 
Glucagon ng/l  251.0 ± 55.0 (142)    140 - 460 
Insulin:Glucagon ratio  0.033 ± 0.018 (138)  
hGH mU/l  35.7 ± 1.2 (152)  6.8 - 135 
Cortisol nmol/l  139.0 ± 49.0 (153)  38 - 289 
EPI pg/ml 
 83.8 ± 314.5 (142)  3 -3096 
EPI sulfate pg/ml  28.9 ± 34.83 (144)  2 - 316 
NE pg/ml  763.0 ± 2038.0(150)  26 - 19437 
NE sulfate  pg/ml  510.3 ± 389.0 (150)  217 -4740 
DOPA pg/ml  2746.0 ± 674.0 (150)  1665 -8508 
DOPA sulfate pg/ml  331.0 ± 96.0 (150)  144 - 713 
DHPG pg/ml  799.0 ± 422.0 (150)  453 -4467 
DHPG  sulfate pg/ml  396.0 ± 123.0 (150)  167 -1077 
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Table 5.3: continuation from above table 
 
 Mean ± SD (n)    Range 
DOPAC pg/ml  1748.0 ± 454.0 (149)  961 -4108 
DOPAC sulfate pg/ml  270.0 ± 102.0 (105)  95 - 778 
 
FFA free fatty acids, hGH human growth hormone, EPI epinephrine, NE norepinephrine, 
DOPA dihydroxyphenylalanine, DHPG dihydroxyphenylglycol, DOPAC 
dihydroxyphenylacetic acid  
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Table 5.4: Maternal and infant factors that influence the umbilical cord venous  
plasma glucose level 
 
Glucose Effect 
estimate 
    SE t-statistics     95% CI p value 
Ephedrine received 0.0630 0.0442 1.424  -0.0248,  0.1507 0.157 
Neonatal resuscitation 
required 
-0.0715 0.1038 -0.690  -0.2776,  0.1343 0.492 
Reason for C/S      
 Breech 
presentation 
-0.0553 0.0560 -0.987  -0.1664,  0.0558 0.326 
 Maternal request 0.0899 0.8320 1.080  -0.0752,  0.2549 0.283 
 Other reasons# -0.0959 0.0920 -1.042  -0.2785,  0.0867 0.300 
 Previous C/S Reference      
Maternal diabetes -2.6868 0.2661 -10.096  -3.2148,  -2.1587 <0.001*** 
Maternal glucose mmol/l 0.7615 0.0565 13.488  0.6495,   0.8736 <0.001*** 
3-hydroxybutyrate mmol/l -0.0203 0.1548 -0.131  -0.3275,  0.2870 0.896 
Alanine µmol/l 0.0003 0.0004 0.694  -0.0005,  0.0010 0.489 
Lysine µmol/l -0.0001 0.0004 -0.129  -0.0009,  0.0008 0.898 
Insulin mU/l -0.0055 0.0055 -1.004  -0.0165,   0.0054 0.318 
Glucagon ng/l 0.0007 0.0004 1.863 -4.800e-5,   0.0015 0.065 
hGH mU/l -0.0021 0.0012 -1.766  -0.0044,  0.0003 0.080 
Cortisol nmol/l -0.0001 0.0005 -0.218  -0.0011,  0.0009 0.828 
EPI pg/ml 0.0007 0.0005 1.332  -0.0003,  0.0017 0.186 
EPI  sulfate pg/ml 0.0019 0.0013 1.512  -0.0006,  0.0044 0.134 
NE pg/ml -0.0001 0.0001 -2.373  -0.0002, -0.0002 0.020* 
 
Adjusted R squared = 0.763 
 
  
*p<0.05, ** p<0.01, ***p<0.001 
 
C/S cesarean section, hGH human growth hormone, EPI epinephrine, NE norepinephrine 
 
#Other reasons included cephalopelvic disproportion, Crohn’s disease, bowel problems as a result of 
a previous delivery, and an unstable lie. 
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Table 5.5: Maternal and infant factors that influence the umbilical cord venous   
plasma lactate level 
 
Log lactate Effect 
estimate 
SE t-statistics 95 % CI p value 
Maternal glucose mmol/l 0.0552 0.0185 2.978  -0.0920,  -0.0183 0.004** 
Maternal lactate mmol/l 0.0918 0.0168 5.460  0.0584,   0.1252 <0.001*** 
Apgar 5 min -0.0142 0.0176 -0.810  -0.0491,  0.0207 0.420 
Arterial BE -0.0192 0.0051 -3.731  -0.0294,  -0.0090 <0.001*** 
Arterial pCO2 kPa 0.0342 0.0075 4.535  0.0191,  0.0491 <0.001*** 
Cord glucose 0.0531 0.0228 2.320  0.0076,  0.0985 0.023* 
Alanine µmol/l 0.0001 0.0002 1.161  -0.0001,  0.0005 0.249 
Isoleucine µmol/l -0.0008 0.0010 -0.758  -0.0028,  0.0012 0.451 
Leucine µmol/l 0.0010 0.0006 1.610  -0.0003,  0.0023 0.111 
Tyrosine µmol/l -0.0006 0.0007 -0.797  -0.0020,  0.0008 0.427 
Valine µmol/l -0.0005 0.0003 -1.575  -0.0012,  0.0001 0.119 
Insulin mU/l -0.0018 0.0018 -1.008  -0.0055,  0.0018 0.316 
Glucagon ng/l -0.0003 0.0001 -2.498  -0.0006, -6.855E-5 0.014* 
hGH mU/l 0.0005 0.0004 1.404  -0.0002,  0.0013 0.164 
Cortisol nmol/l 0.0001 0.0002 0.642  -0.0002,  0.0004 0.523 
EPI pg/ml 9.602E-5 0.0002 0.420  -0.0004,  0.0006 0.675 
EPI sulfate pg/ml 0.0006 0.0004 1.450  -0.0002,  0.0015 0.151 
NE pg/ml 3.789E-5 0.0001 1.962 -5.031E-7, 7.629E-5 0.053* 
NE sulfate pg/ml 1.002E-5 0.0001 0.138  -0.0001,  0.0002 0.891 
DOPA pg/ml -3.592E-7 0.0001 -0.032 -2.247E-5, 2.175E-5 0.974 
DOPA sulfate pg/ml 4.883E-5 0.0001 0.570  -0.0001,  0.0002 0.570 
DHPG pg/ml 4.657E-5 0.0001 0.706 -8.496E-5,  0.0002 0.482 
DHPG sulfate pg/ml -0.0001 0.0001 -1.172  -0.0003, 8.015E-5 0.244 
 
Adjusted R squared = 0.752 
 
 
*p<0.05, ** p<0.01, ***p<0.001 
 
hGH human growth hormone, EPI epinephrine, NE norepinephrine,  DHPG dihydroxyphenylglycol, 
DOPA dihydroxyphenylalanine 
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5.4 COMMENTARY 
5.4.1 Maternal and fetal glucose homeostasis 
Only three infants from the group of 153 infants (1.96%) had an umbilical 
blood glucose level of less than 2.6 mmol/l at birth compared to 13 out of 37 
infants (35%) from pilot study 1. In retrospect, this result was not entirely 
surprisingly as the samples in this main study, unlike the first pilot, were 
taken in a very controlled and timely manner – following the lessons learned 
in pilot studies 2 and 3. Umbilical cord glucose levels decreased over time 
and were significantly lower at 12 minutes compared to the baseline levels at 
two minutes post- delivery of infants (p<0.01) (see Chapter 3).  The high 
incidence of hypoglycaemia found in pilot study 1 was likely due to error 
introduced by the small number of samples, as well as the delay in sampling.   
 
The mean umbilical glucose level in these elective caesarean section infants 
of the current study was lower than the mean umbilical glucose levels of 
infants delivered by spontaneous vaginal delivery, breech vaginal delivery, 
operative vaginal delivery or emergency caesarean section from pilot study 
1.  Labour is a stressful event for the fetus but this degree of stress at birth is 
probably beneficial.  It is widely established that infants who delivered by 
elective caesarean section have higher respiratory morbidity compared to 
infants delivered vaginally (e.g. Zanardo et al., 2004; Hansen et al., 2008).  
Labour may have a beneficial effect on the fetal blood glucose levels.  Infants 
delivered vaginally have higher levels of cortisol (Mears et al., 2004; Miller et 
al., 2005), EPI and NE (e.g. Irestedt et al., 1982; Wang et al., 1995), and 
lower insulin levels (Wang et al., 1995) compared to infants who delivered by 
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elective caesarean section.  Levels of cortisol, EPI and NE are known to 
increase blood glucose levels through various mechanisms.  Cortisol exerts 
hyperglycaemic actions by increasing lipolysis and gluconeogenesis, as well 
as by inhibiting glucose uptake and utilisation by the muscle (Ganong, 
1995b).  EPI and NE cause an increase in blood glucose level by increasing 
gluconeogenesis in the liver, inhibiting glucose disposal by insulin-dependent 
tissues such as skeletal muscle, and by increasing gluconeogenic precursors 
e.g. lactate, alanine and glycerol (Ganong, 1995b). Also, both EPI and NE 
are inhibitors of insulin secretion (Ganong, 1995b).   
 
Could fasting in women who had caesarean sections have had any impact 
on the blood glucose in the infants?  Fetal glucose level is closely related to 
maternal glucose level (Economides et al., 1989).  During labour women are 
allowed to have a light diet, but those who plan a caesarean section are 
required to fast for at least six hours.  In this current study, all women fasted 
for an average of 13.5 hours prior to delivery by elective caesarean sections.  
The mean maternal glucose level was 4.28 mmol/l which is within the normal 
non-pregnant range for adults but the levels could be lower compared to 
other groups of women who had other mode of deliveries.  A randomised 
controlled trial by Scrutton and colleagues (Scrutton et al., 1999)   assessed 
the risks and benefits of eating in labour.  The trial found that plasma glucose 
was significantly lower in the starved group (4.58 mmol/l) compared to the 
group of women, who were allowed to have a light diet (5.20 mmol/l) in 
labour at the end of an average of 11-12 hours of first stage of labour 
(Scrutton et al., 1999).  The mean and standard deviation of time between 
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last maternal meal and delivery of the infant was 13.21 ±2.36 hours.  
Univariate analysis of the current study did not show an association between 
umbilical glucose levels and the time from the last maternal meal until 
delivery of the infant.   Therefore as the time between food consumption and 
delivery in this study resulted in a relatively short period of fasting in the 
women, it is not a likely explanation of the lower blood glucose levels in 
infants delivered by elective caesarean section observed in this study. 
 
The current study showed a significant positive association between 
maternal plasma glucose and umbilical cord venous glucose levels.  This is 
not surprising.  Studies in pregnant sheep have demonstrated a direct 
relationship of both fetal glucose uptake and placenta glucose consumption 
to the maternal blood glucose levels (Hay and Meznarich, 1989).  A study by 
Economides and colleagues (Economides et al., 1989) on the levels of 
glucose and insulin in fetal blood obtained by cordocentesis between 17 to 
38 weeks gestation suggested that the major determinant of blood glucose 
levels in the fetus is the maternal blood glucose level.   
 
The current study has shown that umbilical cord venous glucose levels are 
lower than maternal venous glucose levels.  This is consistent with the 
results shown by Kalhan and colleagues, who studied the source of human 
fetal glucose in ten pregnant women who had undergone elective caesarean 
section at term.  They concluded that during intrauterine life, the 
maintenance of glucose levels in the human fetus is dependent upon the 
maternal supply of glucose (Kalhan et al., 1979).  A study of sheep has 
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confirmed that glucose passes from the maternal circulation to the fetal 
circulation down a concentration gradient (Meschia et al., 1980).  It is 
technically and practically very challenging to confirm this in a human study 
as it would require measurements of maternal uterine artery and venous 
glucose levels at the time of caesarean section.  However using a tracer 
study, Prendergast and colleagues studied glucose metabolism in the human 
placenta and fetus at term by infusing the stable isotope, 6,6-2H2 glucose, 
continuously to 14 patients during elective caesarean section. This study 
showed that the glucose levels were lower in the uterine vein than in the 
maternal artery (arterialized peripheral vein) (Prendergast et al., 1999).   
 
5.4.2 Lactate and glucose homeostasis in infants 
The mean umbilical venous cord lactate level of 2.2 mmol/l found in the 
current study is comparable to that reported by Armstrong and Stenson of 
2.51 mmol/l (Armstrong and Stenson, 2006), and Shirey and colleagues of 
2.52 mmol/l (Shirey et al., 1996) but is higher than that reported by Westgren 
and colleagues of 1.44 mmol/l (Westgren et al., 1998).  My study used the 
wet chemistry method (Roche Modular Serum Work Area Analyser), which 
uses plasma to measure the lactate levels whereas the other three studies 
used the strip method, which uses whole blood to measure the lactate levels 
in umbilical cord venous.  Lactate concentrations are higher in the plasma 
compared to in the whole blood (Foxdal et al., 1990).  Hence different 
methods of analysis cannot explain the differences in findings, as the levels 
from my study would be expected to be higher than those of Armstrong and 
Stenson (Armstrong and Stenson, 2006) and Shirey (Shirey et al., 1996).  
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There are still no agreed normal reference ranges for lactate levels for 
newborn populations.  A level of more than 4.8 mmol/l has been suggested 
as an indicator of fetal asphyxia (Krüger et al., 1999).  However, a recent 
study by Wiberg and colleagues which analysed nearly 18,000 umbilical 
arterial and venous blood lactate levels of ‘vigorous’ newborns, and who had 
a five-minute Apgar score corresponding to the gestational age specific 
median value minus one point score or better at birth, suggested using 
gestational age-dependent lactate reference values instead of a stationary 
cut-off as they found that lactate levels increased with gestational age 
(Wiberg et al., 2008).   
 
In the current study, cord lactate levels were positively and significantly 
associated with maternal lactate levels.  The umbilical cord lactate levels 
were also significantly higher than that of the mother, a finding in accord with 
the study carried out by Suidan and colleagues (Suidan et al., 1984).  The 
fetal-maternal difference is even greater in vaginally delivered infants 
(Suidan et al., 1984).  Like glucose, lactate has been shown to be an 
important substrate for fetal metabolism (Fisher et al., 1980).  In normal fetal 
lambs’ hearts, lactate accounts for nearly 40% of myocardial oxygen 
consumption (Bartelds et al., 2000).  Studies in gravid sheep have 
demonstrated that approximately 50% to 70% of the glucose taken up by the 
placenta is converted into lactate, and the lactate produced then enters the 
fetal and maternal circulations at similar rates, under normal conditions 
(Sparks et al., 1982).  This baseline production of lactate by the placenta 
may not necessarily indicate anaerobic metabolism, but during significant 
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hypoxia, increments in lactate levels are likely to be due to fetal anaerobic 
metabolism (Milley, 1988).  In vitro, lactate causes dilatation of the placental 
vessels and may play an important role in the events of fetal hypoxaemia 
which may occur during delivery (Omar et al., 1993).  Piquard and 
colleagues studied fetal and maternal lactate concentrations and the acid-
base status of 589 women during labour and concluded that the increase in 
cord lactate in the second stage of labour was predominantly fetal in origin 
and only 6% of vaginal deliveries have a significant transfer of lactate from 
the woman to her infant (Piquard et al., 1991).  
 
The mean maternal venous lactate level found in the current study was at the 
upper end of our laboratory normal reference range (0.7 to 1.8 mmol/l) which 
was derived from the local non-pregnant population. Surprisingly, there is no 
lactate reference range published for the pregnant population.  The mean 
maternal level found in the current study was higher compared to other 
studies where the maternal lactate levels were measured between 17 to 41 
weeks gestation (Bon et al., 2007).  There could be a gestational effect on 
the lactate level as there are significant physiological changes in maternal 
circulation as the pregnancy advances.   
 
Hypoglycaemia triggers the release of epinephrine which in turn causes the 
release of lactate from muscle (Ganong, 1995b).  The average duration of 
fasting for women in the current study was 13.46 hours and all women had a 
blood glucose level within the normal range.  Univariate analysis did not 
show an association between maternal or umbilical cord lactate levels and 
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the duration of last meal until delivery of infants.   There is limited evidence in 
the literature on the effect of short period of fasting on the metabolic fuels of 
pregnant women.  Metzger and colleagues studied the effect of fasting on 
the metabolic fuels of pregnant and non-pregnant women and concluded that 
after 12 to 14 hours of fasting, the level of glucose was lower in the pregnant 
group compared to the non-pregnant group, but both groups had similar 
levels of alanine, FFA and 3-hydroxybutyrate (Metzger et al., 1982).  After 16 
hours of fasting, there were significantly greater rises in plasma FFA and 3-
hydroxybutyrate levels, and significantly greater falls in plasma glucose and 
alanine levels in the pregnant women compared to non-pregnant women.  
This exaggerated response to overnight fasting, with a more pronounced 
decrease in plasma glucose and amino acids levels,  and a greater rise in 
plasma FFA and ketone bodies, is termed ‘accelerated starvation’.  Schraag 
and colleagues also reported similar levels of FFA and 3-hydroxybutyrate in 
pregnant and non-pregnant women after 12 hours of fasting (Schraag et al., 
2007).  Lactate levels were not measured in Metzger’s study but with 
unchanged levels of alanine, FFA and 3-hydroxybutyrate in the pregnant 
women after 12 to 14 hours of fasting, this is likely the same for lactate level.  
A randomised controlled study assessing the risk and benefits of eating in 
labour has shown that lactate levels were similar in the eating and the 
starved group after 11.8 and 10.68 hours of labour respectively (Scrutton et 
al., 1999).  Hence it does not appear that short periods of fasting are a likely 
explanation for the relatively high lactate levels in the mothers in the current 
study. 
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Maternal samples were obtained from the foot vein immediately after delivery 
of the infant.  The reason for taking the blood sample from a foot vein was 
simply to reduce any discomfort to the mother, as the majority had spinal 
anaesthesia for the delivery.  It is not known whether the venous stasis 
caused by the spinal anaesthesia would have any effect on the lactate levels, 
but it is possible.  Further studies will be required to examine this effect.  
 
In the current study, umbilical cord lactate levels were also found to be 
significantly positively associated with arterial pCO2 but negatively 
associated with BE.  This is not surprising as lactate is the main contributor 
to the increase of BE in anaerobic metabolism.  Krüger and colleagues have 
demonstrated a close correlation between lactate and both pH and BE 
(Krüger et al., 1998).  BE shows a linear correlation of the degree and 
duration of metabolic acidosis and is adjusted for the variation in pCO2 (Ross 
and Gala, 2002).  
 
In the current study, umbilical venous cord lactate was significantly and 
positively associated with maternal plasma glucose levels.  Under normal 
conditions, there is a steady relationship between lactate and pyruvate with a 
ratio of about ten to one (Nordström, 2004).  Hence, any condition that leads 
to an increase in glucose levels will increase pyruvate as well as lactate 
levels.  Studies have shown that giving women a high dose of glucose (more 
than 25 gram of dextrose) prior to delivery could result in fetal 
hyperglycaemia and hyperinsulinaemia which in turn could lead to an 
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increase in lactate production and acidaemia (Kenepp et al., 1982, Phillipson 
et al., 1987).   
 
Administration of β-mimetic drugs such as terbutalin to the mother has been 
shown to increase maternal and fetal blood glucose levels by accelerating 
glycogenolysis and increasing the release of insulin and glucagon (Westgren 
et al., 1982).  With regards to the relationship between umbilical venous cord 
lactate and catecholamine levels, a positive and significant correlation 
between umbilical venous cord lactate and NE levels were found in the 
current study.  These findings concord with the study carried out by 
Nordström and colleagues who looked at the relationship of cord lactate 
levels to pH and catecholamines in 60 consecutive spontaneous vaginal 
deliveries (Nordström et al., 1996).  They showed a positive and significant 
association between lactate and EPI, NE and DA levels in the umbilical 
arterial blood.  Lactate is the predominant gluconeogenic substrate of EPI-
stimulated gluconeogenesis in both the liver and kidney (Meyer et al., 2003).  
However in another study, the results suggested that fetal lactate production 
in the second stage of labour was mainly due to fetal anaerobic metabolism, 
secondary to hypoxia rather than as a consequence of catecholamine surge 
and increased hepatic glucose release (Nordström et al., 2001).  
 
Umbilical cord lactate levels were not associated with insulin levels but found 
to be significantly and negatively associated with glucagon levels in the 
current study.  In adults, glucagon infusion or a test dose is associated with 
increased hepatic glucose production from both glycogenolysis and 
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gluconeogenesis (Søvik et al., 1981).  G-6-Pase is the rate limiting enzyme 
for pathways of glycogenolysis and gluconeogenesis (Ganong, 1995a) and is 
expressed at low levels in the human fetus in-utero and only increases in the 
postnatal period in term human infants (Burchell et al., 1990).  Hepatic 
glycogen accumulates in the human fetus in the later third trimester but the 
level falls considerably soon after birth (Shelley and Neligan, 1966).  The 
glucagon stimulation test has been used as a diagnostic test in adult and 
children with genetic deficiency of G-6-Pase, and shows a typically flattened 
glucose response and an exaggerated lactate response (Chen and Burchell, 
1995).  The human fetus during labour and delivery is deficient of G-6-Pase 
as the enzyme levels only increase post-delivery.  If glucagon can mobilise 
hepatic glycogen in the human fetus, G-6-P may be converted to lactate.  To 
have a mechanism where lactate is negatively associated with glucagon is 
potentially protective for the fetus, as lactic acidaemia is not worsened. 
 
5.4.3 Amino acids and glucose homeostasis in infants 
A normal reference range for plasma amino acids has been published for 
adults (Armstrong and Stave, 1973), infants aged from day seven to four 
months (Anderson et al., 1977) and children from 0 to 18 years of age 
(Lepage et al., 1997) but no reference ranges have been published for the 
umbilical cord venous or arterial levels.  It is not appropriate to compare the 
umbilical cord values to the postnatal levels as Anderson and colleagues 
have reported for instance that arginine, histidine, leucine, lysine and 
threonine all decrease within hours of birth (Anderson et al., 1977).   
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The current study did not show a significant association between umbilical 
cord amino acid and glucose levels.  This observation is possibly because 
gluconeogenic precursor supply alone does not influence the glucose 
concentration in normal physiological conditions.  A study carried out by 
Jenssen and colleagues demonstrated that in normal adults, infusion of the 
glucogenic substrate, lactate did not increase the hepatic glucose output and 
the plasma glucose concentration under normal conditions (Jenssen et al., 
1990).  They suggested that this was due to hepatic auto-regulation that 
prevented the substrate–induced increase in gluconeogenesis.  A similar 
observation was also found in malnourished and recovered children (Kerr et 
al., 1978).  However, in the prolonged fasted adult, when the gluconeogenic 
precursor supply is low, infusion of alanine resulted in a hyperglycaemic 
response (Felig et al., 1969).  In preterm infants, the administration of alanine 
does not increase plasma glucose levels, which may be due to hepatic 
enzyme immaturity or to the low secretion levels of glucoregulatory 
hormones involved in gluconeogenesis (van Kempen et al., 2003).  The lack 
of association between alanine and glucose in the current study supports this 
view.  Therefore, gluconeogenesis not only depends on an adequate 
precursor supply but it also requires adequate activity of the enzymes 
involved in gluconeogenesis and glycogenolysis which are regulated by an 
integrated metabolic and hormonal response.   
 
5.4.4 Glucagon, insulin and glucose homeostasis in infants 
Insulin to glucagon molar ratios have been used previously as an index of 
the endocrine pancreatic regulation on hepatic glucose metabolism (Unger, 
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1972). High molar ratios of insulin to glucagon favour anabolism whereas a 
low molar ratio favours catabolism.  At term, the plasma insulin to glucagon 
ratio is high in the human fetus but falls rapidly and significantly, and then 
remains low after delivery, which in turn favours hepatic glucose release into 
the circulation through the processes of glycogenolysis and gluconeogenesis 
(Ktorza et al., 1985).  This current study has also shown a similar finding of a 
high insulin to glucagon ratio in the umbilical venous plasma.  It is surprising 
to note that the glucagon levels were high in the umbilical venous cord given 
that the insulin levels were high too, but this may reflect the position that was 
described by Hume and colleagues (Hume et al., 1999) as well as Jackson 
and colleagues (Jackson et al., 2004) where it was concluded that glucagon 
did not play an important role in the neonatal glucose regulation.  
 
The current study did not show an association between umbilical venous 
cord glucose and glucagon level.  This could be due to the fact that the study 
population was in a ‘stress free’ environment during delivery.  The response 
of fetal glucagon secretion to hypoglycaemia depends on the duration of 
hypoglycaemia.  Acute hypoglycaemia does not influence glucagon secretion 
in the fetal mouse (Lernmark and Wenngren, 1972) nor in the human fetus 
(Schaeffer et al., 1973).  However, prolonged maternal fasting appears to 
increase glucagon secretion in fetal rats (Girard et al., 1977) and also in fetal 
sheep (Schreiner et al., 1981).  In human adults, glucagon and epinephrine 
play an important role in increasing glucose levels during acute (Cryer et al., 
1984) as well as prolonged hypoglycaemia (Bolli et al., 1984).  Glucagon 
increases glucose production from the liver through stimulating 
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gluconeogenesis and glycogenolysis (Ganong, 1995b).  However, in infants 
with severe and persistent hypoglycaemia after a controlled fast, cortisol and 
epinephrine levels were elevated but not glucagon levels (Hume et al., 1999; 
Jackson et al., 2004). 
 
The current study also did not show an association between umbilical 
venous cord glucose and insulin levels.  This may be because glucose 
metabolism in the human fetus is relatively unresponsive to insulin (Menon 
and Sperling, 1996).  Studies on the effects of hyperinsulinaemia on glucose 
utilisation in fetal lambs has demonstrated that infusion of insulin results in a 
nearly twofold increase in glucose utilisation (Hay and Meznarich 1986), but 
in the adult humans, this will produce a fivefold increase in glucose utilisation 
(Menon and Sperling, 1996).  
 
There is no normal insulin reference range published for umbilical arterial or 
venous levels at birth or in children.  The mean umbilical venous cord insulin 
level found in the current study was comparable to that reported by Wang 
and colleagues of 10.4 mU/l (Wang et al., 1995).  In the term human fetus, 
the plasma concentration of insulin (Kaplan, 1984) as well as the number 
and affinity of insulin receptors on monocytes (Thorsson and Hintz, 1977) are 
higher than in the adult.  In contrast to the human adult, fetal insulin 
receptors are not down-regulated by hyperinsulinaemia (Kaplan, 1984).  
Insulin may be acting as the major growth driver in-utero;  it is one of the key 
growth promoting hormones in the fetus acting directly through changes in 
fetal metabolism and indirectly through production of insulin–like growth 
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factors (IGF) (Fowden, 1995).  Long term infusions of insulin in fetal rhesus 
monkeys resulted in increased fetal growth and eventually fetal macrosomia 
(Susa et al., 1984).  In diabetic pregnant women, hyperglycaemia can lead to 
an increase in insulin secretion and beta cell hyperplasia in the fetus, which 
can result in a macrosomic infant (Nelson-Piercy, 2002).  Such infants are at 
risk of hypoglycaemia due to hyperinsulinaemia in the early neonatal period.  
Insulin increases glucose uptake in insulin-sensitive tissue and promotes 
glyconeogenesis, as well as lipid synthesis; whereas human GH antagonises 
the effects of insulin on carbohydrate and lipid metabolisms (Ganong, 
1995b). Therefore, increased GH secretion may be associated with insulin 
resistance initially, but eventually hypersecretion of insulin occurs to 
counterbalance the insulin resistance (Menon and Sperling, 1996).  During 
puberty, there is decreased sensitivity to insulin (Bloch et al., 1987) and high 
levels of hGH found in children (Rose et al., 1991).  Similar changes may 
also occur in the fetus towards the end of a pregnancy when the fetus gains 
most weight (Gilstrap, 1999b).   
 
5.4.5 Cortisol and glucose homeostasis in infants 
There are limited reference data for plasma cortisol levels at birth reported in 
the literature.  A recent study by Garagorri and colleagues reported reference 
values for plasma adrenal steroid levels, from birth until six months of age, 
generated from 138 term well infants delivered by spontaneous vaginal 
delivery (Garagorri et al., 2008).  They showed that the level of cortisol 
remains unchanged from birth until six months of age (Garagorri et al., 
2008).  The mean umbilical venous cortisol level of 139 nmol/l found in the 
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current study was lower than the reported value of 490 nmol/l by Garagorri 
and colleagues (Garagorri et al., 2008).  This is not surprising as several 
studies have shown that umbilical cortisol levels were significantly lower in 
infants delivered by elective caesarean section than those delivered vaginally 
(Lao and Panesar, 1989; Mears et al., 2004; Miller et al., 2005).  However, 
there appears to be a big variation in the mean umbilical venous cord cortisol 
levels in infants delivered by elective caesarean section reported in the 
literature (Gitau et al., 2001; Vogl et al., 2006; Zanardo et al., 2006).  The 
mean umbilical venous cord cortisol level found in the current study was 
lower than that reported by Vogl and colleagues of 225 nmol/l (Vogl et al., 
2006) as well as Gitau and colleagues of 347 nmol/l (Gitau et al., 2001) but 
higher than that reported by Zanardo and colleagues of 125 nmol/l (Zanardo 
et al., 2006).  However, all these studies were small studies with only 12 to 
29 samples and hence the results may not be valid.   
 
This current study did not find an association between umbilical venous cord 
glucose and cortisol levels.  This could be due to the fact that during 
intrauterine life, the maintenance of glucose levels in the human fetus is 
dependent upon the maternal supply of glucose and there is no significant 
production of glucose by the fetus in-utero (Kalhan et al., 1979).  Maternal 
cortisol levels were not measured in this current study but one would expect 
that the concentrations of cortisol levels in the mother are appreciably higher 
than that of the fetus (Gitau et al., 1998).  The placenta exhibits high levels of 
the enzyme 11β-hydroxysteroid dehydrogenase type 2 (11β-HSD-2) in the 
syncytiotrophoblastic cells, which converts cortisol to metabolically inert 
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cortisone and thus, protects the fetus from the high maternal cortisol 
concentrations (Seckl et al., 1995).  Gitau and colleagues also demonstrated 
that there was a linear relationship between fetal and maternal cortisol 
concentrations, and that the levels were not related to gestational age (Gitau 
et al., 1998).  A study of the conversion of maternal cortisol to cortisone 
during placental transfer to the human fetus at mid-gestation showed that 
15% of 3H-cortisol crossed the placenta unmetabolised (Murphy et al., 1974).  
Despite the presence of 11β-HSD-2, a functional barrier to restrict the 
transfer of cortisol from the mother to the fetus, there is still approximately 
10% to 20% of maternal cortisol transfer across the placenta to the fetus 
(Gitau et al., 1998).  Therefore, any condition that increases maternal cortisol 
levels could lead to an increase in the fetal cortisol levels during pregnancy.   
 
5.4.6 Catechols and glucose homeostasis in infants 
The current study demonstrated high levels of catecholamines in the 
umbilical venous plasma which is in keeping with the results of other studies 
(Lagercrantz and Bistoletti, 1977; Eliot et al., 1980).  As discussed before 
(see pages 25 to 27), this postnatal surge is important for the neonatal 
cardiovascular, respiratory and metabolic adaptation at birth (Sperling et al., 
1984).   
 
Studies in fetal sheep showed that the placenta is responsible for the 
clearance of a large fraction of circulating catecholamines (Bzoskie et al., 
1995).  Eisenhofer concluded that as much as 50% of the circulating 
catecholamines in the fetus are cleared by the placenta (Eisenhofer, 2001).  
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MAO-A activity in the placenta is high, second only to the liver, and localized 
predominantly to the syncytiotrophoblastic layer (Billett, 2004).  In the 
placenta, NET supports both the uptake of NE and DA (Ramamoorthy et al., 
1993).  Bzoskie and colleagues have shown an inverse relationship between 
placenta NET mRNA expression and umbilical cord NE levels (Bzoskie et al., 
1995).  Trophoblastic cells invade the media of maternal spiral arteries and 
these cells express high levels of NET and VMAT2 mRNA so may prevent 
maternal plasma NE from contracting the uterine vessels and hence maintain 
circulatory homeostasis (Bottalico et al., 2004).  NET mRNA is also 
expressed in the syncytiotrophoblast cells of the chorionic villi of the placenta 
and expression in such cells may function to reduce the fetal NE plasma 
levels (Bottalico et al., 2004).  High plasma levels of NE were found in 
pregnancies complicated with pre-eclampsia (Manyonda et al., 1998; Kaaja 
et al., 1999).  Expression of NET and EMT in the placenta from pre-eclamptic 
pregnancies is reduced, which supports the concept that placenta blood flow 
may be compromised through inappropriate vascular exposure to higher 
catecholamines as the expression of transporters is reduced (Bottalico et al., 
2004).  Several studies have also shown that the expression and activity of 
MAO-A is reduced in the placentae from pre-eclamptic pregnancies 
(Carrasco et al., 2000, Sivasubramaniam et al., 2002) consistent with 
reduced NET expression and higher maternal NE levels.  
 
Fetal membranes have also been found to be responsible for catecholamine 
metabolism.  MAO, COMT, and PNMT have been shown to be present in 
human fetal membranes at term, with MAO activity particularly high in 
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chorion compared to amnion (Casimiri et al., 1991).  Hence, at birth, the 
increase in circulating catecholamine levels is due partly to the significant 
decrease in clearance rates, secondary to the removal of the placenta (Stein 
et al., 1993) as well as the fetal membranes.  
 
The limited human data available suggest that levels of the sulfated 
catechols (EPI sulfate, NE sulfate, DHPG sulfate, DOPA sulfate, DOPAC 
sulfate) were lower in umbilical venous plasma than in venous plasma of 
children and adults (Ratge et al., 1986; Eichler et al, 1989).  As mentioned 
earlier (see page 33), SULT1A3 is expressed at high levels in the fetal liver 
but decreases significantly in the late fetal-early neonatal period (Richard et 
al., 2001).  Richard and colleagues speculated that prior to delivery the 
active hepatic sulfoconjugation would cease to allow free catechols to rise for 
adaptation to extrauterine life to take place (Richard et al., 2001).  The 
results of this current study, where there are low levels of sulfated catechols 
in the umbilical venous plasma, would be in keeping with this speculation.  
The combined effects of the cessation of hepatic sulfoconjugation as well as 
the decreased clearance from the placenta and fetal membrane secondary to 
disconnection allow the free catecholamine levels to rise, an essential pre-
requisite for adaptation to extrauterine life.  
 
Measurement of catechols in the umbilical venous cord in the current study 
showed a marked predominance of NE, as much as ten times over EPI 
levels in these term infants.  This result is similar to other studies (Falconer 
and Lake, 1982; Vogl et al., 2006).  Adults and children between 5 to 17 
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years old also showed a similar pattern of higher plasma NE levels 
compared to EPI levels under resting conditions (Weise et al., 2002).  
However, this is in contrast to the study carried out by Ekblad and colleagues 
on preterm infants where the ratio of NE to EPI was reversed; preterm 
infants were found to have a higher level of EPI than NE on day two (Ekbla d 
et al., 1992).  Postnatal changes in EPI and NE levels in infants are more 
problematic to interpret as they may be related to differences in degrees of 
prematurity and mode of delivery.  
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 CHAPTER 6 
 
DISCUSSION 
 
Preterm infants are at high risk of adverse neonatal outcome including brain 
damage, chronic lung disease, retinopathy of prematurity, necrotizing 
enterocolitis, infection, behavioural problems, and neurodevelopmental 
delay.  There are many factors, which can result in brain damage in this 
population; one such factor is hypoglycaemia.  In preterm infants, failure to 
up-regulate G-6Pase, the key enzyme of hepatic gluconeogenesis, in the 
immediate postnatal period is common.  This may result in defective glucose 
homeostasis.  Previous work by our group has shown that up to 18% of 
preterm infants at the time of discharge home have low blood glucose levels 
leaving them vulnerable to repeated hypoglycaemia and risk of brain damage 
(Hume et al., 1999).  Normally the hepatic control of glucose production 
switches on at the time of birth but this appears to fail in some preterm 
infants.  These failures to switch on the key gluconeogenic genes are not 
confined to preterm infants but also to some term infants.  In 1989, Burchell 
and colleagues described a small cohort of eight term cases of sudden infant 
death syndrome (SIDS) and found that these infants had low G-6-PC1 
activity and expression (Burchell et al., 1989b).  The proportion of term 
infants who have delayed onset of expression of G-6-Pase is not known.  
The reasons for failure to switch on in some infants is not known.  Since the 
mid 1990s, investigators taken two distinct paths to further investigate this 
delay in expression of hepatic G-6-PC1.  
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 Firstly, a genetic approach particularly of term and preterm infants who had 
sudden and unexpected deaths.  Forsyth and colleagues confirmed that G-6-
PC1 activity is low in term SIDS infants as well as preterm SIDS and non-
SIDS infants in a large cohort of such infants (Forsyth et al., 2007).  The 
study also showed that a functional polymorphism in the promoter region of 
G-6-PC1 was associated with reduced expression of the protein and reduced 
hepatic enzyme activity and that this was more common in infants who died 
of SIDS (Forsyth et al., 2007).  
 
Secondly, through understanding the regulation and hormonal control 
mechanism in the switching on of perinatal genes, it was postulated that 
there may be defects in such mechanisms in some infants.  Hormonal 
dysfunctions have now been described in preterm infants including 
hypothalamic-pituitary-thyroid insufficiencies at birth (Murphy et al., 2004), 
transient hypothyroxinaemia (Frank et al., 1996), glucagon 
unresponsiveness and insulin resistance (Jackson et al., 2003).  It is highly 
probable that a combination of hormonal dysfunctions are present at the time 
of birth especially in preterm infants but these need to be assessed against a 
background of normal adaptation of the term infant.   
 
At present there is little information about the normal hormonal profiles in 
term and preterm infants around the time of delivery.  The conventional 
concepts of glucose homeostasis and regulation during labour and the early 
postnatal period in humans are extrapolated mainly from animal studies 
under controlled laboratory conditions.  Studies that have been done in 
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humans have been limited to circumscribed areas of investigation of 
particular hormones or metabolites, which can create a very misleading 
picture.  Hence the studies undertaken for this thesis were carried out to 
inform the investigation of hormonal and metabolic control, and to establish 
“normal” ranges for infants delivered by elective caesarean section.  Three 
pilots studies were carried out to clarify the methodology to enable the main 
study to be undertaken.  These preliminary studies emphasised the 
importance of prompt sampling of cord blood and subsequent analysis of 
samples, as some hormones and metabolites such as glucose, lactate and 
catechols, change significantly with post-delivery time.  
 
The main study (described in Chapter 5) is the largest series of data 
combining assays of representative alternative metabolic substrates for brain 
metabolism (glucose, lactate, 3-hydroxybutyrate, FFA and amino acids), the 
regulatory hormone insulin, and those counter-regulatory to insulin 
(glucagon, cortisol, hGH and catechols) in term infants at birth.  Only three 
infants were found to have an umbilical blood glucose level of  less than 2.6 
mmol/l at birth and this was entirely expected as the study population was in 
a ‘stress-free’ environment during delivery.  However the effect of ‘stress’, for 
example from vaginal delivery or emergency caesarean section, may 
increase the number of hypoglycaemic infants at birth.  If this scenario is 
correct it is crucial (for protection of brain integrity) that infants are able to 
use alternative substrate(s) in the event of low blood glucose levels. Overt 
hypoglycaemia at delivery has been described in infants (Burchell et al., 
1989b) but more subtle presentations are likely to exist.  The most vulnerable 
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infant is likely to be the one with a severe metabolic or hormonal defect or 
where compensatory mechanisms are defective or compromised.  Further 
studies are clearly required in infants delivered vaginally, or by emergency 
operative deliveries, to define the range of metabolites and hormones in 
these circumstances, and to consider whether an observational study should 
be planned on blood glucose levels at birth in term infants in relation to long-
term neurodevelopment outcomes.  
 
The current study showed a significant and positive association between 
maternal and fetal glucose levels, but no association of umbilical venous 
cord glucose with insulin, glucagon, hGH, cortisol, amino acids and catechols 
levels.  High levels of insulin and catechols were noted at birth.  The majority 
of the infants at delivery showed normal glucose levels despite higher levels 
of insulin.  Insulin appears to act as the major growth driver in-utero, and this 
state of hyperinsulinaemia is countered by a positive maternal-placental 
glucose gradient as well as higher fetal glucagon and hGH levels which 
maintain normoglycaemia.  Catecholamines play an important role in 
intrauterine life adaptation but may also play an important role in triggering 
the transition from maternal dependence to independent postnatal glucose 
homeostasis.  The evidence to support this hypothesis was not provided by 
the current study and will need to be evaluated in a larger study with a larger 
proportion of infants with a wider range of blood glucose levels, particularly 
where these are low and in the conventional range for hypoglycaemia.  
There is evidence to show that there is an arterio-venous difference in EPI 
and NE in cord infant blood with venous levels lower than arterial (Eliot et al., 
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1980, Falconer and Lake, 1982).  Postnatal levels of EPI and NE are high 
(e.g. Eliot et al., 1980) consistent with high amounts of VMA and HVA in 
postnatal urine (Gabriel et al., 1983).  These observations suggest that there 
is a feto-placental-maternal metabolism or transport of catechols.  This thesis 
describes for the first time a full range of catechols and their sulfated 
conjugates levels in non-stressed term infants; this baseline information can 
now be used to research a variety of perinatal scenarios, including 
establishing the inter-relationship between fetal and maternal metabolism of 
catechols.   
 
The main strength of this work is that a whole of range of analytes were 
measured in one infant as opposed to many other studies which only 
measured one or two analytes which could create a misleading picture. At 
the same time, this was also the limitation of the study as the range of 
analytes measured necessitated the use of venous blood samples as 
opposed to arterial cord blood samples, which would have provided a more 
accurate reflection of the fetal metabolism.  Our unpublished data on the 
catechols levels from 60 paired arterial and venous samples from infants 
who delivered by elective caesarean section showed that the mean catechol 
levels were significantly higher in the umbilical artery compared to the 
umbilical vein samples.  The sulfated conjugates levels were also 
significantly higher in the umbilical artery compared to the umbilical vein 
samples, with the exception of DOPA sulfate.  Studies have shown that there 
are no corelations between maternal and fetal catecholamine levels 
(Gülmezoglu et al., 1996) and that the fetus is able to mount a sympatho-
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adrenal response independent from the mother (Giannakoulopoulos et al., 
1999). As discussed in the previous chapter, the placenta plays an essential 
role in catecholamine homeostasis in the fetus and as much as 50% of the 
circulating catecholamines are cleared by the placenta (Eisenhofer, 2001).  
The placenta has high MAO-A activities (Billet, 2004) and SULT1AS 
expression (Stanley et al., 2001).  
 
A small study carried out by Scheepers and colleagues showed no 
differences between umbilical arterial and venous levels of glucose, FFA, 
lactate and beta-hydroxybutyrate (Scheepers et al., 2004).  Further studies 
are clearly required to establish the arterio-venous difference of various 
hormones and metabolites to determine whether the venous and arterial 
levels are comparable as well as to investigate the role of placenta 
metabolism and feto-maternal transfer.  
 
In conclusion, the importance of this dataset has been the provision of 
normal values which can inform management of term infants and provide 
comparative data for future research projects.  This extensive data set has 
produced a baseline data in which reference values can be generated and 
will be valuable in evaluating any effects of antenatal or intrapartum factors 
on the hormonal and metabolic profiles of infants at birth.   
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Table 5.6: Univariate analysis model for cord glucose and lactate  
 
Step 1 Outcome 
dependent 
Explanatory variables 
Bivariate analysis Cord glucose 
Cord lactate 
Categorical variables 
Maternal smokers 
Antenatal events 
   Antepartum haemorrhage 
Asthma 
Epilepsy 
Thyroid disease 
Diabetes 
Hyperemesis gravidarum 
Streptococcus agalactia carriage 
Tractocile treatment 
Betamethasone injection 
Hypertension 
Treated UTI 
Treated vaginal discharge 
  Reason for C/S 
   Breech presentation 
Maternal request 
Other reasons# 
Previous caesarean section 
  Ephedrine received 
Phenylephrine received 
Atropine received 
Glycopyrrolate received 
SCBU admission 
Infant sex 
Neonatal resuscitation 
 
  
Continuous variables  
  Gestational age 
Maternal age 
Maternal BMI at delivery 
Placenta weight 
Apgar score at 1 min 
Apgar score at 5 min 
Cord blood arterial pH 
Cord blood arterial BE 
Cord blood arterial pO2  
Cord blood arterial pCO2 
Cord blood arterial cHCO3 
Infant birth weight
 
Infant birth weight ratio 
Infant OFC 
Infant birth length 
Maternal glucose 
Maternal lactate 
Time interval from maternal fasting to cord 
sampling 
Cord insulin 
Cord glucagon 
Cord hGH 
Cord cortisol 
Cord EPI 
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Table 5.6: continuation from above table 
 
Step 1 Outcome dependent Explanatory variables 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Continuous variables 
Cord EPI sulfate 
Cord NE 
Cord NE sulfate 
Cord DOPA  
Cord DOPA sulfate 
Cord DHPG  
Cord DHPG sulfate 
Cord DOPAC  
Cord DOPAC sulfate 
Cord 3-hydroxybutyrate 
Cord free fatty acids 
Cord amino acids 
   Alanine  
Aminobutyric acid 
Arginine  
Citrulline  
Cystine  
GABA 
Glutamic acid 
Glutamine 
Glycine  
Histidine  
Isoleucine  
Leucine 
Lysine  
Methionine 
Ornithine  
Phenyalanine  
Serine  
Taurine  
Threonine  
Tyrosine 
Valine 
 
 
UTI urinary tract infection,  C/S caesarean section,  SCBU special care baby unit,  BMI body mass 
index, BE base excess, cHCO3 bicarbonate, OFC occipital-frontal head circumference, hGH  human 
growth hormone, EPI epinephrine, NE norepinephrine, DOPA dihydroxyphenylalanine, DHPG 
dihydroxyphenylglycol, DOPAC dihydroxyphenylacetic acid 
 
#Other reasons included cephalopelvic disproportion, Crohn’s disease, bowel problems as a result of a 
previous delivery, and an unstable lie 
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Table 5.7: Univariate regression model for cord glucose and lactate 
 
Step 2 Outcome 
dependent 
Explanatory variables 
Univariate regression 
analysis  
Cord glucose 
 
 Significant factors from step 1 (Table 4.6) 
 
  Ephedrine received 
Neonatal resuscitation required 
Reasons for caesarean section 
Maternal glucose   
Cord EPI  
Cord EPI sulfate 
Cord NE 
Cord 3-hydroxybutyrate 
Cord alanine 
Cord lysine  
 
  Important factors identified from literature 
   Maternal diabetes 
Cord insulin 
Cord glucagon 
Cord hGH 
Cord cortisol  
 
 Cord lactate Significant factors from step 1 (Table 4.6) 
   Apgar 5 min 
Arterial BE 
Maternal glucose 
Maternal Lactate 
Cord EPI 
Cord EPI sulfate 
Cord NE 
Cord NE sulfate 
Cord DOPA 
Cord DOPA sulfate 
Cord DHPG  
Cord DHPG sulfate 
Cord alanine 
Cord leucine 
Cord tyrosine 
Cord isoleucine 
Cord valine 
 
 Important factors identified from literature 
  
 Cord glucose 
Cord insulin 
Cord glucagon 
Cord hGH 
Cord cortisol 
 
 
EPI epinephrine, NE norepinephrine, hGH human growth hormone, BE base excess, DOPA 
dihydroxyphenylalanine, DHPG dihydroxyphenylglycol, 
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GLUCOSE AND LACTATE LEVELS IN CORD BLOOD SAMPLES 
ROUTINELY COLLECTED AT DELIVERY FOR ESTIMATION OF BLOOD 
GAS AND ACID-BASE STATUS IN TERM INFANTS 
 
(Reference number 033/04) 
 
We invite you to participate in a research project.  We believe it to be of 
potential importance.  However, before you decide whether or not you wish 
to participate, we need to be sure that you understand firstly why we are 
doing it, and secondly what it would involve if you agreed.  We are therefore 
providing you with the following information.  Read it carefully and be sure to 
ask any questions you have, and, if you want, discuss it with outsiders.  We 
will do our best to explain and to provide any further information you may ask 
for now or later.  You do not have to make an immediate decision. 
THE BACKGROUND TO THE STUDY 
Every year, there are a few babies who suffer from brain damage at delivery.  
There are a number of possible causes.  We suspect that low blood glucose 
(sugar) level at birth is one of the possible causes.  We would like to study 
this further in healthy term infants.  If this study shows low blood glucose 
(sugar) level may be a problem then we will seek a solution to this in the 
future.  
  
We would like to ask mothers who deliver their infants at term to participate 
in this initial study. 
 
The University of Dundee pays the salaries of the researchers. We will seek 
further funds from charities to pay for the blood tests.  
WHAT DOES THE STUDY ENTAIL?  
We routinely take blood from the umbilical cord after the baby is delivered to 
measure the oxygen level.  This is done for all deliveries.  For this study, an 
additional small sample of blood will also be retained (about a teaspoonful).  
It does not involve taking blood from you or your baby.   We will use this 
blood to measure the glucose levels and other related substances, which are 
used for energy, as well as hormones which regulate glucose levels.  We 
shall also abstract from your medical notes information about your health 
during pregnancy, your progress in labour and about your baby at birth 
WHAT ARE THE DISCOMFORTS, RISKS AND SIDE EFFECTS? 
There are no risks to your baby as the blood sample will be taken from the 
umbilical cord after delivery of the placenta.   
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NINEWELLS HOSPITAL & MEDICAL SCHOOL • Tayside Institute of Child Health Dundee DD1 9SY Scotland 
UK  t +44 (0) 1382 632594   f +44 (0) 1382 632597   e r.hume@dundee.ac.uk  
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WHAT WILL HAPPEN TO THE INFORMATION COLLECTED IN THE 
STUDY? 
All aspects of the study concerning you and your baby will remain 
confidential.  Only the project researchers will have access to the information 
collected in the study.  The information about you will be stored in a locked 
computer file accessed by password.  Your name will be not be entered in 
this file, only a unique record number.  Only a limited number of researchers 
in Dundee will know the names of the participants.  A floppy disc containing 
unique record numbers and names will be kept in a locked filing cabinet.   
 
This is a study to find out what are the normal levels of glucose and other 
related substances in cord blood at the time of delivery.  It is possible we 
may find babies who have higher or lower levels than other babies.  If we 
think this may affect the future health of your baby, we will discuss this with 
you.  You will be offered an appointment with Professor Robert Hume 
Consultant Paediatrician at Ninewells to discuss this further.  We will not tell 
your GP that you are taking part in this study but if there is concern about 
your baby’s health we will involve your GP.  If your baby’s results are similar 
to other babies in the study we will not routinely tell you the results. 
WHAT ARE MY RIGHTS? 
Participation in this study is entirely voluntary and you are free to refuse to 
take part or to withdraw from the study at any time without having to give a 
reason and without this affecting your future medical care or your relationship 
with medical staff looking after you.  
 
You are free to discuss the study and seek advice about participation from 
others. There will be no payment for participation.   
 
We believe it is safe for you to take part in this study but you are insured 
through NHS Tayside should something go wrong and compensation is 
needed. 
   
The Tayside Committee on Medical Research Ethics, which has 
responsibility for scrutinising all proposals for medical research on humans in 
Tayside, has examined the proposal and has raised no objections from the 
point of view of medical ethics.  It is a requirement that your records in this 
research, together with any relevant medical records, be made available for 
scrutiny by monitors from NHS Tayside and the Regulatory Authorities.  But 
should you not wish this you can refuse and this information will be recorded 
on your consent form.  
 
A copy of this information sheet and consent form will be given to you to 
keep. Should you require more information or have any questions, you could 
contact Dr. Daisy Koh, the main co-ordinator of this study at Ninewells 
Hospital on 01382 660111 Bleep 4165.   
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Professor  Robert Hume BSc MBChB PhD FRCPEdin FRCPCH  
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BACKGROUND INFORMATION 
 
  
1   Mother's surname 
 
  
2   Mother's DoB 
  _____/_____/_______ 
  dd mm yyyy 
3. Mother's CHI or ID number 
 
  
  
  
5   Gestation at delivery   completed weeks 
 
  
  
6   Current smoker  1 Non-smoker 2 Ex-smoker 3 
 
7a Booking Weight (Kg) •   8 Booking height (m) •   
 
  
 
  
 
MATERNAL MEDICAL HISTORY  
 
 Yes    No 
9 ANTEPARTUM HAEMORRHAGE g 1 2   
 
 if yes,  episode 1 at gestation    weeks 
  episode 2 at gestation    weeks 
 episode 3 at gestation    weeks 
 
what was the cause?  Tick if yes 
 abruption 1 
 placenta praevia 2 
 vasa praevia  3 
 other  4 please specify_____________________________________________ 
 Not known 5 
 
  Yes No 
10 ASTHMA g 1 2    specify treatment 
  Yes  No 
11 EPILEPSY g 1 2   specify treatment 
             Yes No 
12  THYROID DISEASE concurrent with pregnancy 1 2 
                                                          
g
  Antepartum haemmorrhage is vaginal bleeding after 24 weeks 
  Asthma and epilepsy should be considered present if the women is on current treatment 
 
A study of glucose and 
lactate levels on cord blood 
SER No 
 
office use only 
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 Tick all that apply 
 a  if yes,  hyperthyroid 1 
   hypothyroid 1 
  
simple non-toxic goitre 1 
 
other thyroid enlargement 1 
  
auto immune thyroiditis 1 
 Other, please specify 1 
 
 Yes No 
 b  Current T4 treatment 1 2   if yes,T4 mg/day/Last menstrual period      
                                                                          T4 mg/day/delivery      
 
                                                                         Yes               No 
 c  Family history thyroid disease 1 2 if yes, Mother 1 
      Father 1 
      Siblings 1   out of 
 
 Yes   No   
 d  Hyperthyroid treatment 1 2  
 if yes: Regimen prior  
To pregnancy 
Regimen during  
pregnancy 
 Carbimazole 1 1 
 Surgery 1 1 
 Thiouracil 1 1 
 radioactive iodine 1 1 
 
                                                    Yes  No  
13 DIABETES MELLITUS         1 2 
 a if yes,  Insulin dependent diabetes mellitus      1 
  or, Gestational diabetes:  insulin required    2 
  or Gestational diabetes:  non-insulin            3 
 
  
 b  Age IDD diagnosed   yrs 
  
 c  IDD insulin at booking    units/day 
  
 d  IDD insulin at delivery    units/day 
  
  
  
 e  Gestational diabetes fasting blood glucose   mmol/l 
 
 f  Gestational diabetes 2 hour blood glucose    mmol/l 
 after 75g OGTT 
  
 g  Gestational diabetes diagnosis made at       completed weeks gestation 
  
 h  Insulin for Gestational diabetes started at                 completed weeks gestation 
 
 
 
 i  Gestational diabetes max insulin dosage           units/day      Diet only 1 
  
 
14  HYPEREMESIS             Yes 1            No 2 
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 if yes,   tick as many as apply admitted  1 
  Ketonuria 1 
  
IV
 
fluids given 1 
 
15  ANY OTHER CONDITIONS  please specify 
 
                                                                                        Yes      No 
16 a  DID THE MOTHER HAVE GROUP B STREPTOCOCCUS 1 2 
   If yes 
 b  At what gestation was Group B identified   weeks 
 c  If yes  was treatment   tick as appropriate     antenatal 1     intrapartum 2       post natal 3 
 d  Antibiotic please specify 
 
 
 
 
MATERNAL MEDICATIONS   
 Yes No                                                                                                      Yes No 
17 a  Ritodrine 1 2 17aa       Tractocile        1 2 
  
 b  initial _____/_____/_______c  finalg_____/_____/_______d  total daysg treatment    •  
                               dd         mm          yyyy                dd           mm             yyyy   
 
     e total ritodrine dosage (mg) 
  
 
  
 f  maternal weight start treatment (kg)                   •   
    g  Date & time final dose   _____/_____/_____      
            dd        mm         yyyy                 24 hour clock       
 Yes No   
18  a Nifedipine 1 2   
  
 b  initial _____/_____/_______ c  finalg_____/_____/_______  d  total daysg treatment •  
                      dd        mm         yyyy                            dd        mm         yyyy 
 
      e total nifedipine dosage (mg)  
 
 
  
 f  maternal weight start treatment (kg)             •   
      g Date & time final dose_____/_____/_____    
                                                                  dd      mm        yyyy               24 hour clock     
  
  
             Yes           No   
19  a  First Steroid Course 1 2    if yes,  Name of steroid 
  
 b  initial _____/_____/_______c  finalg_____/_____/_______ d total steroid dosage (mg) 
     dd         mm           yyyy         dd          mm              yyyy  
 
  
 e  maternal weight start treatment (kg)            •   
    f  Date & time final dose_____/_____/_____    
                     dd         mm         yyyy              24 hour clock     
  
 
               
                                                                     Yes                No  
 
                                                          
 
 
g
  Final date is the date is the final date of treatment or the date of delivery whichever is first 
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20  a  Second Steroid Course 1 2  if yes,  Name of steroid _______________________ 
  
 b  initial _____/_____/_______c  finalg_____/_____/_______ d total steroid dosage (mg) 
     dd      mm          yyyy       dd          mm          yyyy  
 
  
 e  maternal weight start treatment (kg)            •   
    f  Date & time final dose_____/_____/_____    
                    dd          mm          yyyy              24 hour clock    
 
IF MORE COURSES GIVEN, USE OPPOSITE PAGE 
 
21 a  Indomethacin Yes No  
 
  1 2 
 
  
 b  initial _____/_____/_______c  finalg_____/_____/_______ d total indomethacin dosage (mg) 
     dd       mm          yyyy       dd         mm            yyyy  
 
  
e  maternal weight start treatment (kg)           •   
f  Date & time final dose_____/_____/_____    
     dd          mm       yyyy          24 hour clock  
 
 
MATERNAL HYPERTENSION during pregnancy g 
 Yes No 
22 Is the mother hypertensive? 1 2 
 
23 a Max Systolic BP during pregnancy       b  Max Diastolic BP during pregnancy 
    mmHg   mmHg 
 
c Gestation at max BP  weeks 
 
d Max urinary protein    g/l             e  Gestation at max urinary protein  weeks 
 
f Max plasma urate     •  mmol/l    g  Max plasma creatinine          µmol/l 
 
h Min blood platelets     109/l         I  Max plasma alanine aminotransferase  u/l 
 
ANTI HYPERTENSIVE DRUGS  during pregnancy ONLY 
NB  final date is date finish treatment OR delivery WHICH EVER IS FIRST 
 
24 a  First drug  please specify    
 
 
 b  start _____/_____/_______ c  final_____/_____/_______ 
 dd     mm      yyyy   dd     mm     yyyy 
 
 
25 a   Second drug  please specify    
 
 
 b  start _____/_____/_______ c  final_____/_____/_______ 
 dd    mm       yyyy   dd    mm    yyyy 
 
 
26 a  Third drug  please specify    
 
 b  start _____/_____/_______ c  final_____/_____/_______ 
 dd     mm      yyyy    dd    mm     yyyy 
 
 
 
MATERNAL ANTICONVULSANT DRUG  during pregnancy ONLY  
  
NB  final date is date finish treatment OR delivery WHICH EVER IS FIRST 
 
                                                          
  
Go to  Q27 
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27 a  Drug 1  please specify    
 
 
  b  start _____/_____/_______ c  final_____/_____/_______ 
    dd    mm       yyyy   dd     mm     yyyy 
 
28 a Drug 2  please specify    
 
  b  start _____/_____/_______ c  final_____/_____/_______ 
   dd         mm             yyyy    dd      mm     yyyy 
 
 
29   a  Drug 3  please specify    
 
 
 b  start _____/_____/_______ c  final_____/_____/_______ 
 dd   mm        yyyy    dd    mm     yyyy 
 
 
ANY (ORAL OR IV) MATERNAL STEROIDS (eg for asthma) other than dexamet etc.  
for prevention of RDS. g 
 
 
 Course 1 
30 a Name   
 
  
 b  start g   _____/_____/_______ c  finishg     _____/_____/_______ 
 dd    mm         yyyy    dd     mm         yyyy 
 
  
 d  total daily dosage   
 mg 
e total days treatment   
  
 f  maternal weight start treatment • kg 
 
 
 
 
 Course 2 
31 a  Name   
 
  
 b  start g   _____/_____/_______ c  finishg     _____/_____/_______ 
   dd     mm         yyyy dd      mm        yyyy 
 
  
 d  total daily dosage   
 mg 
e total days treatment   
  
 f  maternal weight start treatment • kg 
 
 
 Course 3 
32 a  Name   
 
  
 b  start g   _____/_____/_______ c  finishg     _____/_____/_______ 
 dd      mm        yyyy dd     mm        yyyy 
 
  
 d  total daily dosage   
 mg 
e total days treatment   
  
 f  maternal weight start treatment • kg 
 
 
 
TREATED MATERNAL GU INFECTIONS (In the week prior to delivery)g 
                                                                                         Yes         No 
 a  Urinary tract infection 1 2  if yes, 
 
 b  Treatment (specify)    c  Dosage  
 
 d  Organism (specify) e  Date ______/______/_____ 
34 Yes No  
                                                          
g
  Finish date is date finish treatment OR delivery WHICH EVER IS FIRST 
 Start date is the date of last menstrual period for mothers who were on steriods throughout pregnancy, OR,  true start date           
as applicable 
  Treated maternal GU infections defined as treated and not simply culture positive 
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 a  Vaginal discharge 1 2  if yes, 
 
 b  Treatment (specify)_______________________ c  Dosage  
 
 d  Organism (specify)__________________________ e  Date ______/______/_____ 
 
 
DELIVERY AND BIRTH DETAILS 
 
 
35  a  Was labour onset           Spontaneous 1 Induced 2 
 b  if induced, how    Artifical rupture membranes 1 
 
                                                               Prostaglandins pessary 2 
                                                                                                          
Syntocin         3 
 
 c  reason(s) for induction  please specify 
 
  
36 a  Was
 
labour augmented?  Yes  1 No 2 
  b  if yes was this by  Syntocin Yes    1 No 2 
 
 c  reason(s) for augmention  please specify 
 
 
     
37 Type of delivery  tick one box 
                            
  
 a  Spontaneous cephalic vaginal 1  d  Elective caesarean 4 
 b  Vaginal breech 2  e  Emergency caesarean 5 
 c  Instrumental cephalic vaginal 3  
  
38  Drugs received during labour  tick as many as apply 
  
 a  None received 1  d  Epidural / spinal 1 
 b  Entonox 1  e  Opiate 1 
 c  General anaesthesia 1 f   Other,  please specify 1 
 
 
39 a  Duration of first stage labour ___  ___  hrs ___  ___  mins 
 
  
40 How long were the membranes ruptured?___  ___  days ___  ___  hrs ___  ___  mins  
 
41   Placental weight  gm   
 
 
 
DELIVERY OUTCOMES 
 
  
  
42a Date of birth _____/_____/_____   42b  Time of birth      24 hour clock 
  
43   Apgar score 1 minute  44   Apgar score 5 minutes  
  
47   Resuscitation required Yes 1          No 2   
 
 if yes, Narcan and/or facial O2 1 IPPV by tube 3 
 
IPPV
 
by mask
 2  IPPV and drugs 4 
 
 
 
INFANT CHARACTERISTICS 
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48 Infant's name 
  
 First                                  Surname  _______________ 
49  Infant's DoB 
 _____/_____/_______    
   dd  mm yyyy   
  
50  Infant's sex Male 1 Female 2 
 
 
51  Multiple birth? Yes 1 No 2  
if yes,          twin 1 Triplet 2  Other 3 
  
52  Infant's CHI or ID number 
 
53  Infant's birth weight  
  gm 
  
54  Birth length •  cm 55  Birth OFC  •  cm 
  
 
BIOCHEMISTRY:  INFANT  
 
AT BIRTH 
   
45  Umbilical artery pH   
 
83 Umbilical vein pH   
46b Umbilical artery pCO2    kPa 
 
83a Umbilical vein pCO2    kPa 
 
46c Umbilical artery pO2    kPa 
 
83b Umbilical vein pO2    kPa 
 
46d Umbilical artery cHCO3     mmol/l 
 
83c Umbilical vein cHCO3     mmol/l 
 
46a Umbilical artery BE      mmol/l 
 
83d Umbilical vein BE    mmol/l 
 
 
 
 
 
84 Glucose level       mmol/l 85 Lactate level      mmol/l 
 
 
 
Name of person who completed the abstraction form 
 
Position 
 
Date completed _____/_____/_____ 
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 Additional steroid courses 
 
Third Steroid Course  
 Yes No  
 
 a 1 2 if yes,  Name of steroid   
  
 b  initial _____/_____/_______c  finalg_____/_____/_______ d total steroid dosage (mg) 
 dd mm yyyy dd mm yyyy  
 
  
 e  maternal weight start treatment (kg)            •  
  
    f  Date & time final dose_____/_____/_____    
            dd       mm        yyyy       24 hour clock  
  
Fourth Steroid Course  
 Yes No  
 
 a 1 2 if yes,  Name of steroid   
  
 b  initial _____/_____/_______ c  finalg_____/_____/_______ d total steroid dosage (mg) 
 dd mm yyyy dd mm yyyy 
 
  
 e  maternal weight start treatment (kg)            •  
  
    f  Date & time final dose_____/_____/_____    
                                      dd mm         yyyy 24 hour clock   
  
Fifth Steroid Course  
 Yes No  
 
 a 1 2 if yes,  Name of steroid   
  
 b  initial _____/_____/_______ c  finalg_____/_____/_______ d total steroid dosage (mg) 
 dd mm yyyy dd mm yyyy  
 
  
 e  maternal weight start treatment (kg)            •  
  
    f  Date & time final dose_____/_____/_____    
          dd            mm         yyyy          24 hour clock   
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MEASURING CHANGES IN VENOUS CORD BLOOD GLUCOSE, LACTATE, 
BLOOD GASES AND ACID-BASE VALUES WITH TIME FOLLOWING 
DELIVERY 
(Reference number 033/04) 
 
We invite you to participate in a research project.  We believe it to be of 
potential importance.  However, before you decide whether or not you wish to 
participate, we need to be sure that you understand firstly why we are doing it, 
and secondly what it would involve if you agreed.  We are therefore providing 
you with the following information.  Read it carefully and be sure to ask any 
questions you have, and, if you want, discuss it with outsiders.  We will do our 
best to explain and to provide any further information you may ask for now or 
later.  You do not have to make an immediate decision. 
 
THE BACKGROUND TO THE STUDY 
Every year, there are a few babies who suffer from brain damage at delivery.  
There are a number of possible causes.  We suspect that low blood glucose 
(sugar) level at birth is one of the possible causes.  We would like to study this 
further in healthy term infants.  If this study shows low blood glucose (sugar) 
level may be a problem then we will seek a solution to this in the future.  
  
We would like to ask mothers who deliver their infants at term to participate in 
this initial study. 
 
The University of Dundee pays the salaries of the researchers. We will seek 
further funds from charities to pay for the blood tests.  
 
WHAT DOES THE STUDY ENTAIL?  
We routinely take blood from the umbilical cord after the baby is delivered to 
measure the oxygen level.  This is done for all deliveries.  For this study, 
additional small samples of blood will also be retained (about a teaspoonful).  
We will use this blood to measure the glucose levels and other related 
substances, which are used for energy.  It does not involve taking blood from 
you or your baby. 
 
WHAT ARE THE DISCOMFORTS, RISKS AND SIDE EFFECTS? 
There are no risks to your baby as the blood sample will be taken from the 
umbilical cord after delivery of the placenta.   
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WHAT WILL HAPPEN TO THE INFORMATION COLLECTED IN THE 
STUDY? 
All aspects of the study concerning you and your baby will remain confidential.  
Only the project researchers will have access to the information collected in the 
study.  The information about you will be stored in a locked computer file 
accessed by password.  Your name will be not be entered in this file, only a 
unique record number.  Only a limited number of researchers in Dundee will 
know the names of the participants.  A floppy disc containing unique record 
numbers and names will be kept in a locked filing cabinet.   
WHAT ARE MY RIGHTS? 
Participation in this study is entirely voluntary and you are free to refuse to take 
part or to withdraw from the study at any time without having to give a reason 
and without this affecting your future medical care or your relationship with 
medical staff looking after you. You are free to discuss the study and seek 
advice about participation from others.  
 
There will be no payment for participation.   
 
We believe it is safe for you to take part in this study but you are insured 
through NHS Tayside should something go wrong and compensation is needed. 
   
The Tayside Committee on Medical Research Ethics, which has responsibility 
for scrutinising all proposals for medical research on humans in Tayside, has 
examined the proposal and has raised no objections from the point of view of 
medical ethics.  It is a requirement that your records in this research, together 
with any relevant medical records, be made available for scrutiny by monitors 
from NHS Tayside and the Regulatory Authorities.  But should you not wish this 
you can refuse and this information will be recorded on your consent form.  
 
A copy of this information sheet and consent form will be given to you to keep. 
Should you require more information or have any questions, you could contact 
Dr. Daisy Koh, the main co-ordinator of this study at Ninewells Hospital on 
01382 660111 Bleep 4165.  
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METABOLIC AND HORMONAL RESPONSES TO HYPOGLYCAEMIA IN 
INFANTS DELIVERED BY CAESAREAN SECTION 
(Reference number 033/04) 
 
We invite you to participate in a research project.  We believe it to be of 
potential importance.  However, before you decide whether or not you wish to 
participate, we need to be sure that you understand firstly why we are doing it, 
and secondly what it would involve if you agreed.  We are therefore providing 
you with the following information.  Read it carefully and be sure to ask any 
questions you have, and, if you want, discuss it with outsiders.  We will do our 
best to explain and to provide any further information you may ask for now or 
later.  You do not have to make an immediate decision. 
THE BACKGROUND TO THE STUDY 
Every year, there are a few babies who suffer from brain damage at delivery.  
There are a number of possible causes.  We suspect that low blood glucose 
(sugar) level at birth is one of the possible causes.  We would like to study this 
further in healthy term infants.  If this study shows low blood glucose (sugar) 
level may be a problem then we will seek a solution to this in the future.  
  
We would like to ask mothers who deliver their infants at term to participate in 
this initial study. 
 
The University of Dundee pays the salaries of the researchers. We will seek 
further funds from charities to pay for the blood tests.  
WHAT DOES THE STUDY ENTAIL?  
We routinely take blood from the umbilical cord after the baby is delivered to 
measure the oxygen level.  This is done for all deliveries.  For this study, an 
additional small sample of blood will also be retained (about a teaspoonful).  We 
also require a blood sample from you (about a teaspoonful) just before and after 
delivery.  No further blood samples are required from you or your baby.  We will 
use this blood to measure the glucose levels and other related substances, 
which are used for energy, as well as hormones which regulate glucose levels.  
We shall also abstract from your medical notes information about your health 
during pregnancy, your progress in labour and about your baby at birth 
WHAT ARE THE DISCOMFORTS, RISKS AND SIDE EFFECTS? 
There are no risks to your baby as the blood sample will be taken from the 
umbilical cord after delivery of the placenta.  Taking a blood sample from you 
may cause a little discomfort. 
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WHAT WILL HAPPEN TO THE INFORMATION COLLECTED IN THE 
STUDY? 
All aspects of the study concerning you and your baby will remain confidential.  
Only the project researchers will have access to the information collected in the 
study.  The information about you will be stored in a locked computer file 
accessed by password.  Your name will be not be entered in this file, only a 
unique record number.  Only a limited number of researchers in Dundee will 
know the names of the participants.  A floppy disc containing unique record 
numbers and names will be kept in a locked filing cabinet.   
 
This is a study to find out what are the normal levels of glucose and other 
related substances in cord blood at the time of delivery.  It is possible we may 
find babies who have higher or lower levels than other babies.  If we think this 
may affect the future health of your baby, we will discuss this with you.  You will 
be offered an appointment with Professor Robert Hume Consultant 
Paediatrician at Ninewells to discuss this further.  We will not tell your GP that 
you are taking part in this study but if there is concern about your baby’s health 
we will involve your GP.  If your baby’s results are similar to other babies in the 
study we will not routinely tell you the results. 
WHAT ARE MY RIGHTS? 
Participation in this study is entirely voluntary and you are free to refuse to take 
part or to withdraw from the study at any time without having to give a reason 
and without this affecting your future medical care or your relationship with 
medical staff looking after you.  
 
You are free to discuss the study and seek advice about participation from 
others. There will be no payment for participation.   
 
We believe it is safe for you to take part in this study but you are insured 
through NHS Tayside should something go wrong and compensation is needed. 
   
The Tayside Committee on Medical Research Ethics, which has responsibility 
for scrutinising all proposals for medical research on humans in Tayside, has 
examined the proposal and has raised no objections from the point of view of 
medical ethics.  It is a requirement that your records in this research, together 
with any relevant medical records, be made available for scrutiny by monitors 
from NHS Tayside and the Regulatory Authorities.  But should you not wish this 
you can refuse and this information will be recorded on your consent form.  
 
A copy of this information sheet and consent form will be given to you to keep. 
Should you require more information or have any questions, you could contact 
Dr. Daisy Koh, the main co-ordinator of this study at Ninewells Hospital on 
01382 660111 Bleep 4165.   
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BACKGROUND INFORMATION 
 
1   Mother's surname ____________________ 
  
2   Mother's CHI or ID number 
 
3   Gestation at delivery   completed weeks 
 
4   Current smoker  1 Non-smoker 2 Ex-smoker 3 
 
5a Booking Weight (Kg) •    5b Booking height (m) •   
 
6a   Delivery Weight  (Kg)     •   6b Delivery height (m) •  
 
7  Date & time last meal      _____/_____/_____      
          dd        mm         yyyy            24 hour clock    
    
MATERNAL MEDICAL HISTORY  
 
              Yes        No 
8 ANTEPARTUM HAEMORRHAGE g               1 2   
 
 if yes,  episode 1 at gestation   weeks 
  episode 2 at gestation   weeks 
 episode 3 at gestation   weeks 
 > 3 episodes      
 
what was the cause?  Tick if yes 
 abruption 1 
 placenta praevia 2 
 vasa praevia  3 
 other  4 please specify_____________________________________________ 
 Not known 5 
 
  Yes No 
9 ASTHMA g 1 2    specify treatment 
  Yes  No 
10 EPILEPSY g 1 2   specify treatment 
                                                          
g
  Antepartum haemmorrhage is vaginal bleeding after 24 weeks 
  Asthma and epilepsy should be considered present if the women is on current treatment 
 
Metabolic & Hormonal 
Reponses to Hypoglycaemia in  
Infants delivered by C/S 
SER No 
 
office use only 
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   Yes No 
11  THYROID DISEASE concurrent with pregnancy 1 2 
 Tick all that apply 
 a  if yes,  hyperthyroid 1 
   hypothyroid 1 
  
simple non-toxic goitre 1 
 
other thyroid enlargement 1 
  
auto immune thyroiditis 1 
 Other, please specify 1 
 
 Yes No 
 b  Current T4 treatment 1 2   if yes,T4 mg/day/Last menstrual period  
                                                                         T4 mg/day/delivery   
 
                                                                          Yes               No 
 c  Family history thyroid disease 1 2 if yes, Mother 1 
      Father 1 
      Siblings  1   out of  
 Yes   No   
 d  Hyperthyroid treatment 1 2  
 if yes: Regimen prior  
to pregnancy 
Regimen during  
Pregnancy 
 Carbimazole 1 1 
 Surgery 1 1 
 Thiouracil 1 1 
 radioactive iodine 1 1 
 
                                             Yes             No  
12 DIABETES MELLITUS   1       2 
 a if yes,  Insulin dependent diabetes mellitus      1 
  or, Gestational diabetes:  insulin required    2 
  or Gestational diabetes:  non-insulin            3 
 
  
 b  Age IDD diagnosed   yrs 
  
 c  IDD insulin at booking    units/day 
  
 d  IDD insulin at delivery    units/day 
  
  
  
 e  Gestational diabetes fasting blood glucose   mmol/l 
 
 f  Gestational diabetes 2 hour blood glucose    mmol/l 
 after 75g OGTT 
  
 g  Gestational diabetes diagnosis made at               completed weeks gestation 
  
 h  Insulin for Gestational diabetes started at                 completed weeks gestation 
 
 
 
 i  Gestational diabetes max insulin dosage           units/day      Diet only 1 
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13  HYPEREMESIS             Yes   1               No 2 
 If yes,   tick as many as apply admitted  1 
  Ketonuria 1 
  
IV
 
fluids given 1 
 
14 ANY OTHER CONDITIONS  please specify 
 
 
                                                                                    Yes      No 
15 a  DID THE MOTHER HAVE GROUP B STREPTOCOCCUS 1 2 
   If yes 
 b  Group B identified:        Previous pregnancy      1    Current pregnancy  2   
 
     e At what gestation at current pregnancy was Group B identified   weeks 
  
 c  If yes  was treatment   tick as appropriate     antenatal 1     intrapartum 2   
 d  Antibiotic please specify 
 
 
 
 
MATERNAL MEDICATIONS   
 Yes No   
16 a  Ritodrine 1 2  
  
     e total ritodrine dosage (mg) 
  
 
  
    g  Date & time final dose   _____/_____/_____      
              dd        mm         yyyy             24 hour clock    
    
  
                                                        Yes         No 
 
17  a Tractocile  1 2   
 
      b  initial _____/_____/_______   
                               dd      mm        yyyy           24 hour clock 
 
   c  finalg_____/_____/_______    
                        dd      mm        yyyy                 24 hour clock 
     d  total daysg treatment   
 
     e total tractocile dosage (mg)  
 
 
 
 
                                                                      Yes          No 
 
18  a  First Steroid Course 1 2  if yes,  Name of steroid 
  
  b  initial _____/_____/_______           c  finalg_____/_____/_______     
                     dd              mm         yyyy        24 hour clock                                          dd        mm              yyyy        24 hour clock                     
 
     d total steroid dosage (mg) ______________ 
 
         
  
 
 
 
                                                          
 
g
  Final date is the date is the final date of treatment or the date of delivery whichever is first 
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                                                        Yes           No  
19  a  Second Steroid Course 1 2  if yes,  Name of steroid    
  
 b  initial _____/_____/_______           c  finalg_____/_____/_______     
                     dd              mm        yyyy      24 hour clock                                          dd        mm              yyyy        24 hour clock                     
 
  
     d total steroid dosage (mg) ______________ 
 
        
 
MATERNAL HYPERTENSION during pregnancy g 
 Yes No 
20 Is the mother hypertensive? 1 2 
 
 
     a Chronic Hypertension 
 
     b Gestational Hypertension (>140/90 after 20 weeks) 
 
     c Preeclampsia (PET) (HPT + proteinuria) 
 
     d PET superimposed on chronic HPT     
 
 
1 
 
2 
3 
4 
                                                                                                      
                                                                                     Yes          No  
21 24-hour urine collection for proteinuria  1    2 
 
      if yes,    urine protein  •  g/L     •  g/d 
 
22 BP prior to delivery:  a Systolic BP  mmHg        b Diastolic BP  mmHg   
                                                                                 Yes          No 
23  PET bloods taken prior to delivery  1    2 
 
     If yes,   
a Gestation blood taken  weeks 
 
b   Urea             •  mmol/l                          c   Creatinine       µmol/l 
 
d Urate            •  mmol/l                     e   ALT                U/l 
 
f   Bilirubin          µmol/l                       g  Albumin           g/l 
 
h Platelet          109/l   
 
 
ANTI HYPERTENSIVE DRUGS  during pregnancy ONLY 
NB  final date is date finish treatment OR delivery WHICH EVER IS FIRST 
 
24 a  First drug  please specify    
 
 b  start _____/_____/_______ c  final_____/_____/_______ 
 dd     mm      yyyy dd   mm  yyyy 
 
             d Dose per day _________ 
 
 
25 a   Second drug  please specify    
 
Go to  Q27 
  
162 
 b  start _____/_____/_______ c  final_____/_____/_______ 
 dd    mm       yyyy   dd    mm    yyyy 
 
              d Dose per day ____________ 
 
 
26 a  Third drug  please specify    
 
 
 b  start _____/_____/_______ c  final_____/_____/_____ 
                          dd        mm      yyyy            dd  mm  yyyy 
 
              d Dose per day ____________ 
 
 
 
 
 
 
 
MATERNAL ANTICONVULSANT DRUG  during pregnancy ONLY  
  
NB  final date is date finish treatment OR delivery WHICH EVER IS FIRST 
 
27 a  Drug 1  please specify    
 
 
  b  start _____/_____/_______ c  final_____/_____/_______ 
    dd    mm       yyyy   dd     mm     yyyy 
 
28 a Drug 2  please specify    
 
  b  start _____/_____/_______ c  final_____/_____/_______ 
   dd         mm             yyyy    dd      mm     yyyy 
 
 
29   a  Drug 3  please specify    
 
 
 b  start _____/_____/_______ c  final_____/_____/_______ 
 dd   mm        yyyy    dd    mm     yyyy 
 
 
ANY (ORAL OR IV) MATERNAL STEROIDS (eg for asthma) other than dexamet etc. for  
prevention of RDS. g 
 
 
 Course 1 
30 a Name   
 
  
 B  start g   _____/_____/_______ c  finishg     _____/_____/_______ 
 dd    mm         yyyy    dd  mm     yyyy 
 
  
 D  total daily dosage   
 mg 
e total days treatment   
  
 f  maternal weight start treatment • kg 
 
 
 
 
 Course 2 
31 a  Name   
 
  
 B  start g   _____/_____/_______ c  finishg     _____/_____/_______ 
   dd   mm      yyyy dd        mm   yyyy 
 
  
 D  total daily dosage   
 mg 
e total days treatment   
  
 f  maternal weight start treatment • kg 
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 Course 3 
32 a  Name   
 
  
 B  start g   _____/_____/_______ c  finishg     _____/_____/_______ 
 dd      mm        yyyy dd     mm        yyyy 
 
  
 D  total daily dosage   
 mg 
E total days treatment   
  
 f  maternal weight start treatment • kg 
 
 
 
TREATED MATERNAL GU INFECTIONS (In the week prior to delivery) 
  
33             Yes         No 
 A  Urinary tract infection 1 2  if yes, 
 
 b  Treatment (specify)    c  Dosage  
 
 d  Organism (specify) e  Date ______/______/_____ 
34 Yes No  
 A  Vaginal discharge 1 2  if yes, 
 
 b  Treatment (specify)_______________________ c  Dosage  
 
 d  Organism (specify)__________________________ e  Date ______/______/_____ 
 
 
DELIVERY AND BIRTH DETAILS 
 
 
 
Elective caesarean section 
     
35 Reasons for C/S Previous caesarean section 
1 
 Breech presentation 
2 
 Maternal request 
3 
 Placenta praevia 
4 
 Other  
5 
  
Please specify___________________ 
 
36  Drugs received during labour  tick as many as apply 
  
 a  None received 1  d  Epidural / spinal 1 
 b  Entonox 1  e  Opiate 1 
 c  General anaesthesia 1 f   Other,  please specify 1 
 
 
37 a  Type of fluid during caesarean section prior to delivery ______________________ 
 
     b   Total volume______________________   
 
 
  
38   Placental weight  gm   
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DELIVERY OUTCOMES 
 
  
39a Date of birth _____/_____/_____   39b  Time of birth      24 hour clock 
  
40   Apgar score 1 minute    41   Apgar score 5 minutes  
42   Resuscitation required Yes 1    No 2   
 
 if yes, Narcan and/or facial O2 1 IPPV by tube 3 
 
IPPV
 
by mask
 2  IPPV and drugs 4 
 
 
 
INFANT CHARACTERISTICS 
  
43 Infant's Surname  _______________ 44 Infant's DoB  _____/_____/_______      
                              dd     mm     yyyy 
45  Infant's sex Male 1 Female 2 
 
 
46  Infant's birth weight    gm 
 
47  Birth length       •  cm 
48  Birth OFC       •  cm  
 
MATERNAL BIOCHEMISTRY 
49a Glucose (1st) 
 
 
  mmol/l 
 
 
     24 hour clock 
  
49b Lactate (1st)   mmol/l 
 
 
     24 hour clock 
 
50a Glucose (2nd)   mmol/l 
 
 
     24 hour clock 
50b Lactate (2nd)   mmol/l 
 
 
     24 hour clock 
 
 
INFANT BIOCHEMISTRY  
 
Time blood taken 
 
     24 hour clock 
 
  
Umbilical artery 
 
Umbilical vein 
51a  pH    52a  pH 
 
  
    b  pCO2    kPa 
 
    b  pCO2    kPa 
 
    c pO2    kPa 
 
    c  pO2    kPa 
 
    d cHCO3   mmol/l     d  cHCO3   mmol/l 
    e BE 
 
 
  mmol/l     e  BE    mmol/l 
 
53 Glucose    mmol/l 54 Lactate    mmol/l 
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55  Cortisol  
 nmol/l 
 
56  GH   ng/ml 
57  Insulin   mU/l 
 
58  Glucagon    ng/l 
59  3-hydroxybutyrate   mmol/l 60 Free fatty acids  umol/l 
 
 
61 Catecholamine pg/ml   
a. DHPG 
 
 
b. DHPG sulfate 
 
 
c. NE 
 
 
d. NE sulfate 
 
 
e. DOPA 
 
f. DOPA sulfate 
 
 
g. EPI 
 
h. EPI sulfate 
 
i. Dopamine 
 
j. Dopamine sulfate 
 
k. DOPAC 
 
l. DOPAC sulfate 
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 Additional steroid courses 
 
Third Steroid Course  
 Yes No  
 
 a 1 2 if yes,  Name of steroid   
  
 b  initial _____/_____/_______ c  finalg_____/_____/_______ d total steroid dosage (mg) 
 dd mm yyyy dd mm yyyy  
 
  
 e  maternal weight start treatment (kg)                    •  
  
          f  Date & time final dose_____/_____/_____    
                    dd mm        yyyy 24 hour clock   
Fourth Steroid Course  
 Yes No  
 
 a 1 2 if yes,  Name of steroid   
  
 b  initial _____/_____/_______ c  finalg_____/_____/_______ d total steroid dosage (mg) 
 dd mm yyyy dd mm yyyy 
 
  
 e  maternal weight start treatment (kg)                      •  
  
            f  Date & time final dose_____/_____/_____    
                                      dd mm         yyyy 24 hour clock   
  
Fifth Steroid Course  
 Yes No  
 
 a 1 2 if yes,  Name of steroid   
  
 b  initial _____/_____/_______ c  finalg_____/_____/_______ d total steroid dosage (mg) 
 dd mm yyyy dd mm yyyy  
 
  
 e  maternal weight start treatment (kg)            •  
  
    f  Date & time final dose_____/_____/_____    
          dd            mm         yyyy          24 hour clock   
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CONSENT FORM 
 
NB. This form must be completed and signed by the research subject in the presence of 
someone with knowledge of the research designated by the Principal Investigator. This may a 
doctor, nurse, clinical research assistant or other member of the research team who must 
countersign the form as witness to the subject signature. 
Please tick () appropriate box 
Have you read and understood the Subject Information Sheet?  Yes  No  
 
Have you been given an opportunity to ask questions and further discuss this study?
          Yes  No  
Have you received satisfactory answers to all of your questions?  Yes  No  
 
Have you now received enough information about this study?  Yes  No  
 
Who have you spoken to? Dr/Mr/Mrs/Miss …………………………………………… 
 
Do you understand that your participation is entirely voluntary?  Yes  No  
 
Do you understand that you are free to withdraw from this study: 
 
At any time?        Yes  No  
Without having to give a reason for withdrawing?   Yes  No  
Without this affecting your present or future medical care?  Yes  No  
 
Do you agree that your records in this research and supporting medical records be 
made available for inspection by monitors from: 
University of Dundee        Yes  No  
NHS Tayside monitors?      Yes  No  
Regulatory authorities?      Yes  No  
 
Do you agree to take part in this study?     Yes  No  
 
Do you agree to any blood used in this study being  
retained for use in future research?   Yes  No   Not applicable  
 
Subject’s signature …………………………………… Date ………………….……………… 
Subject’s name in block capital letters ……………………………………………………….. 
 
Telephone contact (Patient) …………………… (Home) ………………………….. (Work) 
Signature witnessed by ……………………………… Date.…………………………………. 
Witness name in block capital letters    ………………………………………………...........
 
